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ABSTRACT
Flores, Victoria. Exploring sex differences in the effect of cannabidiol on physical activity,
cognition, psychological wellbeing, and inflammatory and neural health biomarkers.
Published Doctor of Philosophy dissertation, University of Northern Colorado, 2022.

Cannabidiol (CBD) is believed to improve physical and mental health in recreationally
active men and women. The purpose of this study was to investigate the biological sex-related
differences in physical activity, health-related fitness, mental and cognitive health, and
biomarkers of inflammation and neural health before and after an 8-week CBD intervention.
Participants (N =49; CBD Treatment Group (CG): n =24; Placebo Treatment Group
(PG): n = 25; Females: n = 25; Males: n = 24; Males in CBD Group (CF-M): n = 12; Females in
CBD Group (CG-F), n = 12; Males in Placebo Group (PG-M): n =12; Females in Placebo Group
(PG-F): n = 13) completed a total of 8 visits, separated by an 8-week intervention period of either
50 mg of CBD or a calorie-matched placebo to consume daily. Before and after the intervention,
participants completed a fasted blood draw, psychological and cognitive function questionnaires,
and assessments for body composition, peak oxygen uptake, anaerobic fitness, and muscular
strength. Isolated serum was used to determine resting concentrations of C-reactive protein
(CRP) and brain-derived neurotrophic factor (BDNF) using enzyme-linked immunoassays. Data
were analyzed with SPSS using independent t-tests and 2 and 3-way mixed analysis of variance
(α = 0.05).
An interaction (time*treatment) on anaerobic fitness was found in which PG experienced
a 9% and 3% decline in mean peak power (p = 0.006) and relative peak power (p = 0.006)
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compared with CG. Another interaction (treatment*sex) was found on overall CRP
concentrations in which CG-F had 92% and 115% greater overall mean CRP concentrations than
PG-F (p = 0.026) and CG-M (p = 0.012), respectively. Another interaction (treatment*sex) was
also found on overall BDNF concentrations in which PG-F had 43% and 39% greater overall
mean BDNF concentrations than CG-F (p = 0.014) and PG-M (p = 0.008), respectively.
Results suggest that 8 weeks of CBD does not alter body composition, cardiorespiratory
fitness, and muscular strength. However, results suggest that it may serve as a potential aid in
preventing decreases in anaerobic fitness, and that its effect on resting concentrations of CRP
and BDNF are different between males and females.
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CHAPTER I
INTRODUCTION TO THE STUDY
Chronic inflammation is defined as inflammation lasting for prolonged periods of time
and is correlated with many negative health outcomes, such as loss of cognitive function,
development of fatigue and depression, and increased mortality rates (Jehn et al., 2015; Kumari
et al., 2016). In clinical situations, the inflammatory status of an individual may be determined
by monitoring measurements of peripheral concentrations of the inflammatory biomarkers
interleukin-6 (IL-6) and C-reactive protein (CRP) in blood (C. H. Liu et al., 2017). Interleukin-6
is most well-known for the regulation of local inflammation which often involves the production
and recruitment of leukocytes and acute-phase response proteins (Murphy & Weaver, 2017). Creactive protein is an acute-phase protein synthesized in the liver during inflammation and assists
in acute infection or injury by opsonizing contaminants or agents (Murphy & Weaver, 2017).
Normal concentrations of serum and plasma IL-6 and CRP can vary depending on age (Stewart
et al., 2007), acute infection (Thompson et al., 1999), and health and disease status (Marzolini et
al., 2020). Typically, IL-6 concentrations are within 0.9-3 pg/mL (Herder et al., 2007; Maachi et
al., 2004) and CRP concentrations are around 6 mg/L (Marzolini et al., 2020) in those with
chronic inflammation such as obesity, and ≤ 1.8 pg/mL and <3 mg/L, respectively, in healthy
individuals (Libardi et al., 2012; Ridker, 2003).
Neuroinflammation, which is defined as inflammation in the brain and spinal cord, is
mediated by microglia, which is an innate cytokine-producing immune cell in the central nervous
system (CNS; Lenz & Nelson, 2018). In chronic neuroinflammatory conditions, microglia

2
release pro-inflammatory cytokines including IL-6, interleukin-1 beta (IL-1β), interferon gamma,
and tumor necrosis factor alpha (TNF-α) which are associated with reduced neuronal plasticity
and cognitive impairments (Lenz & Nelson, 2018; C. H. Liu et al., 2017; Mosser & Edwards,
2008). Microglia also release anti-inflammatory cytokines including interleukin-10 (IL-10) and
interleukin-13 (IL-13) in periods of early life development, acute growth stress, and exercise.
These cytokines assist with tissue growth, remodeling, and repair (Lenz & Nelson, 2018;
Littlefield et al., 2015; Lobo-Silva et al., 2016). Microglia also release brain-derived
neurotrophic factor (BDNF), a neurotrophin that regulates neuronal development and function
(Gomes et al., 2013; Norden et al., 2016). Murine models show that acute activation of microglia
cause the release of the anti-inflammatory cytokines IL-10 and IL-13 which will, in turn, act to
increase central BDNF secretion resulting in improvements in neuroprotection (Gomes et al.,
2013; Lobo-Silva et al., 2016). Conversely, chronic activation of the microglia can cause the
release of the pro-inflammatory cytokines IL-6 and others, which can reduce central BDNF
secretion resulting in diminished neuroprotection (Gomes et al., 2013). Central BDNF can cross
the blood brain barrier and act through autocrine and paracrine mechanisms in peripheral tissues
and organs (Pan et al., 1998), and peripheral BDNF can be produced from non-CNS tissues as
well (Kerschensteiner et al., 1999; Matthews et al., 2009; Urabe et al., 2013).
Exercise volume, duration, and body composition are factors that influence the
relationship among IL-6, CRP, and BDNF. Although IL-6 is pro-inflammatory, its release during
exercise has positive effects by upregulating the anti-inflammatory cytokines IL-10 and
interleukin-1ra (IL-1ra), and inhibiting TNF-α (Petersen & Pedersen, 2005). Although an acute
inflammatory event associated with exercise may be beneficial, chronic low-grade inflammation,
such as persistent elevated circulating concentrations of IL-6, can be detrimental. Additionally,
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chronic exercise training decreases both IL-6 and CRP concentrations and these decreases are
associated with lower risk for cardiovascular disease (CVD; Smith et al., 1999) and hypertension
(Smith et al., 1999). Regular physical activity, which is usually measured as daily step counts
with an accelerometer, is recognized as a cost-effective and non-pharmaceutical method aimed at
reducing IL-6 and CRP concentrations in individuals with disease. Completing more than 5,000
steps per day reduces IL-6 and CRP concentrations in those with obesity (Renault et al., 2017;
Zang et al., 2019), autoimmune disorders (Moy et al., 2014), and other inflammatory diseases
(Webb et al., 2018). A single bout of exercise also transiently increases BDNF concentrations
(Briken et al., 2016; Cabral-Santos et al., 2016; Castellano & White, 2008), but other research
shows that chronic exercise training increases resting BDNF concentrations (Erickson et al.,
2011; Nofuji et al., 2008), or has no effect (Schiffer et al., 2009).
Brain-derived neurotrophic factor and its relationship to inflammatory cytokines also
appear to be sex-dependent. Preclinical studies show that female rodents display significantly
greater microglial density and heightened microglial activation in the prefrontal cortex when
subjected to stress compared to male rodents (Bilbo et al., 2012; Bollinger et al., 2016; L. L. Liu
et al., 2019). Female mice also experience significant reductions in hippocampal BDNF
messenger RNA (mRNA) expression and these reductions are positively correlated with
depressive-like behaviors, and negatively correlated with TNF-α mRNA expression when
compared to males (L. L. Liu et al., 2019). Additionally, female mice are thought to be more
sensitive to stress than males (L. L. Liu et al., 2019). The relationship among sex, BDNF
concentrations, and inflammatory cytokines is thought to be the same in humans, but the
relationship has yet to be fully elucidated. Human females demonstrate a significantly greater IL6 response in stress-evoked situations than males (Lockwood et al., 2016). Neuropsychiatric
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research also shows that BDNF concentrations are correlated with IL-6 concentrations in those
diagnosed with depression (Patas et al., 2014) and that females are 1.5-2 times more likely to
experience mood and anxiety disorders than males (McLean et al., 2011).
Additionally, IL-6 is associated with increased body mass index (BMI) and fat mass as
well as elevated abdominal adiposity (Bermudez et al., 2002; Festa et al., 2001; Lear et al., 2003;
Rexrode et al., 2003). Greater central abdominal adiposity is significantly linked to elevated IL-6
and CRP concentrations more so in females, even after accounting for other lifestyle factors
including physical activity, smoking, or alcohol intake (Thorand et al., 2006). Overweight and
obese women also have 25% higher serum BDNF concentrations compared to overweight and
obese men (Glud et al., 2019). These findings suggest that women may experience differences in
the degree of BDNF expression related to higher fat mass and central adiposity. However, the
relationship between BDNF and inflammatory cytokines has not been fully explored and it is
possible that high concentrations of systemic IL-6 and CRP can affect neural health differently in
each sex.
Cannabidiol (CBD), the non-psychoactive phytocannabinoid contained in Cannabis
sativa L., has become a popular supplement marketed with claims to help control chronic
inflammation and neuroinflammation. Cannabidiol is most recognized as a potential treatment
for neuroinflammatory diseases and disorders including models of depression (Gáll et al., 2020;
Maroon & Bost, 2018; Premoli et al., 2019; Sales et al., 2019, 2020; Silote et al., 2019; Solowij
et al., 2018), anxiety (Gáll et al., 2020; Maroon & Bost, 2018; Premoli et al., 2019; Solowij et al.,
2018), Parkinson’s Disease (Peres et al., 2018), Alzheimer’s Disease (Peres et al., 2018; Premoli
et al., 2019), and a variety of cancers (Maroon & Bost, 2018). In fact, CBD is approved by the
United States Food and Drug Administration (FDA) for the treatment of two severe forms of
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epilepsy (Khan et al., 2018; Maroon & Bost, 2018; Premoli et al., 2019). Cannabidiol regulates
inflammation through mechanisms involving the endocannabinoid system (ECS) which consists
of the cannabinoid type 1 receptors (CB1r) and cannabinoid type 2 receptors (CB2r), and the
endocannabinoids N-arachidonoyl-ethanolamine, also known as anandamide (AEA), and 2arachidonoylglycerol (2-AG; Di Marzo, 2018; Fine & Rosenfeld, 2013). Cannabidiol is a
negative allosteric modulator of human CB1r (Laprairie et al., 2015) and has a higher affinity to
CB2r (Tham et al., 2019). The anti-inflammatory effects of CBD are recognized by its
antagonistic effect on CB2r in various human cells (Couch et al., 2017; Muthumalage &
Rahman, 2019; Petrosino et al., 2018). For example, CBD reduced the production of IL-6, TNFα, and the chemokines involved in the recruitment of macrophages in human keratinocytes
exposed to allergens (Petrosino et al., 2018), and in macrophages and fibroblasts stimulated with
lipopolysaccharide (LPS; Muthumalage & Rahman, 2019). Cannabidiol was found to increase
endogenous AEA concentrations which, in turn, acted on immune cells through CB2r which
resulted in the downregulation of leukocyte pro-inflammatory cytokine release (Petrosino et al.,
2018; Turcotte et al., 2016).
Preclinical studies illustrate that CBD may also mediate neuroinflammation and brain
health as measured by changes in BDNF concentrations. The evidence from animal studies is
convincing. For example, in mice with induced brain ischemia, 3 weeks of intraperitoneal (i.p.)
CBD injections decreased hippocampal neurodegeneration and improved hippocampal BDNF
concentrations (Mori et al., 2017). In a separate study, which used a murine model of
Alzheimer’s Disease, a 24-hour repeated i.p. CBD treatment reduced neuroinflammation from
astrocytes and promoted neurogenesis in injured hippocampi (Esposito et al., 2011). Lastly, a
single dose of i.p. CBD attenuated IL-6 and TNF-α production and also attenuated decrements in
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hippocampal BDNF concentrations and cognitive impairment in mice that underwent bacterial
inoculation (Barichello et al., 2012).
Clinical studies also suggest that CBD treatment positively affects brain function and
neuroinflammation. For example, one dose of oral CBD attenuated intravenous THC-induced
psychosis and striatal and amygdala activation during a fearful visual stimulation task in healthy
men (Bhattacharyya et al., 2010). In the same study, the CBD-only group also performed better
during the verbal recall test compared to the THC and placebo-only groups (Bhattacharyya et al.,
2010). Clinical studies also demonstrate that CBD treatment improves psychotic symptoms in
psychiatric patients (Shannon et al., 2019), anxiety in patients with post-traumatic stress disorder
(Elms et al., 2019), and general anxiety disorder (Bergamaschi et al., 2011). Given that CBD
improves these outcomes, CBD may mediate the control of brain function and
neuroinflammation in healthy individuals. Although these findings are intriguing, the
relationship among CBD, inflammatory cytokines, BDNF, and improved cognitive function is
still not clearly understood (Fumagalli et al., 2006; Premoli et al., 2019; Silote et al., 2020).
There is very little information about whether sex plays a role in mediating similar CBDinduced physiological and psychological responses. There are sex-related differences in the
inflammatory response and in the degree of muscle damage from eccentric exercise in animals
and humans (Komulainen et al., 1999; Stupka et al., 2000), in ECS function in mice and rats
(Dow-Edwards, 2020; Fattore & Fratta, 2010), in brain structure and function (Eggers et al.,
2014; Kaczkurkin et al., 2019), and in microglial density and stress response (Bollinger et al.,
2016). Taken together, males and females may differ in their response to CBD use. This
difference may, in turn, affect circulating concentrations of IL-6, CRP, and BDNF as well as
brain function and general wellbeing.
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Cannabidiol is easily obtainable and marketed as a health supplement for everyday use
for people who may not be experiencing neurodegenerative and neuropsychiatric disorders.
Unfortunately, many CBD companies rely on anecdotal evidence to support their claims and
market their product without knowledge of the full scope of CBD-related physiological and
psychological responses. This is surprising given that a study found that 55% of 2,400 medicinal
cannabis community members in America used CBD-only products identified as women, and
44% of the CBD-only users identified as men (BrightfieldGroup, 2017). Additionally, no human
research exploring the effects of CBD on measures of physical activity and exercise exists. This
is alarming because an exercise and cannabis use survey found 70% of 605 respondents use
cannabis before working out to make exercise feel more enjoyable (YorkWilliams et al., 2019).
This suggests that CBD and THC may induce endorphins, activate opioid receptors, and alter
physical activity behavior, but no studies have explored these mechanisms. There are currently
no studies investigating sex differences related to CBD, inflammation, and BDNF, and whether
CBD may affect cognitive function and wellbeing in physically active and healthy adults.
In summary, healthy individuals who may or may not have inflammation and are
recreationally active may experience alterations with CBD use in their overall wellbeing. It is
unknown whether these alterations are associated with sex and result in any benefit or harm to
the user. There are not enough studies involving healthy men and women to fully understand the
relationship among inflammation, physical activity, mental and physical health, and long-term
CBD use. This raises the following questions in CBD-related research:
Q1

Is there a difference by sex or by treatment with respect to physical activity
patterns, health-related fitness, measures of mental and cognitive health, and
concentrations of CRP and BDNF?
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Q2

Does 8 weeks of CBD affect physical activity patterns, health-related fitness,
measures of cognitive and mental health, and resting concentrations of CRP and
BDNF?

More research is needed to match the exponential production and consumption of CBD
to help inform both public and health care officials about any potential effects it may have.
Purpose and Hypotheses
The purpose of this double blind, placebo-controlled, clinical trial with parallel group
design was to investigate the biological sex-related differences in physical activity patterns,
health-related fitness, mental and cognitive health before and after an 8-week CBD intervention.
This study also aimed to explore whether 8 weeks of CBD treatment would significantly alter
biomarkers of inflammation and neural health. The specific aims for this study were:

A1

Explore potential overall differences at the pre-intervention time point, by sex or
by treatment assignment, with respect to physical activity patterns, health-related
fitness, measures of mental and cognitive health, and concentrations of
inflammatory and neural health biomarkers.

H1

At the pre-intervention time point, females will have lower average daily step
counts and distance traveled, lower muscular strength, relative peak oxygen
uptake (V̇O2 peak) values, and anaerobic fitness performance measures, higher
percent body fat and concentrations of CRP, and similar BDNF concentrations
and measures of cognitive function and psychological wellbeing when compared
with males.

H2

It was also hypothesized that, when the sexes were combined into treatments of
males and females consuming CBD and males and females consuming placebo,
those assigned placebo will not be different than those assigned CBD with respect
to physical activity patterns, health-related fitness, measures of mental and
cognitive health, and concentrations of inflammatory and neural health
biomarkers at the pre-intervention time point.

A2

Explore the treatment effects of an 8-week CBD intervention on physical activity
patterns, health-related fitness, measures of mental and cognitive health, and
concentrations of inflammatory and neural health biomarkers.

H3

Both sexes consuming CBD will experience increases in average daily step counts
and distance traveled, decreases in percent body fat, improvements in relative
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V̇O2 peak, as well as increases in muscular strength and anaerobic fitness
performance measures over the course of the intervention period when compared
to those consuming placebo. Both sexes consuming CBD will also experience
improvements in cognitive function and psychological wellbeing scores, reduced
concentrations of CRP, and an increase in concentrations of BDNF over the
course of the intervention period when compared to those consuming placebo.
H4

It was also hypothesized that females consuming CBD will experience a greater
increase in average daily step counts and distance traveled, greater reduction in
percent body fat, greater improvements in V̇O2 peak, cognitive function, and
psychological wellbeing scores, a more significant reduction in concentrations of
CRP, and a more significant increase in concentrations of BDNF when compared
with males consuming CBD.
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CHAPTER II
REVIEW OF LITERATURE
Inflammation
Inflammation is a necessary response elicited by the body to address tissue damage,
infection, or injury. The process by which inflammation begins involves the activation and
recruitment of macrophages, neutrophils, mast cells, and other leukocytes from the innate or
adaptive immune systems. The type of coordinated response is dependent on the distress signals
released from immune cells following recognition by pathogen-associated molecular pattern
molecules and damage-associated molecular pattern molecules through pattern recognition
receptors (Murphy & Weaver, 2017). As inflammation progresses, leukocytes work to repair the
damaged area by producing more chemotactic factors that induce unidirectional leukocyte
movement to reinforce the inflammatory signal, increase phagocytic activity, and promote
degranulation and secretion of precursor zymogens (Murphy & Weaver, 2017). In instances that
require a stronger immune response, immune cells will further enhance activation by releasing
more pro-inflammatory soluble factors. Acute responses to local inflammation are accompanied
by up to 5 main characteristics in the infected area, which include redness, pain, heat, swelling,
and immobility, and are dependent on the severity of the inflammatory response (Murphy &
Weaver, 2017).
Prolonged activation and recruitment associated with the inflammatory response may
lead to chronic inflammation which is defined as inflammation lasting for several months to
many years. This maladaptive response results in increased cellular stress and malfunction
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(Medzhitov, 2008). This condition is associated with many deleterious health outcomes,
including the development and progression of cancer (Li et al., 2020), CVD (Fioranelli et al.,
2018), obesity and metabolic diseases (Ramos-Arellano et al., 2020; Zatterale et al., 2020), as
well as neuropsychiatric disorders that impact brain function, emotion, and mood. The persistent,
low-grade stimulation of the leukocytes and their specific signal-transduction pathways
contributes to the phenotypic symptoms experienced in these disorders such as tumor growth (Li
et al., 2020), vascular endothelial dysfunction (Fioranelli et al., 2018), mood disorders (M. H.
Chen et al., 2021; Wright et al., 2005), and cognitive deficit disorders (Parbo et al., 2017).
Biomarkers of Inflammation
Current research related to the development of therapeutic targets has focused on the
potential causes and subsequent signs of chronic inflammation. One of these strategies involves
measuring peripheral biomarkers to help gauge the presence and severity of inflammation and
determine risk for disease. Elevated circulating concentrations of the biomarker interleukin 6
(IL-6) and its induced protein, C-reactive protein (CRP), are commonly associated with both
acute and chronic inflammatory episodes and are used in both clinical and research environments
(Murphy & Weaver, 2017).
Interleukin-6 is a member of the hematopoietin superfamily of cytokines which
stimulates the production of new monocytes and granulocytes in the bone marrow and plays a
crucial role in inducing the acute-phase response in the liver (Murphy & Weaver, 2017). This
biomarker is produced by a variety of cells but mostly in macrophages and monocytes in
response to inflammation. The local effects of IL-6 include lymphocyte activation and
maturation and increased antibody production, while the systemic effects of IL-6 include
increased body temperature leading to fever, and induction of acute-phase proteins (Murphy &
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Weaver, 2017). Interleukin-6 has both pro- and anti-inflammatory functions when secreted by
other tissues. It is also known as one of the main myokines, or cytokines secreted by skeletal
muscle, that plays an integral role in crosstalk between muscle with bone, liver, adipose, and
other organs (Gomarasca et al., 2020; Pedersen & Febbraio, 2012; Petersen & Pedersen, 2005).
Interleukin-6 can regulate bone resorption and formation, and stimulate metabolism through the
promotion of glycogenolysis, gluconeogenesis, fatty acid oxidation, protein catabolism, glycerol
release, and lipolysis (Gomarasca et al., 2020). When IL-6 is released from skeletal muscle and
hepatic cells, it is more commonly associated with anti-inflammatory actions (Karsenty &
Ferron, 2012; Karsenty & Mera, 2018; Pedersen & Febbraio, 2012). When IL-6 is secreted from
adipose tissue, it tends to have a pro-inflammatory effect due to the ability of fatty acids to
stimulate the release of IL-6 with other pro-inflammatory biomarkers including TNF-α, and
monocyte-chemotactic proteins (He et al., 2018; Watanabe et al., 2004). These biomarkers
activate pro-inflammatory signaling pathways such as janus kinase, a signal transducer and
activator of transcription proteins, protein kinase B (PKB and/or AKT), and extracellular signalregulated kinases (ERK), that when dysregulated from persistent IL-6 release, may result in
cancer growth and CVD (He et al., 2018; Watanabe et al., 2004).
In clinical settings, IL-6 is measured to indicate the presence of activated and migrating
macrophages and lymphocytes. Normal serum concentrations in healthy individuals without
disease or chronic inflammation are usually ≤ 1.8 pg/mL (Libardi et al., 2012), and normal
plasma concentrations are usually considered < 6.4 pg/mL in men and < 5.8 pg/mL in women
(Fernandez-Real et al., 2001). In situations involving acute inflammation, serum IL-6
concentrations can become elevated. For example, serum IL-6 concentrations are as high as 64
pg/mL in those with acute respiratory syndrome coronavirus 2 (X. Chen et al., 2020). The
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primary action of IL-6 is to control the intensity of inflammatory response; however,
overproduction can lead to tissue damage. In chronic inflammatory states, concentrations of IL-6
can vary. For example, serum IL-6 concentrations can range between 0.9-3 pg/mL in those with
obesity (Herder et al., 2007; Maachi et al., 2004), 30-494 pg/mL in those with autoimmune
disorders (Ali et al., 2019), and 2.4-3.1 pg/mL in those with major depressive disorder (Karlović
et al., 2012).
C-reactive protein is an important acute-phase protein that is synthesized in the liver
during inflammation (Gabay & Kushner, 1999). Interleukin-6 is one of the main signals which
stimulates the production of CRP. It is important to note that there are other regulatory
inflammatory cytokines including IL-1β and TNF-α, and other acute-phase proteins involved in
the systemic response to inflammation as well (Gabay & Kushner, 1999). C-reactive protein has
several isoforms and is also synthesized in smooth muscle cells, macrophages, endothelial cells,
lymphocytes, and adipocytes (Sproston & Ashworth, 2018). In the inflammatory process, the
function of monomeric CRP is to respond to acute infection by binding to and/or coating the
bacterium or fungal cell wall, a process known as opsonization. This action will, in turn, activate
complement system proteins to ultimately generate a large phagocytic cell response at the site of
infection (Murphy & Weaver, 2017). Increasing concentrations of monomeric CRP further
activates leukocytes and increases the production of IL-6 as well as TNF-α, IL-1β, and IFN- γ
(Gratacos et al., 1994; Schindler et al., 1990). As a result, the pro-inflammatory signaling
pathways phosphatidylinositol-3-kinase (PI3K), AKT, and ERK are activated (Khreiss et al.,
2002). C-reactive protein also has anti-inflammatory actions which are related to its cyclic,
pentameric structure. This structure allows CRP to regulate apoptosis by affecting the cell cycle
kinetics of monocytes (Kim et al., 2014). Pentameric CRP is also known to regulate PI3K/AKT
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and ERK pathways which may lead to the inhibition of apoptosis, opsonization of apoptotic
cells, and phagocytosis of damaged neutrophils (Khreiss et al., 2002).
In clinical settings, concentrations of CRP are monitored to measure infection, CVD risk,
and other chronic inflammatory conditions. Normal concentrations of serum CRP in healthy
individuals are usually around 0.8 mg/L and normal plasma concentrations are usually < 0.3
mg/L (Fernandez-Real et al., 2001; Libardi et al., 2012; Ridker, 2003). It is important to note that
concentrations of serum and plasma CRP can vary. C-reactive protein concentrations can
increase 1,000-fold in acute, bacterial infections (Thompson et al., 1999) and serum CRP can
also increase to 89 mg/L in patients with acute viral infections such as acute respiratory
syndrome coronavirus 2 (X. Chen et al., 2020). In more chronic conditions, serum CRP is around
6 mg/L in obese individuals, and ranges between 2.2-3.2 mg/L in those with major depressive
disorder (Marzolini et al., 2020). It is also important to note that the definition of a healthy CRP
concentration can vary depending on health status (Tsalik et al., 2012), thereby making it
difficult to establish universal standards. For example, according to the CVD risk stratification
system that uses CRP to predict the risk of CVD events, serum CRP concentrations < 1 mg/L are
considered low risk, 1-3 mg/L are considered moderate risk, and > 3 mg/L are considered high
risk (Lee et al., 2019; Ridker, 2003). On the other hand, the rheumatoid arthritis (RA) risk
stratification system which measures CRP to gauge RA activity and subsequent RA episodes,
considers serum CRP concentrations < 3.0 mg/L as normal, 3-10 mg/L as high risk, and > 10
mg/L as the RA diagnostic indicator (Sokka & Pincus, 2009).
Acute and Chronic Exercise and
Inflammation
While exercise is defined as planned and structured activity such as aerobic exercise or
resistance training, physical activity is a more general term and is defined as any activity that
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involves caloric expenditure. Both exercise and physical activity influence inflammatory
processes in the body. A single bout of exercise increases concentrations of IL-6 (Cipryan et al.,
2015; Mendham et al., 2011). Though plasma IL-6 concentrations can increase as much as 100fold in the bloodstream after intense exercise of either heavy volume or duration (Fischer, 2006;
Gomarasca et al., 2020; Hardee et al., 2018), the increases are transient, and do not remain
elevated in the blood stream (Cipryan et al., 2015; Fischer, 2006; Mendham et al., 2011). After a
single bout of strenuous aerobic exercise, the plasma concentration of the inflammatory
cytokines TNF-α and IL-1β increase along with IL-6, but cytokine inhibitors IL-1ra and soluble
tumor necrosis factor receptors 1 and 2 are also secreted which help to control the inflammatory
response (Ostrowski et al., 1999). Furthermore, when IL-6 is infused at concentrations similar to
those observed during strenuous exercise (140 pg/mL), there is an increase in IL-10 and IL-1ra
production. These cytokines are also known to mitigate TNF-α and IL-1β actions (Steensberg et
al., 2003).
Chronic exercise training consisting of aerobic and resistance exercise reduces resting
concentrations of IL-6 in a wide variety of special populations (Abd El-Kader & Al-Jiffri, 2019;
Dieli-Conwright et al., 2018; Oberbach et al., 2008; Sardeli et al., 2018). In older adults with
age-related, low-grade inflammation, higher frequency and longer duration of resistance training
reduces resting concentrations of IL-6 (Sardeli et al., 2018). In elderly individuals, 6 months of
aerobic exercise training significantly decreased IL-6 concentrations by 40% (Abd El-Kader &
Al-Jiffri, 2019). Additionally, IL-6 concentrations are reduced after 9 weeks of exercise training
in those with impaired glucose intolerance (Oberbach et al., 2008), and after a 16-week
combined aerobic and resistance exercise intervention in cancer survivors (Dieli-Conwright et
al., 2018). In healthy populations, some research showed that exercise training significantly
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reduces resting IL-6 concentrations (Forti et al., 2017; Tesema et al., 2019), and other research
did not (Stewart et al., 2007). This variation in response may be linked to the large range of
resting IL-6 values observed in the healthy population, which often makes it difficult to detect
statistically significant changes.
Acute exercise does not immediately affect serum CRP concentrations (Cipryan et al.,
2015; Mendham et al., 2011). Though CRP concentrations increased to 0.68 mg/L and 0.84
mg/L after a 40-minute bout of moderate-vigorous intensity resistance exercise and moderatevigorous intensity aerobic exercise, respectively, these values were not significantly different
from basal values (Mendham et al., 2011). No differences from pre-exercise values were
observed after a single bout of maximal exercise in 30 males (Cipryan et al., 2015), and after a
60-minute bout of treadmill walking at personalized speeds and 8% incline in hyperglycemic
men and women (Nygaard et al., 2017). This lack of an acute exercise-induced CRP response is
likely because IL-6 needs time to signal for CRP synthesis in hepatocytes, resulting in a longer
period before CRP can enter the blood stream.
Chronic exercise decreases concentrations of CRP (Mattusch et al., 2000; Smith et al.,
1999; Stewart et al., 2007). In individuals at risk for CVD, 6 months of an individualized
exercise program reduced CRP concentrations from 5.3 mg/L to 4.4 mg/L (Smith et al., 1999),
and in patients with hypertension and chronic kidney disease, 16 weeks of aerobic and resistance
training reduced CRP by 85% (Barcellos et al., 2018). These effects are not limited to the
diseased population. Average CRP concentrations were observed to decrease by 31% in healthy
adults after 9 months of marathon training (Mattusch et al., 2000), and by 58% in both young and
old adults after 12 weeks of aerobic and resistance training (Stewart et al., 2007). These studies
support the notion that exercise training affects the inflammatory process which is reflected in
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circulating concentrations of CRP. This action may be linked to the consistent, transient
increases in IL-6 produced by exercise, which over time, may downregulate basal CRP
production (Beavers et al., 2010).
Physical Activity and Inflammation
Regular physical activity, which is typically measured using daily step counts with an
accelerometer, is also known to affect IL-6 and CRP concentrations (Kasapis & Thompson,
2005; Moy et al., 2014; Webb et al., 2018). These improvements have been noted in situations
where step counts were increased or when individuals met a specific step count cut point. For
example, in older adults with chronic obstructive pulmonary disease, adding 1000 steps/day
resulted in a 39% decrease in CRP concentrations and a 32% decrease in IL-6 concentrations
(Moy et al., 2014), and in women diagnosed with polycystic ovary syndrome, adding 1000
steps/day resulted in a 13% decrease in both IL-6 and CRP concentrations (Webb et al., 2018).
These findings are similar in those with chronic kidney disease in which walking more than
10,000 steps/day for 3 months significantly reduced CRP and IL-6 concentrations compared to
<5,000 and 5,000-9,999 steps per day (Zang et al., 2019). Obtaining 11,000 steps/day also
resulted in a 21% decrease in CRP concentration in obese women (Renault et al., 2017). High
levels of physical activity might also help reduce the potential for an exaggerated inflammatory
response. For example, individuals who met a criterion of at least 12,500 steps per day for 14
days had a reduced IL-6 response to 14 days of high fructose meals (Bidwell et al., 2014).
Additionally, cancer patients who experience treatment-related inflammation benefit from
physical activity and exercise, suggesting that muscle-derived IL-6 from physical activity and
exercise may be a mechanism to assuage the inflammatory response (Wood et al., 2009). Taken
together, these studies suggest that increasing physical activity as measured through steps per
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day or trying to meet a specific step count goal can reduce chronic inflammation as measured by
both IL-6 and CRP.
Neuroinflammation and Brain
Derived Neurotrophic Factor
Neuroinflammation, or inflammation of the brain and spinal cord, is mediated by local,
resident immune cells in the brain, known as microglia (Lenz & Nelson, 2018). Microglia can
produce cytokines and chemokines similar to M1 and M2 type macrophages, depending on the
needs of the microglia (Lenz & Nelson, 2018). For example, microglia adopt the proinflammatory M1 phenotype and release IL-6, IL-1β, interferon gamma, and TNF-α in chronic
neurological diseases. This transition is associated with reduced neuronal plasticity and cognitive
impairment (Lenz & Nelson, 2018; C. H. Liu et al., 2017; Mosser & Edwards, 2008). Microglia
will adopt the anti-inflammatory M2 phenotype and regulate cell proliferation and synaptic
patterning by releasing factors such as IL-10 and IL-13 to remodel and repair tissue in early life
development (Lenz & Nelson, 2018; Lobo-Silva et al., 2016). In exercise, microglia take on an
anti-inflammatory role. In a model using aged mice, voluntary wheel running inhibited
microglial activation by preventing microglia from adopting an M1 phenotype after a
lipopolysaccharide (LPS) challenge which resulted in decreased neuronal degeneration
(Littlefield et al., 2015). In a murine model of Parkinson’s Disease, structured treadmill running
alleviated dopaminergic neuronal loss by inhibiting microglial activation (Sung et al., 2012).
Activation was inhibited through the reduction of cell surface marker CD11b expression on
microglial cells in the striatum (Sung et al., 2012).
Microglia can also synthesize and release brain-derived neurotrophic factor (BDNF), a
critical protein for the maintenance of neuronal health (Brigadski & Leßmann, 2020; Gomes et
al., 2013). Brain-derived neurotrophic factor is synthesized as pro-BDNF, which is involved with
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pathways leading to cell death and apoptosis (pruning mechanisms), or mature-BDNF, which
results in intracellular phosphorylation, triggering cell survival and differentiation pathways
(Thomas & Davies, 2005). In a study evaluating the ability of inflammation to control pro- and
mature-BDNF release from microglia in a N9 murine microglial cell line, 6 hours of LPS
stimulation resulted in no changes in pro-BDNF production and a significant decrease in matureBDNF production compared with non-LPS stimulated cells (Gomes et al., 2013). This suggests
that prolonged inflammation is deleterious to microglial survival and differentiation.
Interestingly, overexpression of BDNF from microglia affects BDNF receptor tropomyosin
receptor kinase B (TrkB), resulting in downstream molecular dysregulation and disease (Ding et
al., 2020; Radin & Patel, 2017). For example, a murine microglial model of cystitis showed that
17 days of i.p. injections of inflammatory cyclophosphamide significantly increased microglial
release of BDNF which subsequently increased concentrations of IL-1β and TNF-α (Ding et al.,
2020). When BDNF and tropomyosin receptor kinase B (TrkB) signaling was blocked using a
TrkB receptor antagonist, microglial activation was reduced; however, when an intrathecal
injection of exogenous BDNF was given, BDNF further promoted the activation of microglia
and increased release of IL-1β and TNF-α (Ding et al., 2020).
Brain-derived neurotrophic factor can cross the blood brain barrier (Pan et al., 1998), act
via autocrine and paracrine mechanisms, and bind to cells with TrkB receptors such as muscle,
liver, heart, immune, and hematopoietic cells (Pan et al., 1998). It is important to note that other
cells beyond the CNS can also produce and store BDNF. Clinical research confirms that
activated T and B cells (Kerschensteiner et al., 1999), hematopoietic cells (Fujimura et al., 2002;
Urabe et al., 2013), and skeletal muscle fibers (Matthews et al., 2009) can produce BDNF, and
approximately 90% or more of peripheral BDNF is stored in platelets (Fujimura et al., 2002).
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Studies show that platelets activated by traumatic injury assist in local repair by releasing BDNF
to bind cells with the TrkB receptor (Fujimura et al., 2002), and skeletal muscles produce BDNF
during muscular contractions to regulate energy homeostasis (Matthews et al., 2009; Yamamoto
& Gurney, 1990). Human skeletal muscle BDNF regulates fatty acid metabolism through
increases in the phosphorylation of AMP-activated protein kinase within the myocyte (Matthews
et al., 2009), suggesting that muscle-derived BDNF functions as a myokine. Overall, BDNF can
be synthesized in both central and peripheral tissues and has local and global effects on many
target cells that play a role in inflammation and energy balance.
Acute and Chronic Exercise, and
Brain-Derived Neurotrophic
Factor
Acute and chronic exercise mitigate neuroinflammation and research suggests that BDNF
may play a role in positive exercise-related responses in patients with neurological diseases.
Clinical trials show that an acute bout of 10-30 minutes of moderate exercise significantly and
transiently increased basal serum BDNF concentrations in individuals with progressive multiple
sclerosis (MS; Briken et al., 2016; Gold et al., 2003). In healthy individuals, acute exercise also
transiently increased concentrations of BDNF. These studies have utilized a 20-minute bout of
treadmill exercise (Boyne et al., 2019), a 30-minute bout of moderate-intensity walking break
between periods of long sitting (Wheeler, Green, et al., 2020), and a 20-minute bout of intense
cycling (Skriver et al., 2014). After acute exercise, BDNF concentrations return to baseline
levels or lower (Briken et al., 2016; Cabral-Santos et al., 2016; Castellano & White, 2008). It has
been proposed that peripheral BDNF clearance reflects movement into the CNS for neuronal
processing (Castellano & White, 2008) and movement into the muscle to assist in lipid oxidation
(Rasmussen et al., 2009).
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Chronic exercise training seems to have the same positive effect in patients with
neurological disease. Serum BDNF concentrations significantly increased in patients with
Parkinson’s Disease after 7 days of motor rehabilitation training (Angelucci et al., 2008), 28 days
of aerobic exercise (Frazzitta et al., 2014), 12 weeks of high intensity interval training (HIT)
(O'Callaghan et al., 2020), and 8 weeks of structured cycling (Zoladz et al., 2014). However, the
effect of exercise training on BDNF concentrations in other neurological disease populations and
in healthy individuals is conflicting. One randomized, controlled trial found that 24 weeks of
aerobic and resistance training in patients with multiple sclerosis significantly increased BDNF
compared with baseline and sedentary controls (Wens et al., 2016). This finding contrasts with
another study that found that 9 weeks of endurance training did not change resting BDNF
concentrations in patients diagnosed with multiple sclerosis (Briken et al., 2016). In healthy
individuals, one study found that chronic exercise training and BDNF are strongly and positively
correlated (De la Rosa et al., 2019), and that a few weeks to one year of chronic exercise training
increases basal BDNF concentrations (Erickson et al., 2011; Nofuji et al., 2008). However, other
studies show that habitual exercise has no effect on BDNF concentrations in healthy individuals
(Schiffer et al., 2009).
Relationship Among Biomarkers
Brain-Derived Neurotrophic
Factor, Interleukin-6, and
C-Reactive Protein
Animal and human research shows that changes in BDNF are associated with changes in
IL-6 and CRP. Several studies exploring the underpinnings of depression revealed an inverse
relationship between BDNF and IL-6 and CRP concentrations. Two weeks of stress-induced
depression in rats resulted in significant increases in plasma IL-6 and CRP concentrations and
these increases were significantly and negatively correlated with BDNF protein expression in the

22
hippocampus (Han et al., 2018). This same IL-6, CRP and BDNF relationship has been observed
in humans. When perimenopausal women were divided into those with and without depression,
the depressed group had significantly higher concentrations of IL-6 and CRP, and significantly
lower concentrations of serum BDNF when compared to the non-depressed group (Guo et al.,
2018).
This inverse relationship between inflammatory proteins and BDNF also seems present in
exercise studies. Clinical studies show that exercise interventions simultaneously reduce IL-6
and CRP, and increase BDNF concentrations in those with cancer (Zimmer et al., 2018), MS
(Briken et al., 2016), mild cognitive impairment (Tsai et al., 2019), and Parkinson’s Disease
(Landers et al., 2019). However, some studies show that long-term exercise in healthy
individuals results in decreased BDNF concentrations with no associated changes in IL-6
concentrations (Wagner et al., 2015). One study found that BDNF concentrations decreased in
young, healthy males after 6 weeks of aerobic exercise, and there were no noteworthy changes or
relationships with respect to IL-6 concentrations (Wagner et al., 2015). This lack of relationship
suggests that there may be unknown BDNF processing mechanisms during exercise that may be
affected by the increase in IL-6 concentrations observed during acute exercise.
Although both BDNF and IL-6 are involved in energy homeostasis during exercise, the
relationship among BDNF, IL-6, and CRP during exercise has yet to be fully elucidated. Like
BDNF, muscle-derived IL-6 regulates fatty acid metabolism through AMP-activated protein
kinase signaling during exercise (Matthews et al., 2009; Pedersen & Febbraio, 2012). High
volume high intensity training results in increased BDNF and IL-6 concentrations compared to
resting values in healthy men (Cabral-Santos et al., 2016). In this study, no significant
interactions were found between BDNF and IL-6 although a significant interaction was found
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between IL-6 and IL-10 (Cabral-Santos et al., 2016). Many other exercise studies with healthy
individuals demonstrate this transient increase and further support the potential for antiinflammatory actions of both proteins (Boyne et al., 2019; Fischer, 2006; Gomarasca et al., 2020;
Hardee et al., 2018; Skriver et al., 2014; Stewart et al., 2007; Wheeler, Green, et al., 2020).
However, more information related to the mechanisms of exercise-induced reductions in BDNF
is needed.
Cannabidiol
Cannabidiol (CBD) is a phytocannabinoid derived from the plant Cannabis sativa L.
There are more than 400 phytocannabinoids; and trans-delta9-tetrahydrocannabinol (THC) and
CBD are the most well-studied (Gaoni & Mechoulam, 1964). These cannabinoids are
biosynthesized, converted into acids, then decarboxylated into their THC and CBD forms
(Bonini et al., 2018). The biosynthesis of THC and CBD begins with geranyl diphosphate and
olivetolic acid which are converted into cannabigerolic acid, the common precursor for
tetrahydrocannabonolic acid and cannabidiolic acid (Bonini et al., 2018). Although
tetrahydrocannabonolic acid and cannabidiolic acid have the same molecular composition,
decarboxylation results in structural changes to the molecule, resulting in a tri-cyclic structure in
THC and a bi-cyclic structure in CBD (Bonini et al., 2018).
Regular use of THC is associated with psychosis and may increase the risk of developing
a psychotic illness later in life (Marconi et al., 2016; Moore et al., 2007). The 1970 Controlled
Substances Act signed by President Nixon established cannabis as a Schedule I drug, conferring
that there was no medical use for cannabis and that the compound had a high potential for abuse
(Spillane & McAllister, 2003). Almost 50 years later in June 2018, overwhelming support for the
use of CBD for treatment-resistant seizures (Devinsky et al., 2014, 2017, 2018) led to FDA
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approval of pharmaceutical grade CBD for the treatment of rare epilepsy disorders. Six months
later, hemp-derived cannabis, including CBD and its derivatives with less than 0.3% THC, were
removed from the definition of marijuana in the Controlled Substance Act. These policy changes
have led to renewed efforts to use CBD in a variety of clinical settings.
The function of CBD was first observed through its interactions with receptors of the
ECS (Matsuda et al., 1990; Munro et al., 1993). The ECS is a conserved biological system
consisting of endocannabinoids AEA and 2-AG, and their G protein-coupled receptors of the G0
and Gi type, known as CB1r and CB2r. Anandamide and 2-AG are degraded by fatty acid amide
hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively (Di Marzo & De
Petrocellis, 2012; Sugiura et al., 2002).
Cannabinoid receptor location and concentration are reported to be species-dependent (Q.
R. Liu et al., 2009; Zhang et al., 2014). Animal models demonstrate high levels of CB1r
expression in the brain, peripheral neurons, and glia (Ativie et al., 2018; Chiarlone et al., 2014;
Navarrete et al., 2020), as well as in the reproductive and endocrine organs (Navarrete et al.,
2020; Walker et al., 2019). Although CB2r was initially thought to exist primarily in the spleen
and immune system (Turcotte et al., 2016), it is also expressed in the brain in a species
dependent manner (Q. R. Liu et al., 2009; Stempel et al., 2016; Zhang et al., 2015, 2014).
Humans have two isoforms, cannabidiol receptor 2a (CB2ra), which is mainly expressed in the
testis and brain, and cannabidiol receptor 2b (CB2rb), which is expressed in the spleen and
leukocytes (Q. R. Liu et al., 2009). Both receptors activate numerous signaling pathways
including PI3K and mitogen-activated protein kinase, regulate cytosolic calcium via
phospholipase C, and act to inhibit other enzymes such as adenylyl cyclase (Luchicchi & Pistis,
2012; Munro et al., 1993; Pertwee, 1997; Turcotte et al., 2016). The regulation of these pathways
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is the proposed mechanism used by the ECS to maintain homeostasis and is also proposed as
potential therapeutic targets for the treatment of pain, inflammation, obesity, anxiety, and fear
(Calignano et al., 1998; Di Marzo, 2018; Fine & Rosenfeld, 2013; Ligresti et al., 2016; Ruehle et
al., 2012; Schulz et al., 2021).
Cannabidiol and Inflammation
The effect of CBD on IL-6 production in inflammatory responses is thought to involve
interaction with ECS and non-ECS receptors (Couch et al., 2017; Muthumalage & Rahman,
2019; Petrosino et al., 2018). Cannabidiol is recognized as a negative allosteric modulator of
human CB1r (Laprairie et al., 2015; Tham et al., 2019), a partial agonist of CB2r (Tham et al.,
2019), and an enhancer of endogenous AEA signaling by inhibiting AEA endocytosis along with
CB1r and CB2r and its breakdown via FAAH (Bisogno et al., 2001; Petrosino et al., 2018). In
human keratinocytes stimulated with 100 μg/mL of polyinosinic:polycytidylic acid (poly I:C) for
6, 12, and 24 hours, cells treated with CBD at 1, 5, 10, and 20 μM significantly inhibited the
release of IL-6, TNF-α, and monocyte chemotactic protein 2 at the 6-hour time point compared
to the control group (methanol) in a dose-dependent manner (Petrosino et al., 2018). The same
study also found that the highest doses of CBD (10 and 20 μM) significantly reduced the largest
increases in IL-6 and TNF-α at the 12- and 24-hour time points. Additionally, the study explored
the mechanisms of CBD-induced reductions in inflammation. Cannabidiol acted through CB2r
and transient receptor potential vanilloid type-1, and increased AEA concentration which
subsequently reduced monocyte-chemotactic proteins 2 and IL-6 levels secreted from treated
cells (Petrosino et al., 2018). In a separate ex vivo model, 10 μM of CBD inhibited cytokine
production and inflammatory pathways after treatment with 10 ng/mL of interferon gamma for 8
hours followed by 10 ng/mL of TNF-α for 16 hours in tissue explants taken from patients with
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bowel cancer, inflammatory bowel disease, and emergency appendectomy (Couch et al., 2017).
These results suggest that in inflammatory conditions, CBD suppresses the pro-inflammatory
cascade in enteric glial cells. Enteric glial cells are similar to microglia in that they mediate
inflammatory responses in the enteric nervous system of the gut (Couch et al., 2017). A second
component of this same study found that the inhibition of inflammation is mediated by the
interaction of CBD with receptors CB2r, transient receptor potential vanilloid type-1,
peroxisome proliferator-activated receptor alpha and gamma, and G protein-coupled receptor 55
(Couch et al., 2017). Given these responses, it appears that the effect of CBD on inflammation
may involve multimodal relationships among many cellular pathways.
Research suggests that CBD has simultaneous pro- and anti-inflammatory actions in
various inflammatory conditions. Intranasal lipopolysaccharide (LPS; 10 µg) administration
followed by 3 days of CBD treatment (75 mg/kg) in mice significantly increased the number of
neutrophils at the 6 and 24-hour time points, and the number of monocytes at the 24-hour time
point, showing that CBD enhances immune cell migration and LPS-induced pulmonary
inflammation (Karmaus et al., 2013). The same study found no effect of CBD on LPS-induced
TNF-α and IL-6 mRNA expression in lung tissue; however, CBD significantly enhanced TNF-α,
IL-6, and granulocyte colony stimulating factor mRNA expression at the 24-hour post-LPS time
point. Other murine models of acute lung injury and function show opposing results with CBD
treatment (Ribeiro et al., 2015, 2012). After LPS was administered intranasally at 100 µg/mL,
treatment with 10, 20, 30 and 80 mg/kg of i.p. CBD produced anti-inflammatory effects in lung
tissue in a dose-dependent manner (Ribeiro et al., 2012). More specifically, 20, 30, and 80 mg/kg
of i.p. CBD decreased leukocyte migration into the lungs 1 day after LPS induction, 10, 20, 30,
and 80 mg/kg of i.p. CBD decreased TNF-α production in the bronchoalveolar lavage fluid 1 day
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after LPS induction, and 20 mg/kg of i.p. CBD decreased neutrophil, lymphocyte, and
macrophage migration into the lungs at 1, 2, and 4 days after LPS induction (Ribeiro et al.,
2012). In a follow-up study by the same authors, 20 and 80 mg/kg of CBD significantly
decreased LPS-induced TNF-α and IL-6 concentrations in lung tissue, reduced lung airway
resistance, and also increased lung elastance in a dose-dependent manner (Ribeiro et al., 2015).
In human cells, CBD also has both pro- and anti-inflammatory effects. Human monocytes
from pleural tissue stimulated with LPS showed that 10.6 µM of CBD treatment significantly
reduced their production of C-C motif chemokine ligands 2 and 5, chemoattractants involved
with inflammation processes that act through transmembrane G-coupled receptors to signal for
migration of immune cells (Muthumalage & Rahman, 2019). The same study found that CBD
treatment reduced nuclear factor kappa B (NF-κB) transcription factor activity and interleukin-8
(IL-8) concentrations in the LPS stimulated human bronchial epithelial cells and lung fibroblasts.
Additionally, the same study also observed that exposure to CBD aerosols without LPS
stimulation significantly elevated concentrations of IL-1ra and IL-8 from the monocytes, IL-8
from the bronchial epithelial cells, and IL-6 and IL-8 from lung fibroblasts compared to
untreated cells. Taken together, these findings suggest that although CBD has an antiinflammatory effect by mitigating LPS-induced cytokines, CBD may also enhance proinflammatory cytokines.
Other research suggests that CBD may not influence overall measures of systemic
inflammation. A rodent study investigating the effect of 5 mg/kg of i.p. CBD on induced
myocardial ischemia found that CBD-treated mice experienced a decrease in serum IL-6
concentrations, but no differences in serum CRP and TNF-α concentrations compared to controls
(Durst et al., 2007). In this study, researchers demonstrated that CBD treatment 1 hour before
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ischemia and daily for 7 days before sacrifice had in vivo cardioprotective effects associated with
reduced IL-6 concentrations, but no other systemic cytokines were changed (Durst et al., 2007).
Human research suggests that CBD has no effect on systemic inflammatory markers. One study
showed that after 8 weeks of 20 mg of sublingual CBD oil per day, CRP concentrations in
individuals with Crohn’s Disease were unchanged (Naftali et al., 2017) and 13 weeks of 200 mg
of daily oral CBD failed to change concentrations of CRP, TNF-α, and IL-6 in subjects with type
2 diabetes and dyslipidemia (Jadoon et al., 2016). It is important to note the difficulty in
comparing all CBD studies due to differences in CBD dosages, administration routes, durations
of CBD administration, as well as the models used to test the compound. In general, rodent
models utilize intranasal application or i.p. CBD injections ranging from 1 mg/kg/day to 10
mg/kg/day (Barichello et al., 2012; Durst et al., 2007; Esposito et al., 2011; Mori et al., 2017),
and human neurological research uses oral CBD solutions ranging from 50 mg/day to 800
mg/day, depending on the age range and disease type (Carlini & Cunha, 1981; Consroe et al.,
1986; Leweke et al., 2012).
The Influence of Cannabidiol on
Exercise and Physical Activity
Research evaluating the effects of CBD in response to acute and chronic exercise is
currently nonexistent in humans and scarce in animals (Langer et al., 2021). Only one recent
study evaluated the effects of a single dose of CBD (100 mg/kg) 18 hours following an acute
bout of eccentric hindlimb loading in rodents (Langer et al., 2021). When the tibialis anterior
muscle and liver tissues were analyzed, no differences in downstream targets of mechanistic
target of rapamycin 1were found between CBD-treated rats and controls; however,
phosphorylation of NF-κB was significantly lower in CBD-treated rats (Langer et al., 2021). This
suggests that CBD may have no effect on anabolic or catabolic muscle functions. However,
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phosphorylation of NF-κB was higher in the liver of the CBD-treated rats compared to controls
(Langer et al., 2021), suggesting that CBD may be acting in a tissue-dependent manner during
exercise. It is unknown as to whether CBD affects molecular signaling in skeletal muscle during
chronic aerobic and/or resistance training, and if any effect is similar in all skeletal muscle fiber
types.
Despite anecdotal claims made by both recreational and elite athletes, there is no
convincing evidence supporting the use of CBD for performance enhancement. More
specifically, the popular medical belief is that CBD has anti-inflammatory, analgesic, and
anxiolytic effects, neuroprotective benefits, and helps with sleep disturbances, but these
speculations are only substantiated by results from preclinical studies (McCartney et al., 2020).
There is some literature exploring the effects of cannabis on cardiovascular measures, pulmonary
function, grip strength, work capacity, and metabolic rate in healthy individuals (Lisano et al.,
2020, 2019; Renaud & Cormier, 1986; Steadward & Singh, 1975), but these studies do not
separate CBD from cannabis and do not include an exercise component. Additionally, some
suggest that cannabis use may help with chronic pain and exercise recovery, but more human
studies with both a cannabis use group and a CBD-only group are necessary (Gillman et al.,
2015; Kennedy, 2017; Ware et al., 2018).
There was scant human research exploring the effects of CBD on measures of physical
activity including total exercise time and steps per day. One survey on cannabis use before and
after exercise found that 70% of 605 respondents prefer to use cannabis before working out to
make exercise feel more enjoyable, 79% strongly agreed cannabis enhances recovery, and 52%
strongly agreed that cannabis increased their motivation to exercise (YorkWilliams et al., 2019).
Interestingly, bivariate analyses revealed respondents who used cannabis with exercise were
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younger, male, and had lower BMI than those who did not use cannabis with exercise
(YorkWilliams et al., 2019). This survey agrees with others that found that athletes use CBD for
perceived pain and recovery benefits (Kasper et al., 2020; Zeiger et al., 2019). These findings
suggest that perhaps a mixture of CBD and THC induces endorphins, activates opioid receptors,
and alters physical activity behavior; however, very little research has explored these
mechanisms. When cannabis was used in a mouse model to explore wheel-running preference
and running motivation, THC had no effect on exercise motivation (Hurel et al., 2021). There are
no studies using CBD in this model. Consequently, when it comes to the effect of CBD on
physical activity behavior, no conclusive evidence exists.
Cannabidiol and Brain-Derived
Neurotrophic Factor
Much of the evidence exploring the effects of CBD on BDNF has originated in animal
studies aimed at exploring the potential of CBD to provide neuroprotective effects in
neurodegenerative conditions (Barichello et al., 2012; Esposito et al., 2011; Mori et al., 2017). In
a murine model of transient cerebral ischemia, in which carotid arteries were occluded with
clamps for 20 minutes, i.p. CBD (10 mg/kg) 30 minutes before and 3, 24, and 48 hours after
ischemia significantly decreased hippocampal neurodegeneration, which was verified by lowered
expression of apoptotic factors including caspase-9 proteins in hippocampal tissue (Mori et al.,
2017). Additionally, these same CBD-treated mice experienced decreased hippocampal
neuroinflammation and only the CBD-treated mice increased hippocampal BDNF concentrations
compared to the sham and vehicle groups (Mori et al., 2017). In another compelling study, CBD
attenuated neuroinflammation through interaction with the transcription factor peroxisome
proliferator-activated receptor gamma in both an in vitro rodent model of cultured astrocytes and
an in vivo rodent model of Alzheimer’s Disease (Esposito et al., 2011). More specifically,
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astrocytes treated with pathological amyloid beta peptides Aβ1−42 for 24 hours increased
production of IL-1β and TNF-α, but treatment with CBD significantly attenuated cytokine
production in a dose-dependent manner through peroxisome proliferator-activated receptor alpha
and gamma activation and inhibition of NF-κB (Esposito et al., 2011). Hippocampal tissue
collected from amyloid beta peptides Aβ1−42 injected rats showed that 15 days of i.p. CBD (10
mg/kg) inhibited microglial reactivity, maintained neuronal integrity of the CA1 region of the
hippocampus, and stimulated basal neurogenesis compared to the control group (Esposito et al.,
2011). Though BDNF concentrations were not directly measured in this study, the hippocampal
CA1 region is usually included in models of brain plasticity where BDNF/TrkB is observed to
increase neuronal density during periods of growth or cellular survival (Alonso et al., 2004).
The duration of CBD treatment may also play a significant role in the ability of the
compound to alter BDNF. For example, a single dose of i.p. CBD (2.5, 5, and 10 mg/kg) differed
from extended treatments of CBD (2.5, 5, and 10 mg/kg for 9 days) with respect to TNF-α, IL1β, IL-6, and BDNF concentrations in rats subjected to pneumococcal meningitis (Barichello et
al., 2012). Acute treatment of i.p. CBD (2.5, 5, and 10 mg/kg) to rats 6-hours post meningitis
induction showed no significant reduction in TNF-α, IL-1β, and IL-6 response, nor stimulation
of BDNF in the hippocampus and frontal cortex (Barichello et al., 2012). However, extended
treatment reduced TNF-α and increased BDNF concentrations in the frontal cortex, but not in the
hippocampus (Barichello et al., 2012). These results demonstrate that chronic administration of
CBD has the potential to decrease inflammation and increase neuroplasticity in the areas most
affected by the neuroinflammatory disease; however, these responses are time- and dosedependent. Therefore, there is support for the use of CBD as a medical treatment, but
significantly more evidence related to these issues is necessary.
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Sex Differences
Biological sex is an important factor in structural, cellular, and molecular functions that
affect overall health. These differences are linked to sex chromosomes and sex hormones.
Generally, females have two X chromosomes and males have one X chromosome and one Y
chromosome. In mammalian gonadal development, these sex chromosomes cause differentiation
of sex organs. For example, the Sry gene, which is involved in making sex-determining region Y
protein, is only located on the Y chromosome and the protein produced from this gene acts as a
transcription factor in gonadal primordia to develop testes and prevent uterus and fallopian tube
formation in males (Eggers et al., 2014). The differentiation of the testes establishes further
developmental processes including gonadal hormone production of testosterone, estradiol, and
progesterone (Eggers et al., 2014). The sex hormones estrogen and testosterone have permanent
effects on body development such as in the development of the genitals or the brain. Other
actions of these hormones are more temporary and depend on how long testosterone, estradiol, or
progesterone are present (McEwen & Milner, 2017). Both sex chromosomes and sex hormones
act on other organs and tissues and give rise to crucial differences in the structure and function of
bodily systems. For example, the XX chromosome has regional effects on the brain that are
independent of sex hormones, specifically in the growth and formation of the amygdala,
hippocampus, and prefrontal cortex (Lentini et al., 2013). Additionally, higher levels of
testosterone during brain development increase white-matter volume (Perrin et al., 2008).
Sex differences are present in the ECS. In the rodent amygdala, males have greater
concentrations of AEA and 2-AG, and females have greater concentrations of the enzymes
FAAH and MAGL (Krebs-Kraft et al., 2010). The endocannabinoids present in female rodents
also have lower binding affinity for CB1r in the hypothalamus and enhanced binding affinity to
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CB1r in the amygdala compared to males (C. J. N. Riebe et al., 2010). Research suggests that
estrogen interacts with the components of the ECS. Estrogen administration affecting FAAH
concentrations may lead to alterations in regulation of pain, inflammation, obesity, anxiety, and
fear (Calignano et al., 1998; Di Marzo, 2018; Fine & Rosenfeld, 2013; Ligresti et al., 2016;
Ruehle et al., 2012; Schulz et al., 2021). The interaction between estrogen and the ECS may
provide a mechanism for sex-related disparities observed in metabolism and pain perception
reported in men and women (Mogil, 2012; Paller et al., 2009).
Sex Differences in Inflammation
Although there are many potential sex differences with respect to the inflammatory
process, the IL-6 response is one of the most explored. In resting conditions, average IL-6
concentrations are not significantly different between males and females (Edwards et al., 2006;
Lockwood et al., 2016; Prather et al., 2009; Steptoe et al., 2002). However, there are sex
differences in the IL-6 response to injury and stress. For example, male patients with acute
injuries had 122% and 70% higher concentrations of systemic IL-6 concentrations after one day
and two-days post trauma, respectively, compared to females (Mörs et al., 2016). Conversely,
after an acute mental stress test, females had higher IL-6 concentrations compared to males,
independent of age, BMI, and smoking status (Hackett et al., 2012). This study agrees with
others supporting a more drastic and longer duration IL-6 response in females after stressinduced situations when compared to males (Edwards et al., 2006; Lockwood et al., 2016;
Prather et al., 2009; Steptoe et al., 2002).
Sex differences with respect to CRP concentrations are most attributed to differences in
adiposity and BMI (Khera et al., 2009; Rexrode et al., 2003; Thorand et al., 2006). Adipose
tissue is a secretory organ known to contribute to low-grade systemic inflammation (Pedersen &
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Febbraio, 2012). Women generally tend to have greater body fat percentage and fat mass when
compared to men (Lovejoy et al., 2009; Thorand et al., 2006). In individuals (n = 1,413 males;
n=1,166 females) ages 30-65 years old participating in the Dallas Heart study, average resting
CRP concentrations for women and men were 3.6 mg/L and 1.9 mg/L, respectively, and CRP
values were positively correlated to total fat mass in women (Khera et al., 2009). Interestingly,
BMI and body fat percentage are significantly correlated with CRP concentrations in women,
and BMI and waist to hip ratio are significantly and positively correlated to CRP concentrations
in men (Thorand et al., 2006). However, stress-induced inflammatory responses may result in
sex-related differences in CRP concentrations that are independent of body composition
(Lockwood et al., 2016). For instance, after an acute mental stress test, IL-6 responses were
positively correlated with high CRP concentrations in males, and IL-6 responses were negatively
correlated with CRP concentrations in females (Lockwood et al., 2016). This suggests that CRP
may be an indicator of current inflammatory status and the relationship between acute and
chronic inflammation may be related to biological sex.
Sex Differences in Brain-Derived
Neurotrophic Factor
Biological sex is also a major determinant of cortical and serum BDNF concentrations
(Bus et al., 2011). Both clinical and preclinical studies suggest that the highest concentrations of
BDNF are found in the neurons of the hippocampus, amygdala, cerebellum, and cerebral cortex
(Hofer et al., 1990; Timmusk et al., 1993). Structural magnetic resonance imaging (MRI) studies
demonstrate sex-related differences in both volume and tissue density of the amygdala and
hippocampus (Kaczkurkin et al., 2019). These areas are implicated in emotional processing and
cognitive function and have high concentrations of cannabinoid receptors (Ativie et al., 2018;
Chiarlone et al., 2014; Navarrete et al., 2020). It is possible that BDNF concentrations may differ

35
in each brain structure according to sex, and that these differences may affect emotion and
cognition. This regional difference hypothesis is clinically supported by sex-related disparities in
the occurrence and diagnoses of neuropsychiatric disorders. Females are 1.5-2 times more likely
to experience mood and anxiety disorders (McLean et al., 2011), and males are 4 times more
likely to be diagnosed with schizophrenia and autism (Lenz & McCarthy, 2015). Low
concentrations of BDNF are observed in patients with major depressive disorder and
schizophrenia (Kang et al., 2015; Lang et al., 2004; Shoval & Weizman, 2005; Szuhany & Otto,
2020) which suggests BDNF may have a crucial role in mood and anxiety disorders.
Literature demonstrates that estrogen and testosterone affect brain structure and function
and interact with BDNF in the CNS (Lentini et al., 2013; Lenz & Nelson, 2018; McEwen &
Milner, 2017; Scharfman & MacLusky, 2006; Sohrabji & Lewis, 2006). Animal research on the
effect of estrogen on neurons, glial cells, and hippocampal tissue shows that both estrogen and
BDNF share common cellular targets and signaling pathways (Scharfman & MacLusky, 2006;
Toran-Allerand, 2004; Warren et al., 1995). These cellular targets are located in the cerebral
cortex, basal forebrain, hippocampus, and striatum, and involve the mitogen-activated protein
kinase, PI3K, and phospholipase C pathways (Scharfman & MacLusky, 2006; Toran-Allerand,
2004; Warren et al., 1995). One study showed that when exogenous estrogen (10 µg of 17βestradiol) was administered for 2 weeks to ovariectomized female rodents after artery occlusion
to induce stroke-like symptoms, estrogen treatment resulted in increased hippocampal BDNF
protein expression and reductions in depression-like symptoms (Su et al., 2016). In
ovariectomized, young and middle-aged, female mice, estrogen (5 µg of 17β-estradiol) dorsally
infused into the hippocampus decreased levels of histone deacetylases, increased BDNF protein,
and increased the acetylation of BDNF gene promotors (Fortress et al., 2014). These results
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suggest that estrogen has epigenetic effects on BDNF production. However, increased
concentrations of estrogen can also affect BDNF regulation of synaptic transmission resulting in
altered nerve terminal excitability which may increase seizure risk (Scharfman et al., 1999).
Testosterone is reported to have similar effects on neurogenesis, BDNF concentrations,
and interactions with BDNF. For example, testosterone (2 mg/kg/day) treatment for 10 days after
cerebral ischemia in castrated male rats increased serum and brain tissue (striatum, cortex and
subventricular zone) BDNF concentrations (Fanaei et al., 2014; Yang & Arnold, 2000), and
testosterone and BDNF (75 µL) treatment after axotomy in castrated male rats restored androgen
receptor expression (Yang & Arnold, 2000). These studies suggest that BDNF and testosterone
are interdependent. Overall, estrogen and testosterone contribute to sexual dimorphism in
specific brain structures and interact with BDNF which suggests males and females experience
differences in information processing, memory, cognitive function, emotion and mood, and
behavior.
There is also evidence that stress may mediate an interaction between BDNF and
inflammatory cytokines in a sex-dependent manner. For instance, an animal model of depression
(exposure to 4 weeks of chronic, unpredictable mild stress) revealed sex-related differences in
neuroinflammatory response (L. L. Liu et al., 2019). More specifically, female mice experienced
a significant decrease in hippocampal BDNF mRNA expression and a significant increase in
TNF-α mRNA expression compared to males. This decrease in BDNF was also positively
corelated with depressive-like behaviors. Although both sexes experienced no differences in IL-6
mRNA expression, there was a significant interaction between stress and biological sex on IL-6,
indicating that female mice were more sensitive to stress than males (L. L. Liu et al., 2019).
Along these same lines, BDNF-knockout females were more sensitive to anxiety and depression-
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like behavior after 52 days of mild stress when compared to wild type females (Autry et al.,
2009). In the same study, no significant difference in behavior was observed between BDNFknockout males and wild type males. Interestingly, this study also found that stress did not
further reduce hippocampal BDNF concentrations in knockout mice (Autry et al., 2009),
suggesting that some reduction in BDNF affects depression-related behaviors in females more
than males.
In humans, the relationship between BDNF concentrations and biomarkers of
inflammation is unclear. Resting, serum BDNF and inflammatory biomarker concentrations are
reported to be similar in men and women in good health (Lang et al., 2004; Ziegenhorn et al.,
2007). In patients with MS, biological sex does not contribute to differences in serum BDNF, IL6, or TNF-α concentrations compared with healthy controls (Patanella et al., 2010). However, in
adolescents with bipolar disorder, females had 8% higher BDNF and 44% higher CRP
concentrations compared to males, and no sex-related differences in IL-6 concentrations
(Goldstein et al., 2011). Taken together, animal and human research suggests that, in times of
chronic stress, females experience declines in BDNF, which may in turn, translate to a greater
vulnerability to higher inflammation, depression, and anxiety-related behaviors than males.
Sex Differences in Response to
Exercise
Sex differences in the inflammatory response following acute and chronic exercise have
been demonstrated in animal and human models. Mouse models of eccentric exercise show that
females have less myofiber swelling, necrosis, and structural protein disruption compared with
males (Komulainen et al., 1999) and less monocyte, macrophage, and neutrophil invasion into
myofibers than males (St. Pierre Schneider et al., 1999). Sex-related differences in the
inflammatory response and degree of muscle damage are also observed in humans. For example,
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women had less leukocyte invasion into vastus lateralis myofibers compared to men after 3 sets
of eccentric unilateral leg press and extension exercises performed at 120% of concentric one
repetition maximum, and men had significantly higher plasma granulocyte counts and B-cell
lymphoma positive inflammatory cells than women at the 48-hour time point (Stupka et al.,
2000). In a separate study, young girls experienced significant increases in leukocyte and
lymphocyte invasion, as well as increases in IL-6 concentrations after 60 minutes of cycling at
70% maximal oxygen uptake (V̇O2 max) compared to young boys of the same age (Timmons,
Tarnopolsky, et al., 2006).
Research suggests that menstrual phase and contraceptive use may alter the female
response to exercise. One study showed that women in the follicular and luteal phases taking oral
contraceptives experienced fluctuations in leukocytes, neutrophils, and monocyte invasion after
prolonged cycling and had 80% greater concentrations of IL-6 compared to women in the
follicular phase without oral contraceptives (Timmons, Hamadeh, et al., 2005). In a similar study
evaluating the influence of sex, age, and puberty on lymphocytes after 60 minutes of acute
cycling, lymphocyte counts were greater in older men and women compared to younger boys
and girls and 35% higher in prepubertal girls compared to prepubertal boys (Timmons,
Tarnopolsky, et al., 2006).
In contrast, several studies suggest that the inflammatory response to chronic exercise
and training is similar in men and women (Abd El-Kader & Al-Jiffri, 2019; Abd El-Kader & AlShreef, 2018; Beavers et al., 2010). After 12 months of moderate intensity exercise, IL-6, IL-8,
and tumor necrosis factor receptor 1 concentrations were significantly decreased compared to a
non-exercise control group and no differences were observed between men and women (Beavers
et al., 2010). Although CRP concentrations had decreased at the 12-month time point, this
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change failed to reach significance (Beavers et al., 2010). A similar response was observed after
6 months of structured aerobic and resistance training in elderly adults, in which average TNF-α
and IL-6 concentrations, and CD3, CD4, and CD8 cell counts decreased with no sex-related
differences (Abd El-Kader & Al-Jiffri, 2019; Abd El-Kader & Al-Shreef, 2018).
Proposed explanations for sex differences in the inflammatory response to acute exercise
compared with chronic exercise may be linked to estrogen concentrations. Although some
animal studies demonstrate that 17β-estradiol may help to alleviate muscle damage from exercise
by influencing satellite cell activation and myoblast formation (Enns & Tiidus, 2008, 2010), this
proposed explanation is not clear in human studies using exogenous estrogen treatment in
healthy young men (MacNeil et al., 2011; Timmons, Hamadeh, & Tarnopolsky, 2006) . One
study found that after 17β-estradiol treatment (1 mg for 2 days followed by 2 mg for 8 days)
following a max eccentric exercise protocol (15 sets of 10 repetitions of leg extension and
flexion), participants experienced attenuated neutrophil infiltration into rectus femoris myofibers
and no changes in macrophage infiltration (MacNeil et al., 2011). However, another study found
no changes in circulating neutrophil counts after 17β-estradiol treatment (2 mg/day for 8 days)
following 90 minutes of cycling at 65% V̇O2 max (Timmons, Hamadeh & Tarnopolsky, 2006).
Taken together, these studies suggest that there may be other mechanisms beyond estrogen
signaling that contribute to sex differences in exercise-induced inflammation.
Sex Differences in Response to
Physical Activity
Although research suggests a strong, negative correlation between physical activity and
the incidence of chronic inflammation in both men and women, correlations with respect to sexrelated differences in circulating inflammatory biomarkers are inconclusive (Pischon et al., 2003;
Reuben et al., 2003; Taaffe et al., 2000). Healthy individuals (n = 405 males; n = 454 females)
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ages 25-75 years old who reported more vigorous physical activity such as running, playing
tennis, and calisthenics, appear to have a strong, negative correlation between energy
expenditure from leisure-time physical activity, expressed as metabolic equivalent hours
(METs), and plasma concentrations of tumor necrosis factor rector 1, soluble tumor necrosis
factor receptor 2, IL-6, and CRP (Pischon et al., 2003). When adjusted for sex, women had
significantly higher concentrations of tumor necrosis factor receptors than men, but there were
no differences with respect to concentrations of IL-6 and CRP (Pischon et al., 2003). In older
individuals (n = 412 males; n = 468 females) ages 70-79 years, physical activity, measured in
hours of moderate and strenuous activity per year, was significantly correlated with lower
concentrations of IL-6 and CRP (Taaffe et al., 2000). Sex-adjusted IL-6 concentrations were also
significantly higher in men; however, no differences were found in concentrations of CRP
(Taaffe et al., 2000).
Other large population studies consisting of older men and women also support the
correlation between physical activity and lower concentrations of IL-6 and CRP, but these
studies do not adjust for sex nor use accelerometers to measure average daily step counts
(Colbert et al., 2004; Reuben et al., 2003). A cross-sectional study that measured physical
activity using daily step counts in healthy individuals (n = 737 males; n = 1,101 females) ages
40-69 years old found that higher step counts were significantly correlated with lower circulating
TNF-α concentration (Nishida et al., 2014). In the same study, men reported more moderate and
vigorous intensity physical activity than women and also had greater IL-8 and TNF-α
concentrations than women (Nishida et al., 2014). Though these studies provide evidence for the
beneficial effect of physical activity on markers of chronic inflammation, they do not provide
definitive evidence that benefits are equal in men and women.
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Sex Differences in Cannabidiol
Use and Response
Both survey and observational studies suggest that CBD use differs between males and
females. In fact, most CBD users in both recreational and medicinal cannabis communities
identify as women (BrightfieldGroup, 2017). An industry report of Americans (N = 2,400) that
use cannabis revealed that 58% of CBD-only users were female and 59% of hemp-derived CBD
users were female (BrightfieldGroup, 2017). The largest age group of CBD users were between
35-49 years old (33%) and the second largest age group of CBD users were between 26-34 years
old (25%; BrightfieldGroup, 2017). When both sexes were combined, 80% of CBD-only users
preferred vaping and 41% used CBD daily (BrightfieldGroup, 2017). These findings are similar
to a more recently published survey with CBD-only users (n = 1,013 males; n = 1,087 females)
which found that more females (67%, n = 729) used CBD for medical conditions compared to
males (55%, n = 559), and that both sexes used CBD to help improve general health and
wellbeing (Corroon & Phillips, 2018). Interestingly, the most reported medical condition
associated with CBD use was chronic pain, but both reports did not stratify pain condition by sex
(BrightfieldGroup, 2017). These data suggest that CBD is used as an alternative medicine for
pain by both sexes with women using it more frequently.
Animal models designed to explore sex differences in CBD responses, have yielded
mixed results. Sex-related differences are present in rodent models after administering CBD for
pain (Linher-Melville et al., 2020) and models of neuropsychiatric disorders (Osborne, Solowij,
Babic, et al., 2017; Osborne et al., 2019; Shbiro et al., 2019). Rodents exposed to peripheral
nerve constriction injury benefited from i.p. CBD (25 mg/ml) treatment for 14 days after the
injury which resulted in sex-related differences in pain perception 7 weeks following CBD
treatment (Linher-Melville et al., 2020). More specifically, males experienced an alleviation of
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mechanical hypersensitivity, but females were more hypersensitive and responded faster to
mechanical pain on weeks 4, 5, and 6 post-treatment (Linher-Melville et al., 2020). In a rodent
model of schizophrenia, i.p. CBD (20 mg/kg/day) treatment for 3 weeks resulted in
improvements in working memory and social interaction of male rats (Osborne, Solowij, Babic,
et al., 2017), and only working memory in female rats (Osborne et al., 2019). Other rodent
experiments found no sex-related differences when CBD was administered for pain (Britch et al.,
2020, 2017; Javadi-Paydar et al., 2018), leading researchers to hypothesize that small doses of
THC may be needed in conjunction with CBD to have pain relieving effects. On the contrary,
one recent rodent study that administered CBD and THC separately and combined found no sex
differences in measures of pain and only the THC-treated rodents experienced an antinociceptive
response (Britch et al., 2017). Very little progress has been made with respect to translating these
studies to humans. In fact, there is a significant gap in the research related to the actions of CBD
in men versus women. It is also necessary to recognize the importance of research related to the
action of CBD in individuals who express different gender identities such as those who identify
as transgender and/or transitioning as these groups may include a higher percentage of cannabis
users (Hughto et al., 2021).
Although men and women tend to use CBD for the same reasons, there is lack of clarity
with respect to potential sex-related differences in how CBD acts once inside the body. In fact,
there are currently no studies investigating whether biological sex plays a role in mediating
CBD-induced physiological responses. Just recently, the FDA Office of Women’s Health virtual
scientific conference “CBD & Other Cannabinoids, Sex and Gender Differences in Use and
Responses” held November 19, 2020, from 9:00 a.m. to 4:00 p.m. Eastern Time, provided a
platform for multiple perspectives on the issue (Food and Drug Administration, 2020). The
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speakers and public officials represented various scientific fields including neuroscience,
psychology, environmental health sciences, behavioral pharmacology, human behavior,
biobehavioral sciences, pediatric and maternal health, cell biology, physiology, gynecology,
reproductive sciences, and complementary and integrative health. Although informative, no firm
conclusions regarding the efficacy and safety of CBD in humans without preexisting conditions
and neurological disorders could be determined. Consequently, the FDA is now supporting
further sex-related studies in healthy populations and agrees that more research is required to
determine the potential benefits and risks of CBD use by both men and women.
Cognitive Health
Cognitive health is defined as the ability of an individual to perform mental processes
such as memory, recall, judgement, and the ability to learn new things, and is inferred from
behavior and response to cognitive assessments (Robbins, 2011). An assessment of cognitive
health is frequently used as a measure of brain function in a wide variety of human populations.
Cognitive neuroscience research has established frameworks and approaches to measure and
compare cognition in different contexts including social and affective factors, disease states, and
neural development (Greenwald et al., 1998; Robbins, 2011). In healthy individuals, cognitive
function and ability are commonly inferred by responses to a neuropsychological battery of tests
consisting of questions and tasks designed to gauge memory, recall, judgement, and the ability to
learn new things (Borson et al., 2003; McDowell et al., 1997; Nasreddine et al., 2005). Cognitive
impairment, which is defined as difficulty in remembering, learning new things, and
concentrating is often included as a major outcome in cancer (Wefel et al., 2011), alcohol and
substance abuse (Evert & Oscar-Berman, 1995), and mental health research (Stetz et al., 2007).
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Cannabidiol and Cognitive Function
There is a plethora of animal research that demonstrates that CBD administration
improves measures of cognitive impairment and mental health (Barichello et al., 2012; Campos
et al., 2015; Mori et al., 2017; Osborne, Solowij, Babic, et al., 2017; Sales et al., 2020; Schiavon
et al., 2016). Animal research shows i.p. CBD (10 mg/kg) treatment before and after cerebral
ischemia result in less anxiety-like behavior in an open field test, improved memory and ability
to recognize patterns from the spatial recognition test, and more exploration of new surroundings
in mice (Mori et al., 2017), and 9 days i.p. CBD (10 mg/kg) treatment after inoculation with
meningitis improves information retention and recall in a memory test in rodents (Barichello et
al., 2012). Additionally, a rodent poly I:C model demonstrated that 3 weeks of i.p. CBD (20
mg/kg) treatment resulted in improved learning and memory (Osborne, Solowij, Babic, et al.,
2017), and CBD-treated rats scored higher in the novel object recognition test and rewarded
maze test compared to non-CBD treated rats (Osborne, Solowij, Babic, et al., 2017).
Cannabidiol may also be helpful in attenuating the side effects of other drugs. For
example, 3 days of i.p. CBD (30 mg/kg) treatment along with the anti-malaria drug Artesunate in
mice with cerebral malaria improved scores from the novel object recognition test, the elevated
maze, and the water maze hidden platform test compared to Artesunate-only controls (Campos et
al., 2015). This same study also found that CBD combined with Artesunate increased BDNF
expression in the prefrontal cortex and decreased IL-6 and TNF-α concentrations in the
hippocampus compared to the Artesunate-only and saline control groups (Campos et al., 2015).
These findings suggest that CBD has a neuroprotective effect against cognitive impairment.
Although the effects of CBD on cognitive function are also reported in both clinical and
non-clinical human populations, results are inconclusive. Clinical studies on patients with
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schizophrenia suggest that CBD may affect cognitive function (Bhattacharyya et al., 2018;
Boggs et al., 2018; McGuire et al., 2018; Osborne, Solowij, & Weston-Green, 2017). A 6-week
adjunctive intervention with an oral solution of CBD (1000 mg/day) in patients with
schizophrenia significantly improved scores on the Brief Assessment of Cognition in
Schizophrenia test compared to the placebo group (McGuire et al., 2018). However, a similar
study that administered oral CBD (600 mg/day) to patients with schizophrenia for 6 weeks found
no significant changes in the Brief Assessment of Cognition in Schizophrenia test, verbal and
visual learning tasks, and working memory tests (Boggs et al., 2018). When a single dose of
CBD (300 and 600mg) was provided acutely in patients with schizophrenia, dosages failed to
alter attention task performance (Hallak et al., 2010). These findings are in agreement with
previous research that also found no changes in cognitive function after 4 weeks of CBD (150
mg/day) treatment in patients with Parkinson’s Disease (Zuardi et al., 2009).
In individuals without disorders, research suggests that CBD may have protective effects
against induced psychosis (Bhattacharyya et al., 2010; Bloomfield et al., 2020) and anxiety
(Crippa et al., 2004). An MRI study in healthy men given both THC and CBD found that a single
dose of oral CBD (600 mg) attenuated THC-induced psychosis and retained cognitive function
(Bhattacharyya et al., 2010). The same study also observed increased blood flow to the prefrontal
cortex, amygdala, and hippocampus during verbal memory and response inhibition tasks
(Bhattacharyya et al., 2010). Another study supports the findings related to CBD-induced
changes in blood flow in healthy individuals (Bloomfield et al., 2020). In this study, a single
dose of oral CBD (600 mg) significantly increased cerebral blood flow to the hippocampus, but
there were no differences in memory tasks between CBD and placebo groups (Bloomfield et al.,
2020). Other neuroimaging studies provide evidence that acute oral CBD (400 mg)
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administration increases cerebral blood flow specifically in the amygdala, hippocampus, and
posterior cingulate gyrus of healthy men (Crippa et al., 2004). Although these studies suggest
that CBD confers neuroprotective effects, more studies are needed to provide a consensus on the
action of CBD in healthy individuals.
Cannabidiol, Cognitive Function,
and Sex Differences
Animal literature suggests that there are sex differences in response to CBD with respect
to cognitive function and behavior (Jimenez Naranjo et al., 2019; Osborne, Solowij, Babic, et al.,
2017; Osborne et al., 2019; Osborne, Solowij, & Weston-Green, 2017). In the aforementioned
male poly I:C rat model that demonstrated CBD-treated males improved cognitive function by
scoring higher in cognitive and behavioral tests compared to non-CBD treated males (Osborne,
Solowij, Babic, et al., 2017), a second follow-up study by the same authors using females found
that females exhibited deficits in recognition memory and social interaction, but not working
memory (Osborne et al., 2019). Additionally, only recognition memory and social interaction
were improved by CBD treatment in females (Osborne et al., 2019). In a third follow-up study
by the same authors, analyses between males and females revealed that concentrations and
densities of neuronal markers acetylcholine esterase and choline acetyltransferase were
significantly correlated with the rewarded maze performance scores in CBD-treated females, and
concentrations of choline acetyltransferase were significantly correlated with maze test
performance scores in CBD-treated males (Jimenez Naranjo et al., 2019).
In human studies, cannabis research shows sex differences in response to cannabis use on
cognitive function (Crane, Schuster, Fusar-Poli, et al., 2013; Crane, Schuster, & Gonzalez, 2013;
Crane et al., 2015; Matheson et al., 2020), but very few have evaluated sex differences in
response to CBD (Schoedel et al., 2018; Spindle et al., 2020). A within-subjects crossover design
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evaluating the pharmacokinetics of acute oral and vaporized CBD (100 mg) found that men
performed worse on cognitive tasks than women after both oral and vaporized CBD were
consumed (Spindle et al., 2020). Although participants (n = 9 males; n = 9 females) were
healthy, there were no sex differences in cognitive task performance (Spindle et al., 2020). This
response is similar to another crossover, phase 1, single-dose study designed to assess the
therapeutic dose and abuse potential of highly purified oral CBD (Epidiolex, 750 mg, 1500 mg,
and 4500 mg) (Schoedel et al., 2018). No differences in cognitive and psychomotor tasks were
observed in healthy men and women regardless of CBD dose (Schoedel et al., 2018). When CBD
use was analyzed with sex as a covariate, there were significant differences in verbal learning
test scores between men and women; however, the specific dose of CBD and degree of
difference were not reported (Schoedel et al., 2018). Although other pharmacokinetic research
investigating the safety and tolerability of acute doses of CBD includes even numbers of men
and women, they do not report sex-related analyses of CBD on cognitive function (Arndt & de
Wit, 2017; Babalonis et al., 2017; Haney et al., 2016). Taken together, schizophrenia rodent
models (poly I:C) suggest that CBD affects regions of the brain related to memory and learning,
and these effects are influenced by sex. In humans, it is possible that healthy men and women
may also experience changes in cognitive function after acute CBD administration though it is
difficult to draw conclusions from the studies currently available. There are currently no
longitudinal studies which explore the potential for biological sex to play a role in mediating the
physiological and psychological responses to CBD.
Conclusions
Decades of research have focused on exploring the physiological and psychological
effects of CBD in animal models and human populations. Animal studies suggest that there are
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sex differences in inflammatory and behavioral responses to CBD, but these studies are focused
on neurological models of depression (Sales et al., 2019; Shbiro et al., 2019), schizophrenia
(Osborne, Solowij, Babic, et al., 2017; Osborne et al., 2019; Osborne, Solowij, & Weston-Green,
2017), and acute injury (Linher-Melville et al., 2020). A few human studies have come close to
establishing a relationship between CBD and health (Arndt & de Wit, 2017; Babalonis et al.,
2017; Bhattacharyya et al., 2010; Carlini & Cunha, 1981; Consroe et al., 1986; Crane, Schuter, &
Conzalez, 2013; Cuñetti et al., 2018; Haney et al., 2016; Laczkovics et al., 2020; Leweke et al.,
2012; Lisano et al., 2020; Martin-Santos et al., 2012; McGuire et al., 2018; Schräder et al., 2019;
Solowij et al., 2018). However, these studies exclude females (Bhattacharyya et al., 2010; Crane,
Schuster, & Gonzalez, 2013; Martin-Santos et al., 2012; Solowij et al., 2018), THC-free CBD
(Crane, Schuster, & Gonzalez, 2013; Lisano et al., 2020; Solowij et al., 2018), do not analyze
data by sex (Arndt & de Wit, 2017; Babalonis et al., 2017; Haney et al., 2016), and do not focus
on the effects of CBD in healthy individuals (Carlini & Cunha, 1981; Consroe et al., 1986;
Laczkovics et al., 2020; Leweke et al., 2012). Currently, there are no studies investigating the
mechanisms associated with potential sex-related physiological responses to CBD in healthy
individuals. There is no literature exploring the potential relationship as it relates to the
inflammatory biomarkers IL-6 and CRP, as well as the neural health biomarker BDNF.
Furthermore, these responses have not been linked to cognitive function and psychological
wellbeing (PWB) in healthy and physically active adults. There are 295 CBD trials in the
recruiting phase on clinicaltrials.gov to date where CBD is being used for various conditions
including coronavirus, alcohol and substance use disorders, chronic pain, inflammatory bowel
disorders and Crohn’s Disease, and various neuropsychiatric and neurological disorders. Only 31
related clinicaltrials.gov studies using CBD are recruiting healthy participants. They are focused
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on determining drug interactions, pharmacokinetics, bioavailability, safety, and tolerability of
CBD, as well as potential CBD-induced changes in autonomic, emotional, and cognitive
function.
Although these findings are fascinating, the relationships among CBD inflammatory
cytokines, BDNF, and cognitive function are still not clearly understood in healthy humans and
non-stressed animal models. There is a great need for understanding the safety and efficacy of
daily CBD treatment in healthy males and females who are not diagnosed with neuropsychiatric
conditions. Research matching CBD use patterns is needed because observational and
prospective studies suggest that females tend to use hemp-derived and highly purified CBD more
than males (BrightfieldGroup, 2017; Corroon & Phillips, 2018). Consequently, these findings
suggest that healthy physically active males and females may differ in response to CBD which
may affect concentrations of IL-6, CRP, and BDNF, and subsequent cognitive function and
PWB.
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CHAPTER III
METHODOLOGY
Participants
The purpose of this double blind, placebo-controlled, clinical trial with parallel group
design was to investigate the biological sex-related differences in physical activity patterns,
health-related fitness, mental and cognitive health before and after an 8-week cannabidiol (CBD)
intervention. This study also aimed to explore whether 8 weeks of CBD treatment would
significantly alter biomarkers of inflammation and neural health.
Adult males and females were recruited into two groups, a CBD intervention group (CG)
and a placebo group (PG) through flyers and word of mouth at the University of Northern
Colorado and nearby communities. Individuals met eligibility requirements including an age
range of 18 to 50 years, 6 weeks of abstinence from cannabis (either tetrahydrocannabinol (THC)
and/or CBD), a body mass index (BMI) of ≤ 29.9 kg/m2, and additional inclusion criteria
requirements outlined in Table 1. Eligible participants were also free from significant
cardiovascular disorders, neurological and severe mood and anxiety disorders, chronic alcohol
and/or drug use, and no head trauma with loss of consciousness for more than 30 minutes.
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Table 1
Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

18-50 years old
BMI ≤ 29.9 kg/m2.

Significant cardiovascular disorders including but not
limited to serious arrythmias, cardiomyopathy,
congestive heart failure, stroke, or transient ischemic
attacks, peripheral vascular disease with intermittent
claudication, acute, chronic, or recurrent
thrombophlebitis.

Abstained from THC and/or CBD
for 6 weeks.

Diagnosed neurological disorders including but not
limited to brain tumors, brain injuries, Alzheimer’s
Disease, Parkinson’s Disease, multiple sclerosis,
epilepsy, and seizures.

Able and willing to commit to an
8-week intervention schedule.

Regular use of drugs that significantly alter brain
activity such as selective serotonin reuptake inhibitors,
benzodiazepines, and others used to treat anxiety,
panic, stress, sleep disorders, or increases the risk of
sedation and drowsiness.

Note. BMI = body mass index, THC = delta-9-tetrahydrocannabinol, CBD = cannabidiol.

Study Overview
Participants completed a total of 8 visits consisting of 4 pre- and 4 post-intervention visits
separated by an 8-week intervention period (Figure 1). During the first pre-intervention visit,
participants were asked to review and sign the informed consent form approved by the
University of Northern Colorado Institution Review Board. Participants reviewed the risks and
benefits of participation as described on the form, and a copy was provided for them to keep.
Participants were given an activity tracker (Fitbit, San Francisco, CA) to wear for 7 days before
the 8-week intervention. Then, they completed an 8-hr fasted blood draw, cognitive function and
psychological wellbeing (PWB) scales, and body size and composition assessments. During the
pre-intervention Visits 2-4, participants completed a cardiorespiratory fitness assessment
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measuring their relative peak oxygen uptake assessment (V̇O2 peak), the Wingate anaerobic
fitness assessment measuring their anaerobic power outputs including peak power (PP), mean
power (MP), relative peak power (RPP), relative mean power (RMP), and anaerobic fatigue
(AF), and a muscular strength assessment measuring their bench press one repetition maximum
(BP 1RM) and back squat one repetition maximum (BS 1RM). During the 8-wk intervention,
participants received two, 7-day pill boxes with each slot containing either one liquid gel of 50
mg of purified, hemp-derived CBD (Six Degrees Wellness, Boulder, CO), to consume per day,
or one capsule of 225 mg of medium-chain triglyceride (MCT; Nutiva, Point Richmond, CA) as
a calorie-matched placebo. Participants were instructed to consume the one capsule of either the
CBD or the MCT nightly, after dinner and before bed. Participants were asked to meet every 2
weeks with the investigator to refill the pill boxes, report any sickness and/or injury, and to
report any changes in exercise routine. During week 7, participants were asked to wear their
activity trackers for one final week. They then completed post-intervention Visits 5-8 consisting
of the same measures as the pre-intervention visits. Study participants were not offered monetary
compensation for their time and effort.
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Figure 1
Study Overview
PreIntervention
Measures

Recruitment

Pre-Intervention Measures
Week 00, Visit 1
1. Consent form, Fasted blood
draw, Surveys, Body size and
composition assessments, and
Fitbit Assignment
Week 0, Visits 2-4
2. V̇O2 peak assessment
3. Anaerobic fitness assessment
4. 1RM assessment

PostIntervention
Measures

8-week
Intervention

8-week Intervention
Weeks 1-7
• Weekly pill box refills
• Weekly sickness and injury,
and physical activity reports
• Week 7: Fitbit Assignment

Post-Intervention Measures
Week 8
Visits 5-8
5. Fasted blood draw, Surveys,
and Body size and
composition assessments
6. V̇O2 peak assessment
7. Anaerobic fitness assessment
8. 1RM assessment

Note. V̇O2 = oxygen uptake; 1RM = one repetition maximum.

Visit 1 and Visit 5: Informed Consent, Blood Draw,
Body Size and Composition Assessment, Surveys,
and Physical Activity Measures
Blood Samples
After participants reviewed and signed the informed consent form in Visit 1, an 8-hr
fasted blood sample was collected, and again at the beginning of Visit 5. Blood was collected
into serum separator tubes (SST; Beckton Dickinson, East Rutherford, NJ, USA) by a certified
phlebotomist through venipuncture of the antecubital vein of the forearm. Prior to blood
collection in Visit 1, participants were asked to record their diets for the previous 24 hours and
were asked to follow the same diet prior to the post-intervention Visit 5 blood sample. Whole
blood collected in the SST tubes were positioned vertically in a tube rack and allowed to clot for
at least 30 minutes and no more than 1 hour at room temperature. The SST tube was centrifuged
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at 2000 g for 15 minutes at room temperature and serum was pipetted into 1.5 mL Eppendorf
tubes (Eppendorf AG, Hamburg, Germany) and immediately stored in a -80°C freezer.
Serum concentrations of the inflammatory biomarker C-reactive protein (CRP) and
peripheral concentrations of serum brain-derived neurotrophic factor (BDNF) were determined
with commercially available enzyme-linked immunosorbent assay kits (ELISA; CRP, (ALPCO
Diagnostics, Salem, NH, USA); BDNF (RayBiotech, Norcross, GA, USA)) for each respective
biomarker. Manufacturer inter- and intra-assay coefficient of variabilities (CV) for serum
concentrations of CRP were <6.7% and <9.9%, respectively, and for serum concentrations of
BDNF were < 12% and <10%, respectively. These CVs were used to compare precision and
repeatability of immunoassay test results. Microplates were read with a ELx800 BioTek
microplate reader at the recommended wavelength of 450 nm (BioTek Instruments, Inc.,
Winooski, VT, USA).
Body Size and Composition Analysis
Participants were instructed to remove their shoes, socks, and excess clothing during
height and weight measurements. Height was measured using a stadiometer (SECA 220, Chino,
CA, USA) and weight was measured using a digital scale (Detecto, Webb City, MO, USA).
Height, body mass (BM), lean body mass (LBM) and body fat percentage (BF%), were
evaluated with air displacement plethysmography using a calibrated BodPod and predicted
thoracic gas volumes (Cosmed Inc., Concord, CA, USA; Dempster & Aitkens, 1995).
Cognitive Function Scale
Subjective cognitive function was evaluated by using the National Institute of Health
Patient-Reported Outcomes Measurement Information System (NIH PROMIS) Cognitive
Function–Abilities–Short Form 8a. The 8-item survey indicated perceived level of functional
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ability regarding concentration and memory (Valentine et al., 2019). Objective cognitive
function was measured with the NIH PROMIS Cognitive Function–Short Form 8a, and assessed
mental acuity, concentration, memory, and attention in 8 items (Valentine et al., 2019). Raw
scores from both short forms were reported as T scores using the NIH PROMIS grading tool
(Rothrock et al., 2020).
Psychological Wellbeing Scale
The psychological wellbeing (PWB) scale, also known as the Mental Health ContinuumShort Form (Jovanović, 2015), is an 18-item, 6-minute scale that measures six aspects of
wellbeing and happiness: autonomy, environmental mastery, personal growth, positive relation
with others, purpose in life, and self-acceptance (Ryff & Keyes, 1995). Participants rated how
strongly they agreed or disagreed with each subscale on a 7-point Likert scale, and scores were
determined by summing all items with each subscale. Higher scores indicated greater wellbeing.
Pre- and Post-Intervention Physical
Activity
Participants were given an activity tracker (Fitbit Inspire Heart Rate Fitness Tracker,
Fitbit, San Francisco, CA) to wear on their non-dominant wrist with notifications to move
purposefully turned off, and black tape covering the face of the tracker. Participants were
instructed to wear the tracker at all hours during the pre-intervention week (identified as Week
00 in Figure 1), and during week 7 of the 8-week intervention (Week 7 in Figure 1) to capture
the potential effects of supplement consumption on physical activity measures. To offer an indepth examination of physical activity and movement behavior, average daily steps and average
distance traveled were recorded from the activity tracker. In both activity tracking time periods,
subjects were asked to maintain their normal exercise routines.
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Visit 2 and Visit 6: Cardiorespiratory Fitness Testing
To ensure participants were well hydrated prior to the cardiorespiratory fitness test,
hydration was assessed with a urine specific gravity refractometer (Atago, Tokyo, Japan). If the
urine sample had a urine specific gravity ≥ 1.020 mg/dL, participants were instructed to drink
water and retest. If participants remained dehydrated, cardiorespiratory fitness testing was
rescheduled.
Peak oxygen uptake (V̇O2 peak) was evaluated with a customized protocol using the
Parvomedics TrueOne metabolic cart (Parvomedics, Sandy, UT, USA). The assessment was
performed on a treadmill (Trackmaster, Full Vision Inc., Newton, KS, USA) with participants
wearing a heart rate monitor (Polar Electro Inc., Bethpage, NY, USA) and fitted gas collection
mask connected to the metabolic cart. Participants completed a customized protocol based on the
directives provided by the American College of Sports Medicine Guidelines (ACSM) for
multistage exercise testing including an initial warm-up period at low workload followed by
progressive graded exercise with increasing loads, and with 2-minute stages (Pescatello et al.,
2014). A customized protocol was chosen due to the large increments in workload (treadmill
incline) between stages in the standard Bruce protocol. The customized protocol for testing V̇O2
peak was selected based of the modified Åstrand test, which compares favorably to the Bruce,
Balke, and Ellestad protocols (Beltz et al., 2016; Pollock et al., 1976). The protocol consists of a
5-minute warmup at 3.5 mph with 0% incline, a 2-minute self-selected pace for a 5 km run at 0%
incline, and 2-minute stages consisting of variations in treadmill speed and incline until
volitional fatigue has been reached (Table 2). Heart rate, blood pressure, blood lactate, and rate
of perceived exertion were measured at the end of each 2-minute stage (Borg, 1982).
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Table 2
Customized Peak Oxygen Uptake Protocol
Stage

Speed (mph)

Grade (%)

Time (mins)

Warm Up

3.5

0

5

1

SS

0

2

2

SS + 1

0

2

3

(SS + 1) +1

0

2

4

Stage 3 speed

2

2

5

Stage 3 speed

4

2

6

Stage 3 speed

6

2

7

Stage 3 speed

8

2

Note. Mph = miles per hour, SS = self-selected pace in mph, mins = minutes.

Visit 3 and Visit 7: Anaerobic Fitness Testing
Peak power, mean power, and anaerobic fatigue were assessed with the 30-second
Wingate test (Bar-Or, 1987) on a cycle ergometer (Monark, Varberg, Sweden). Participants
began with a 5-minute warmup by cycling between 60-75 revolutions per minute at a selfselected resistance. After the warmup, the resistance was removed, 7.5% of the participant’s
body weight was added to the weight basket of the cycle ergometer, and the participant was
instructed to pedal as fast as they could. Once participants reached max pedal cadence, the
weight basket was released, and the test began. Participants cycled for a total of 30 seconds as
hard and as fast as possible. After the 30 second test, participants completed a 5-minute
cooldown for with a self-selected resistance.
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Visit 4 and Visit 8: Muscular Strength Testing
Muscular strength was assessed with a one repetition maximum (1RM) test for the bench
press (BP) followed by the back squat (BS) exercise to measure upper and lower body muscular
strength. Strength testing guidelines set forth by the National Strength and Conditioning
Association (NSCA) were used to conduct 1RM testing (Baechle & Earle, 2008). Briefly, the
warm-up consisted of an unloaded barbell (1 set of 8-10 reps), followed by a warm-up consisting
of 40-60% of the body weight added to the bar (1 set of 3-5 reps), and a final warm-up of 9095% of body weight added to the bar (1 set of 1-2 reps). Participants were asked to rest for at
least 2 minutes and no more than 4 minutes in between 1RM attempts. Participants were required
to squat to parallel which is defined as the position where the top of the thighs are parallel to the
floor. Rate of perceived exertion was asked to assist in deciding how much weight to add to the
bar within 5–20-pound increments. Weight was only added to achieve 100% of each
participant’s 1RM. If the participant successfully completed the lift at this weight, additional
weight was added in a conservative fashion until the participant failed to lift the weight. To
ensure safety during all 1RM testing, participants were spotted by a trained exercise professional
in accordance with NSCA spotting techniques, and with additional spot bars implemented in the
lifting cage.
Cannabidiol Intervention Period
After completing all baseline and physiological characteristic measurements in the week
prior to supplementation, participants were randomly assigned to the CBD (CG) or placebo (PG)
intervention groups to ensure an even number of 12 males and 12 females per group: males
consuming CBD (CG-M), females consuming CBD (CG-F), males consuming placebo (PG-M),
and females consuming placebo (PG-F). Both participants and investigators were blinded to the
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intervention groups. Participants were given two, 7-day pill boxes which supplied 14 capsules of
either 50 mg of CBD or a calorie-matched placebo. These pill boxes were refilled biweekly
throughout the 8-week intervention period. Participants were instructed to consume one pill once
per day after dinner and before bed. Randomization was conducted by the principal investigator
in a parallel design to determine superiority or equivalence to reduce systematic error bias and
assessment bias by the experimenters. The principal investigator was also chosen to ensure
blinding between research participants and the experimenters who will administer the treatment,
collect the data, and analyze the outcomes.
Statistical Analyses
This study addressed the following research questions:
Q1

Is there a difference by sex or by treatment with respect to physical activity
patterns, health-related fitness, measures of mental and cognitive health, and
concentrations of CRP and BDNF?

Q2

Does 8 weeks of CBD affect physical activity patterns, health-related fitness,
measures of cognitive and mental health, and resting concentrations of CRP and
BDNF?

To address the first research question, an independent-samples t-test was used to compare
means of each outcome by biological sex and treatment at the pre-intervention time point. The
independent t-test was chosen over the paired-samples t-test because both sexes and treatments
were independent of each other (participants in the male and female groups, and in CG and PG
were separate individuals). The first independent samples t-test included one independent,
categorical variable (sex) with two levels (males and females), and the second independent
samples t-test included one, independent, categorical variable (treatment) with two levels (CG
and PG). The multiple, continuous, dependent variables consisted of health-related fitness
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measures, physical activity patterns, mental health, cognitive function, and resting concentrations
of CRP and BDNF.
More specifically, these variables included the following: physical characteristics and
resting heart rate and blood pressure (age, resting systolic blood pressure (RSBP), resting
diastolic blood pressure (RDBP), and resting heart rate (RHR)), physical activity patterns
(average steps and distance per day), body size and composition measurements (height, BM,
BMI, LBM, and BF%), cardiorespiratory fitness (relative V̇O2peak), muscular strength (BP 1RM
and BS 1RM), mental health (PWB scores in the autonomy, environmental mastery, personal
growth, positive relation with others, purpose in life, and self-acceptance aspects), cognitive
health (NIH PROMIS cognitive function T scores and cognitive function abilities T scores),
absolute and relative anaerobic capacity (PP, MP, RPP, and RMP, and AF) and resting
concentrations of CRP and BDNF.
Data were assessed for normality and outliers by the Shapiro-Wilks test (p > 0.05),
boxplot inspection, and Q-Q plots. No more than 10% of data were removed if significant
outliers were detected (± 2.5 standard deviations from the mean). Independent t-tests were run on
the data with a 95% confidence interval for the mean difference with significance set to p < 0.05.
All statistical analyses were performed using SPSS 25 (IBM, Corp., Chicago, IL). Effect sizes
(Cohen’s d) were used to assess the magnitude of change for the independent samples t-tests, and
values of 0.2, 0.5 and 0.8 were considered small, medium, and large effects, respectively. Effect
sizes (partial eta squared “η2”) were also used to assess the magnitude of change in the 2-way
analysis of variance (ANOVA), and values of 0.01, 0.06 and 0.14 were considered small,
medium, and large effects, respectively.
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To address the second research question, a 3-way ANOVA consisting of one categorical
within-subjects factor (time: pre-/post-intervention) and two categorical between-subjects factors
(sex: male/female; treatment: CBD/placebo) was used to understand if there were interactions
(time * treatment * sex) on multiple continuous, dependent variables over time. A 3-way mixed
ANOVA was chosen over a 2-way repeated measures ANOVA because there were three
categorical factors: one within-subjects factor (two different time points) and two
between-subjects factors (sex and treatment), whereas a 2-way repeated measures ANOVA
required two categorical, within-subject factors (such as more than two time points or more than
two genders). The 3-way mixed ANOVA model was built using a General Linear Model
“Repeated Measures” and inputting “Time” as the within-subjects factor with 2 levels, and sex
and treatment as between-subject factors (Figure 2).
Data were assessed for outliers by boxplot inspection and Q-Q plots and were removed if
significant outliers were detected (± 2.5 standard deviations from the mean). Normality was
assessed by the Shapiro-Wilk’s test (p > 0.05), homogeneity by Levene’s test for equality of
variances (p > 0.05), and sphericity by Mauchly’s test of sphericity (p > 0.05). Pairwise
comparisons were performed with the Bonferroni post hoc test where significant interactions
were detected. The Bonferroni corrected p value was calculated by dividing the original p value
by the number of comparisons being performed. Partial eta squared was also used to assess the
magnitude of change in mixed ANOVA model.
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Figure 2
3-Way Mixed Analysis of Variance Model

Note. Mixed ANOVA model. The creation of the model in SPSS using body mass (Wt), body
mass index (BMI), and lean body mass (LBM) measures as an example for the body size and
composition analysis.
To avoid Type I error and achieve a desired level of 0.80 power with an α = 0.05, an a
priori analysis (G*Power, Dusseldorf, Germany) showed that a total sample size of 36 was
needed. Means and standard deviations of between pre- and post-exercise intervention CRP
concentrations in healthy young adults were used for computational analyses (Stewart et al.,
2007). The total number of study participants was increased to 48 to maximize potential
detection in differences. Each group was divided as follows: males consuming CBD (CG-M), n =
12; females consuming CBD (CG-F), n = 12; males consuming placebo (PG-M), n = 12; and
females consuming placebo (PG-F), n = 13.
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CHAPTER IV
RESULTS
The purpose of this double blind, placebo-controlled, clinical trial with parallel group
design was to investigate the biological sex-related differences in physical activity patterns,
health-related fitness, mental and cognitive health before and after an 8-week cannabidiol (CBD)
intervention. This study also aimed to explore whether 8 weeks of CBD treatment would
significantly alter biomarkers of inflammation and neural health.
Participants
Age and Ethnicity
A total of 64 individuals from campus and nearby communities were recruited but a total
of 49 participants completed the study. Twenty-four participants were in the CBD group (CG)
and 25 were in the placebo group (PG). Overall, there were 12 in the CBD male group (CG-M),
12 in the placebo male group (PG-M), 12 in the CBD female group (CG-F), and 13 in the
placebo female group (PG-F). Overall mean age was 25.5 ± 5.7 years and ranged from 18 to 42
years. Mean age for CG was 24.3 ± 4.5 years and ranged from 18 to 36 years while the mean age
for PG was 26.6 ± 6.6 years and ranged 20 to 42 years. There were no significant differences
between treatment assignment groups t(47) = -1.409, p = 0.165, d = -0.403. Overall mean age for
females and males was 25.4 ± 6.7 and 25.5 ± 4.5 years, respectively, and there were no
significant differences between groups t(47) = 0.011, p = 0.991, d = 0.003. When age was
analyzed by a 2-way analysis of variance (ANOVA; (treatment assignment * sex), there were no
significant interactions F(1, 45) = 1.497, p = 0.228, η2 = 0.032.
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Most participants identified as Caucasian (61%; n = 30) with others identifying as
Hispanic (12%; n = 6), Latino (4%; n = 2), Asian Pacific Islander (2%; n = 1), Native American
(2%; n = 1), “other” (2%; n = 1), and “more than one race/ethnicity” (12%; n = 6). These
individuals identified as African American and Caucasian, Asian Pacific Island and Caucasian,
Hispanic and Latino, Hispanic and Caucasian, Asian and Caucasian, and Hispanic and Latina.
Self-Reported Physical Activity
Results from the International Physical Activity Questionnaire (IPAQ) revealed that there
was a sex-related difference in which males reported 44% more time spent engaged in vigorous
physical activity than females (p = 0.043), and females reported 24% more days walking than
males (p = 0.001) at the pre-intervention time point (Table 3). There were no other significant
sex differences with respect to days engaged in vigorous physical activity, days and time spent
engaged in moderate physical activity, and time spent walking and sitting between males and
females at the pre-intervention time point. There was a significant treatment difference in which
PG reported 19% more days walking than CG (p < 0.001) at the pre-intervention time point
(Table 4). There were no other significant treatment differences with respect to days and time
spent engaged in moderate and vigorous physical activity, and time spent walking and sitting
between CG and PG at the pre-intervention time point. When IPAQ responses were analyzed
with a 2-way ANOVA (treatment assignment * sex), there were no significant interactions
(Table 5). However, there was a main effect of sex in which females spent an overall of 44%
more days walking than males at the pre-intervention time point (p = 0.043).
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Table 3
Self-Reported Physical Activity Within the Last 7 Days by Sex
Males
± SD (n)

Females
± SD (n)

Overall
± SD (N)

Vigorous (days)

4.1 ± 1.6
(24)

3 ± 2.3
(24)

Time spent in
vigorous (mins)

74 ± 47.5
(24)

Moderate (days)

p

Cohen’s d

3.5 ± 2
(48)

0.063

0.551

47.8 ± 38.4
(23)

61.2 ± 44.8
(47)

0.043 a

0.606

4.4 ± 2
(23)

3.5 ± 2.5
(24)

3.9 ± 2.3
(47)

0.165

0.411

Time spent in
moderate (mins)

59.1 ± 34.7
(22)

47.9 ± 37.2
(24)

53.3 ± 36.1
(46)

0.299

0.310

Walking (days)

5.5 ± 2
(23)

7±0
(20)

6.1 ± 1.6
(43)

0.001 b

-1.078

82.1 ± 75.4
(21)

100.6 ± 106.4
(24)

92.1 ± 91.7
(45)

0.507

-0.196

5.1 ± 2
(20)

6.5 ± 3.6
(24)

5.8 ± 3
(44)

0.110

-0.494

Pre-Physical Activity

Time spent walking
(mins)
Time spent sitting
(hours)
a

Denotes mean time spent in vigorous physical activity was significantly greater in males compared with females
and b Denotes mean days spent walking was significantly greater in females than in males.
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Table 4
Self-Reported Physical Activity Within the Last 7 Days by Treatment
Cannabidiol
Group (CG)
± SD (n)

Placebo
Group (PG)
± SD (n)

Overall
± SD (N)

Vigorous (days)

3.7 ± 1.9
(23)

3.4 ± 2.2
(25)

Time spent in
vigorous (mins)

64.6 ± 48.8
(23)

Moderate (days)

p

Cohen’s d

3.5 ± 2
(48)

0.618

0.145

57.9 ± 41.3
(24)

61.2 ± 44.8
(47)

0.616

0.0147

3.9 ± 2.3
(22)

3.9 ± 2.4
(25)

3.9 ± 2.3
(47)

0.987

-0.005

Time spent in
moderate (mins)

51.6 ± 33.5
(22)

54.8 ± 38.9
(24)

53.3 ± 36.1
(46)

0.767

-0.088

Walking (days)

5.8 ± 1.5
(23)

7±0
(20)

6.3 ± 1.3
(43)

< 0.001 a

-1.103

Time spent walking
(mins)

80.5 ± 83
(21)

107.3 ± 118.9
(23)

84.7 ± 78.9
(44)

0.392

-0.259

Time spent sitting
(hours)

5.3 ± 2.2
(21)

5.8 ± 2.8
(22)

5. ± 3.3
(44)

0.981

0.007

Pre-Physical Activity

Note. There were no treatment differences and a Denotes mean days spent walking was significantly greater in PG
than in CG.
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Table 5
Self-Reported Physical Activity Within the Last 7 Days by Treatment and Sex
± SD
Cannabidiol
Group-Male
(CG-M)
(n = 8)

Cannabidiol
Group-Female
(CG-F)
(n = 11)

Placebo
Group-Male
(PG-M)
(n = 10)

Placebo
Group-Female
(PG-F)
(n = 10)

Overall
(N = 39)

3.7 ± 2

3.5 ± 2

3.3 ± 1.9

3.4 ± 2.3

3.5 ± 2

63.8 ± 33.8

40 ± 26.7

67 ± 46.4

54 ± 41.6

55.4 ± 37.9

Moderate (days)

2.9 ± 2.5

4.5 ± 2

3.3 ± 2.3

4.4 ± 2.6

3.8 ± 2.3

Time spent in
moderate (mins)

40 ± 32.5

54.1 ± 28.9

57.5 ± 45.8

45.5 ± 34.4

49.9 ± 35.2

Walking (days)

5.8 ± 1.1

6.2 ± 1.2 a

5.2 ± 2.2

7±0a

6 ± 1.5

42.5 ± 33.7

113.6 ± 102

131 ± 160.9

84.5 ± 70.2

96 ± 106.3

7.3 ± 4.3

4.9 ± 2.7

6.1 ± 3

6 ± 2.9

6 ± 3.2

Pre-Physical Activity
Vigorous (days)
Time spent in vigorous
(mins)

Time spent walking
(mins)
Time spent sitting
(hours)
a

Denotes mean days spent walking was significantly greater in females than in males (p = 0.043).

Medication, Surgeries, and Medical
History
Almost all participants were not consuming any prescribed therapeutic medications over
the duration of the study (98%; n = 48). Only one male participant was currently taking
medication at the pre-intervention time point (Zoloft, 50 mg/day) and later discontinued its use
during the intervention period. Fifteen of the 25 female participants (60%; n = 15) were using a
birth control method consisting of either an intrauterine device (n = 3) or oral contraceptive (n =
12) during the time of the study. Thirteen of the 25 female participants, (52%, CG-F: n = 6;
PG-F: n = 7) began pre-intervention testing during their follicular phase in the menstrual cycle
which was estimated from their disclosed ovulation cycle and last menses start date.
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Approximately half of the participants (49%; n = 24) had at least one surgery with the
remainder having more than one surgery (15%; n = 9), and no prior surgeries (33%, n = 16).
Previous surgeries within a 29-year time frame included knee surgery (n = 4), wisdom tooth
extraction (n = 3), tonsillectomy (n = 3), appendectomy (n = 3), Cesarean section (n =3 ),
cholecystectomy (n = 2), lasik (n = 2), ankle surgery (n = 2), hip surgery (n = 2), hand and/or
wrist surgery (n = 2), anterior cruciate ligament reconstruction (n = 2), labrum repair (n = 1),
pilonidal cyst removal (n = 1), augmentation mammoplasty (n = 1), rhinoplasty (n = 1),
tympanostomy (n = 1), facial surgery (n = 1), adenoidectomy (n = 1), sinus reconstruction (n =
1), and elbow surgery (n = 1). The most recent surgery was lasik (year 2020) and the oldest was
tympanostomy (year 1996). Participants did not report any long-term discomforts or
complications from previous surgery and were able to complete all study visits.
Medical history included presence of any past medical conditions such as disease, illness,
diagnosis, therapy, and allergy. More than half the participants (57%; n = 28) had no previous
medical history, less than half (29%; n = 14) had at least one previous medical condition, and a
few (14%; n = 7) had more than one previous medical condition. Medical history included
asthma (n = 7), diagnosis and treatment of depression (n = 6), streptococcal pharyngitis (n = 3),
high blood cholesterol and/or triglycerides (n = 3), high blood pressure (n = 2), irritable bowel
syndrome (n = 2), concussion (n = 1), kidney failure (n = 1), gestational diabetes (n = 1), herpes
type 1 (n = 1), typhoid fever (n = 1), back pain (n = 1), and acid reflux (n = 1). The most recent
medical conditions were occasional depression and sporadic irritable bowel syndrome (year
2021), and the oldest was acid reflux (year 1993). Participants with high blood cholesterol and/or
triglycerides and high blood pressure reported no current diagnoses at the start of the study.
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Participants also reported no conflicts from previous medical conditions and were able to
compete all study visits.
Retention and Attrition Rates
Overall retention rate, calculated as the number of participants who completed the study
divided by the number of participants that were recruited at the beginning of the study, times 100
((49/64) *100), was 77% for a 17-month period. Overall attrition rate, calculated as the number
of participants that left divided by the number of participants that started, times 100 [(15/49)
*100], was 32%. Eleven of the 15 individuals who dropped out (73% of dropouts) did not
complete the pre-intervention visits for the following reasons: having no time to complete visits
(n = 2), experiencing an eating disorder trigger (n = 2), no reason and/or communication (n = 2),
mental health issues (n = 1), formation of a medically induced ulcer (n = 1), pain in foot (n = 1),
and knee pain (n = 1). Two individuals (13% of dropouts) left during the 8-week intervention
period due to having no time to complete the rest of the study (n = 1) and no
reason/communication (n = 1). Four individuals (27% of dropouts) completed the intervention
but did not return for post-intervention testing due to having no time. Pre-intervention measures
were completed for all participants except #56 (CG-M) who was unable to complete the
anaerobic Wingate test before starting the supplement intervention due to a busy work schedule.
Post-intervention measures were completed for all participants except for participants #32
(PG-M) and #48 (CG-M) who were unable to complete cognitive function and PWB scales,
participants #54 (CG-M) and #64 (PG-M) who were unable to complete cardiorespiratory fitness
testing due to time constraints, and #59 (PG-M) who refused to have blood drawn due to extreme
anxiety.
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Adverse Events
One male participant (#55 of CG-M) reported experiencing uncomfortable skin rashes on
arms and legs during the first week of the intervention period. The participant was given the
option to discontinue and seek medical treatment if serious; however, the rashes subsided by
week 2 and the participant decided to continue with the study. Another male participant (#59 of
PG-M) experienced a vasovagal reaction during the Visit 5 blood draw in which he had
temporary dizziness, light sweating, and paleness. The blood draw was immediately ended which
resulted in no post-intervention blood sample and the participant was given water and snacks and
monitored until the vasovagal reaction subsided. Two male participants (#1 of CG-M and #48 of
CG-M) experienced emesis after completing the pre-intervention anaerobic Wingate test (#48)
and post-intervention anaerobic Wingate test (#1 and #48). In each situation, participants were
encouraged to complete a 10–20-minute cool down on the treadmill while having their heart rate
and blood pressure monitored and given water and light snacks before leaving the testing center.
There were no life-threatening incidents, hospitalizations, or other serious medical events
through the duration of this study.
Resting Heart Rate and Blood Pressure
Pre-Intervention Comparisons
Mean resting heart rate (RHR), resting systolic blood pressure (RSBP), and resting
diastolic blood pressure (RDBP) by sex and by treatment at the pre-intervention time point are
presented in Tables 6 and 7, respectively. Overall RHR ranged from 42 to 98 bpm, RSBP ranged
from 98 to 152 mmHg, and RDBP ranged from 58 to 100 mmHg when all groups were
combined at the pre-intervention time point. There were significant sex-related differences with
respect to RSBP and RDBP in which males had 6% higher RSBP and 7% higher RDBP than
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females at the pre-intervention time point (p = 0.025 and p = 0.034, respectively). There were no
significant differences between males and females with respect to RHR, and there were also no
significant differences between CG and PG treatments at the pre-intervention time point. When
these outcomes were analyzed with a 2-way ANOVA (treatment assignment * sex), no
interactions were found on RHR F(1, 44) = 0.875, p = 0.355, η2 = 0.020, RSBP F(1, 43) = 0.046,
p = 0.831, η2 = 0.001, and RDBP F(1, 43) = 0.105, p = 0.748, η2 = 0.002 (Table 8). A main effect
of sex was found with respect to RSBP and RDBP in which male RSBP and RDBP were 6% and
7% higher than mean female RSBP and RDBP (p = 0.034 and p = 0.048, respectively).

Table 6
Pre-Intervention Resting Heart Rate and Blood Pressure by Sex
Pre-Intervention
Variable

Males
± SD (n)

Females
± SD (n)

Overall
± SD (N)

Resting heart rate
(RHR) (bpm)

69.0 ± 9.6
(23)

65.9 ± 9.8
(25)

Resting systolic
blood pressure
(RSBP) (mmHg)

121.5 ± 9.5
(22)

Resting diastolic
blood pressure
(RDBP) (mmHg)

77.7 ± 6.9
(22)

a

p

Cohen’s d

67.4 ± 9.6
(48)

0.266

0.326

114.9 ± 10.1
(25)

118.0 ± 10.3
(47)

0.025 a

0.675

72.8 ± 8.2
(25)

75.1 ± 8.0
(47)

0.034 b

0.640

Denotes mean male RSBP was significantly greater than mean female RSBP and b Denotes mean male RDBP
was significantly greater than mean female RDBP.
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Table 7
Pre-Intervention Resting Heart Rate and Blood Pressure by Treatment

Pre-Intervention
Variable

Cannabidiol
Group (CG)
± SD (n)

Placebo
Group (PG)
± SD (n)

Overall
± SD (N)

Resting heart rate
(RHR) (bpm)

68.8 ± 7.7
(23)

66.2 ± 11.1
(25)

Resting systolic
blood pressure
(RSBP) (mmHg)

118.13 ± 9.4
(23)

Resting diastolic
blood pressure
(RDBP) (mmHg)

75.7 ± 8.8
(23)

p

Cohen’s d

67.5 ± 9.6
(48)

0.366

0.264

118 ± 11.4
(24)

118 ± 10.3
(47)

0.955

0.016

74.6 ± 7.3
(24)

75.1 ± 8
(47)

0.652

0.132

Note. There were no significant treatment differences.

Table 8
Pre-Intervention Resting Heart Rate and Blood Pressure by Treatment

Pre-Intervention
Variable

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Overall
± SD (N)

Resting heart rate
(RHR) (bpm)

68.7 ± 7.6
(10)

68.5 ± 8.4
(12)

69.3 ± 11.7
(10)

63.3 ± 11.2
(12)

67.3 ± 9.9
(44)

Resting systolic
blood pressure
(RSBP) (mmHg)

120.4 ± 6.6
(10) a

113 ± 7.9
(11)

122.3 ± 12.4
(10) a

114.6 ± 10.1
(13)

117.2 ± 9.9
(44)

Resting diastolic
blood pressure
(RDBP) (mmHg)

79.4 ± 4.2
(10) b

73.6 ± 10.3
(12)

77.6 ± 8.0
(10) b

72.0 ± 6.1
(13)

75.3 ± 7.9
(45)

a

Denotes mean male RSBP was significantly higher than mean female RSBP (p = 0.034) and b Denotes mean
male RDBP was significantly higher than mean female RDBP (p = 0.048).
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Intervention-Related Outcomes
Mean RHR, RSBP, and RDBP by time point, treatment, and sex are presented in Table 9.
There were no significant 3-way interactions (time * treatment * sex) with respect to RHR,
RSBP, and RDBP. A significant 2-way interaction (time * treatment) was found with respect to
RSBP (p = 0.047); however, the Bonferroni post hoc test did not detect significant betweengroup differences. There were no other significant 2-way interactions (time * treatment or time *
sex) with respect to RHR and RDBP. There was a main effect of sex with respect to RSBP where
males had 7% higher overall RSBP than females (p < 0.001). There was also a main effect of sex
with respect to RDBP where males had 9% higher overall RDBP than females (p < 0.001). There
were no other main effects of time or treatment with respect to RHR, RSBP, and RDBP.
Physical Activity Patterns
Pre-Intervention Comparisons
Mean 7-day steps per day and distance traveled by sex and by treatment at the preintervention time point are presented in Tables 10 and 11, respectively. Overall mean 7-day steps
per day ranged from 6,272 to 24,971 and distance traveled ranged from 2.5 to 11 miles when all
groups were combined at the pre-intervention time point. There were no significant sex-related
differences with respect to each physical activity measure and there were no significant
differences between CG and PG treatment at the pre-intervention time point. When average steps
per day and distance traveled were analyzed by a 2-way ANOVA (treatment assignment * sex),
no interactions or main effects were found with respect to steps per day F(1, 45) = 1.256, p =
0.268, η2 = 0.027 and distance traveled F(1, 45) = 2.062, p = 0.158, η2 = 0.044 (Table 12).
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Table 9
Resting Heart Rate and Blood Pressure by Time, Treatment, and Sex
Pre-Intervention

Post-Intervention

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Resting heart rate
(RHR) (bpm)

68.7 ± 7.6
(10)

68.5 ± 8.4
(12)

69.3 ± 11.7
(10)

63.3 ± 11.2
(12)

68.3 ± 8.7
(10)

71.1 ± 10.6
(12)

71.1 ± 9.9
(10)

64.0 ± 6.3
(12)

Resting systolic
blood pressure
(RSBP) (mmHg)

120.4 ± 6.6
(10) a

113 ± 7.9
(11)

122.3 ± 12.4
(10) a

114.6 ± 10.1
(13)

127.4 ± 8.8
(10) a

113 ± 9.9
11)

120.4 ± 10.4
(10) a

111.6 ± 8.9
(13)

Resting diastolic
blood pressure
(RDBP) (mmHg)

68.3 ± 8.7
(10) b

71.1 ± 10.6
(12)

71.1 ± 9.9
(10) b

64.0 ± 6.3
(12)

81.2 ± 10
(10) b

74.8 ± 9.6
(12)

76.6 ± 8.6
(10) b

68.0 ± 7.5
(13)

Variable

a

Denotes mean male RSBP was significantly greater than mean female RSBP (p < 0.001) and b Denotes mean male RDBP was significantly greater than mean
female RDBP (p < 0.001).
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Table 10
Pre-Intervention Steps Per Day and Distance by Sex
± SD
Pre-Intervention
Variable

Males
(n = 24)

Females
(n = 25)

Overall
(N = 47)

p

Cohen’s d

Steps per day

11,028.1 ±3,893.4

11,581.7 ± 4,545

11,495 ± 4,193

0.650

-0.131

Distance (mi)

4.8 ± 1.7

4.9 ± 2.0

4.9 ± 1.9

0.886

-0.041

Note. Values represent a 7-day average of both steps per day and total distance traveled. There were no
significant sex differences.

Table 11
Pre-Intervention Steps Per Day and Distance by Treatment
± SD
Pre-Intervention
Variable

CG
(n = 24)

PG
(n = 25)

Overall
(N = 49)

p

Cohen’s d

Steps per day

11,613.9 ± 4,186.3

11,019.4 ± 4,286.3

11,310.6 ± 4,204

0.626

0.140

Distance (mi)

4.9 ± 1.9

4.8 ± 2

4.9 ± 1.9

0.856

0.052

Note. Values represent a 7-day average of both steps per day and total distance traveled. There were no
significant sex differences.
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Table 12
Pre-Intervention Steps Per Day and Distance by Treatment and Sex
± SD
Cannabidiol
Group-Male
(CG-M)
(n = 11)

Cannabidiol
Group-Female
(CG-F)
(n = 12)

Placebo
Group-Male
(PG-M)
(n = 11)

Placebo
Group-Female
(PG-F)
(n = 13)

Steps per day

12,526.4 ±
4,681.4

11,200.6 ±
3,654.7

10,266.5 ±
2,553.3

11,933.6 ±
5,366.8

11,495 ± 4,193

Distance (mi)

5.5 ± 2.1

4.5 ± 1.4

4.4 ± 1.0

5.2 ± 2.5

4.9 ± 1.9

Pre-Intervention
Variable

Overall
(N = 47)

Note. Values represent a 7-day average of both steps per day and total distance traveled. There were no
significant interactions or main effects.

Intervention-Related Outcomes
Mean steps per day and distance traveled by time point, treatment, and sex are presented
in Table 13. There were no significant 3-way interactions (time * treatment * sex), 2-way
interactions (time * sex, time * treatment, and treatment * sex), and main effects (time,
treatment, or sex) on mean 7-day steps per day and distance traveled.
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Table 13
Pre-Intervention Steps Per Day and Distance by Time, Treatment, and Sex

Variable

n

Steps Per Day

Distance (mi)

± SD

± SD

Pre-Intervention
Males in the cannabidiol group (CG-M)

11

12,526.4 ± 4,681.4

5.5 ± 2.1

Females in the cannabidiol group (CG-F)

12

11,200.6 ± 3,654.7

4.5 ± 1.4

Males in the placebo group PG-M

11

10,266.5 ± 2,553.3

4.4 ± 1.0

Females in the placebo group (PG-F)

13

11,933.6 ± 5,366.8

5.2 ± 2.5

Males in the cannabidiol group (CG-M)

11

12,172.7 ± 2,956.5

5.2 ± 1.3

Females in the cannabidiol group (CG-F)

12

9,527.7 ± 3,881.9

4.1 ± 1.8

Males in the placebo group PG-M

11

10,043.7 ± 2,406.2

4.4 ± 1.1

Females in the placebo group (PG-F)

13

11,416.1 ± 4,991.1

5.2 ± 2.0

Post-Intervention

Note. Values represent a 7-day average of both steps per day and total distance. There were no significant
interactions or main effects.

Body Size and Composition Measures
Pre-Intervention Comparisons
Mean height ranged from 152 to 195 cm, body mass ranged from 49.48 to 106.41 kg,
body mass index (BMI) ranged from 19.60 to 33.00 kg/m2, lean body mass (LBM) ranged from
36.89 to 83.50 kg, and body fat percentage (BF%) ranged from 8.2 to 51.4% when all groups
were combined at the pre-intervention time point. There were significant sex-related differences
(Table 14). Males were 7.6% taller than females (p = < 0.001) and 16.5% heavier than females (p
< 0.001). Lean body mass was 32% greater in males when compared to females (p < 0.001), and
females had 53% more BF% than males (p = < 0.001). There were no significant sex-related
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differences with respect to BMI (p = 0.258), and no significant treatment differences (Table 15).
When body size and composition were analyzed by a 2-way ANOVA (treatment assignment *
sex), there were no interactions with respect to height F(1, 49) = 0.011, p = 0.918, η2 = 0.000,
BM F(1, 45) = .111, p = 0.740, η2 = 0.002, BMI F(1, 44) = 1.333, p = 0.254, η2 = 0.029, LBM
F(1, 45) = 0.232, p = 0.632, η2 = 0.005, and BF% F(1, 45) = 0.007, p = 0.932, η2 = 0.000 at the
pre-intervention time point (Table 16). The 2-way ANOVA showed a main effect of sex was
found with respect to height, BM, LBM, and BF% where males were 7.6% taller, 16.5% heavier,
had 32% more LBM and 53% less BF than females (p < 0.001, p < 0.001, p < 0.001, and p <
0.001, respectively).

Table 14
Pre-Intervention Body Size and Composition Measures by Sex
Males
± SD (n)

Females
± SD (n)

Overall
± SD (N)

Height (cm)

177 ± 7.0
(24)

164.4 ± 7.4
(25)

Body mass
(BM) (kg)

79.8 ± 12.5
(24)

Body mass index
(BMI) (kg/m2)

p

Cohen’s d

170.6 ± 9.6
(49)

<0.001 a

1.746

67.5 ± 12.3
(25)

73.5 ± 13.7
(49)

0.001 b

0.984

25.4 ± 3.4
(24)

24.3 ± 3.0
(24)

24.8 ± 3.2
(48)

0.258

0.33

Lean body mass
(LBM) (kg)

66.4 ± 7.9
(24)

48.1 ± 5.4
(25)

57.2 ± 11.5
(49)

<0.001 c

2.711

Body fat percentage
(BF) (%)

15.9 ± 6.4
(24)

27.6 ± 8.5
(25)

21.2 ± 8.6
(49)

<0.001 d

-1.528

Pre-Intervention Variable

a

Denotes males were significantly taller than females, b Denotes males had significantly more body mass than
females, c Denotes males had significantly more lean body mass than females, and d Denotes females had
significantly more body fat than males.
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Table 15
Pre-Intervention Body Size and Composition Measures by Treatment
Cannabidiol
Group (CG)
± SD (n)

Placebo
Group (PG)
± SD (n)

Overall
± SD (N)

Height (cm)

170.1 ± 9.7
(24)

171.2 ± 9.8
(25)

Body mass
(BM) (kg)

73.9 ± 16.7
(24)

Body mass index
(BMI) (kg/m2)

Pre-Intervention
Variable

p

Cohen’s d

170.7 ± 9.7
(49)

0.700

-0.111

73.3 ± 10.6
(25)

73.6 ± 13.7
(49)

0.884

0.042

24.7 ± 3.7
(23)

25 ± 2.8
(25)

24.9 ± 3.2
(48)

0.806

-0.071

Lean body mass
(LBM) (kg)

56.8 ± 12.2
(24)

57.4 ± 10.9
(25)

57.1 ± 11.4
(49)

0.865

-0.049

Body fat percentage
(BF) (%)

22.2 ± 10.2
(24)

21.6 ± 9.1
(25)

21.9 ± 9.6
(49)

0.825

0.063

Note. There were no significant treatment differences.
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Table 16
Pre-Intervention Body Size and Composition Measures by Treatment and Sex
± SD

Pre-Intervention
Variable

Cannabidiol
Group-Male
(CG-M)
(n = 12)

Cannabidiol
Group-Female
(CG-F)
(n = 11)

Placebo
Group-Male
(PG-M)
(n = 12)

Placebo
Group-Female
(PG-F)
(n = 13)

Overall
(N = 48)

Height (cm)

176.4 ± 5.7 a

164.1 ± 9.3

178 ± 8.4 a

165 ± 6.3

170.9 ± 7.6

Body mass
(BM) (kg)

80.6 ± 15.4 b

63.6 ± 10.3

79 ± 9.5 b

68 ± 8.8

72.9 ± 13.1

Body mass index
(BMI) (kg/m2)

25.8 ± 4

23.6 ± 3.1

25 ± 2.8

25 ± 3

24.9 ± 3.2

Lean body mass
(LBM) (kg)

66.5 ± 9 c

46.8 ± 5.3

66.5 ± 7.1 c

49 ± 5.6

57.2 ± 11.5

Body fat percentage
(BF) (%)

16.5 ± 7.9

25.8 ± 5.8 d

15.5 ± 4.9

27.3 ± 8.4 d

21.3 ± 8.6

a

Denotes males were significantly taller than females (p < 0.001), b Denotes males had
significantly more body mass than females (p < 0.001), c Denotes males had significantly more
lean body mass than females (p < 0.001), and d Denotes females had significantly more body
fat than males (p < 0.001).

Intervention-Related Outcomes
Mean BM, BMI, LBM, and BF by time point, treatment, and sex are presented in Table
17. There were no significant 3-way (time * treatment * sex) and 2-way (time * sex, time *
treatment, and treatment * sex) interactions on body size and composition measures. However,
there was a main effect of sex with respect to BM where males had 18% higher overall BM than
females (p = 0.001), LBM where males had 28% higher overall LBM than females (p < 0.001),
and overall BF% where females had 55% more body fat than males (p < 0.001).
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Table 17
Mean Body Size and Composition Measures by Time, Treatment, and Sex
Pre-Intervention

Post-Intervention

Variable

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Body mass
(BM) (kg)

80.6 ± 15.3
(12) a

67.1 ± 15.7
(12)

79.0 ± 9.5
(12) a

67.9 ± 8.7
(13)

80.8 ± 15.3
(12) a

67.2 ± 15.8
(12)

79.4 ± 9.3
(12) a

67.8 ± 8.7
(13)

Body mass index
(BMI) (kg/m2)

25.8 ± 4.0
(12)

23.6 ± 3.0
(11)

25.0 ± 2.7
(12)

24.9 ± 2.9
(13)

26 ± 4.1 (12)

23.6 ± 3.1
(11)

25.1 ± 2.7
(12)

24.9 ± 2.9
(13)

Lean body mass
(LBM) (kg)

66.5 ± 9.0
(12) b

47.1 ± 5.2
(12)

66.4 ± 7.0
(12) b

49.0 ± 5.6
(13)

66.7 ± 8.8
(12) b

50.3 ± 9.7
(12)

66.2 ± 7.4
(12) b

50.8 ± 10.5
(13)

Body fat
percentage
(BF) (%)

16.4 ± 7.9
(12)

27.9 ± 9.1
(12) c

15.4 ± 4.8
(12)

27.3 ± 8.3
(13) c

16.5 ± 7.9
(12)

28 ± 9.1
(12) c

16.4 ± 4.9
(12)

28.1 ± 8.3
(13) c

a

Denotes mean male BM was significantly greater than mean female BM (p < 0.001), b Denotes mean male LBM was significantly
greater than mean female LBM (p < 0.001), and c Denotes mean female BF was significantly greater than mean male BF (p <
0.001).
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Cardiorespiratory Fitness and Muscular Strength
Measures
Pre-Intervention Comparisons
Mean relative peak oxygen uptake (V̇O2 peak) and one repetition maximum (1RM)
measures by sex and by treatment at the pre-intervention time point are presented in Tables 18
and 19, respectively. Overall relative V̇O2 peak ranged from 20 to 62.3 ml/kg/min, bench press
(BP) 1RM ranged from 25 to 161 kg, and back squat (BS) 1RM ranged from 27 to 166 kg when
all groups were combined at the pre-intervention time point. There were significant sex-related
differences. The mean, relative V̇O2 peak in males was 14.7% higher when compared to the
mean, relative V̇O2 peak in females (p = 0.006). Mean BP 1RM in males was 80% greater when
compared to the mean BP 1RM in females (p < 0.001) and the mean BS 1RM in males was
46.4% greater when compared to the mean BS 1RM in females (p < 0.001). A 2-way ANOVA
(treatment assignment * sex) revealed no significant interactions with respect to relative V̇O2
peak F(1, 45) = 1.047, p = 0.312, η2 = 0.023, BP 1RM F(1, 44) = 1.924, p = 0.940, η2 = 0.000,
and BS 1RM F(1, 44) = 0.059, p = 0.809, η2 = 0.001 (Table 20). There was a main effect of sex
with respect to mean, relative V̇O2 peak, and BP and BS 1RM. Mean male relative V̇O2 peak, BP
1RM, and BS 1RM were 16%, 80%, and 46% greater than mean female relative V̇O2 peak, BP
1RM, and BS 1RM (p = 0.011, p < 0.001, and p < 0.001, respectively).
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Table 18
Pre-Intervention Peak Oxygen Uptake, Bench Press One Repetition Maximum, and Back Squat
One Repetition Maximum by Sex
Males
± SD (n)

Females
± SD (n)

Overall
± SD (N)

Peak oxygen uptake
(V̇O2 peak) (ml/min/kg)

47.4 ± 8.3
(24)

40.9 ± 7.6
(25)

Bench press
(1 repetition maximum)
(BP 1RM) (kg)

93.4 ± 24.4
(23)

Bench squat
(1 repetition maximum)
(BS 1RM) (kg)

112.8 ± 25.1
(23)

Pre-Intervention Variable

p

Cohen’s d

44.1 ± 8.5
(49)

0.006 a

0.818

40.3 ± 8.6
(25)

65.7 ± 32.2
(48)

< 0.001 b

1.766

70.2 ± 23.0
(25)

90.6 ± 32.1
(48)

< 0.001 c

2.942

Denotes mean, relative V̇O2 peak was significantly greater in males than females, b Denotes
mean bench press 1RM was significantly greater in males than females, and c Denotes mean
back squat 1RM was significantly greater in males than females.
a

Table 19
Pre-Intervention Peak Oxygen Uptake, Bench Press One Repetition Maximum, and Back Squat
One Repetition Maximum by Treatment
Cannabidiol
Group (CG)
± SD (n)

Placebo
Group (PG)
± SD (n)

Overall
± SD (N)

Peak oxygen uptake
(V̇O2 peak) (ml/min/kg)

68.8 ± 7.7
(23)

66.2 ± 11.1
(25)

Bench press
(1 repetition maximum)
(BP 1RM) (kg)

118.13 ± 9.4
(23)

Bench squat
(1 repetition maximum)
(BS 1RM) (kg)

75.7 ± 8.8
(23)

Pre-Intervention Variable

p

Cohen’s d

67.5 ± 9.6
(48)

0.366

0.264

118 ± 11.4
(24)

118 ± 10.3
(47)

0.955

0.016

74.6 ± 7.3
(24)

75.1 ± 8
(47)

0.652

0.132

Note. There were no significant treatment differences.
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Table 20
Pre-Intervention Peak Oxygen Uptake, Bench Press One Repetition Maximum, and Back Squat
One Repetition Maximum by Treatment and Sex
± SD
Cannabidiol
Group-Male
(CG-M)
(n=11)

Cannabidiol
Group-Female
(CG-F)
(n=12)

Placebo
Group-Male
(PG-M)
(n=12)

Placebo
Group-Female
(PG-F)
(n=13)

Overall
(N=48)

Peak oxygen uptake
(V̇O2 peak) (ml/min/kg)

48.5 ± 9.4 a

40.4 ± 8

45.6 ± 7 a

41.4 ± 7.6

43.9 ± 8.4

Bench press
(1 repetition maximum)
(BP 1RM) (kg)

91.9 ± 22.3 b

39.2 ± 8.7

94.9 ± 27.3 b

41.4 ± 8.9

65.8 ± 32.2

Bench squat
(1 repetition maximum)
(BS 1RM) (kg)

113 ± 21.7 c

72.2 ± 27

112.7 ± 29 c

68.5 ± 19.8

90.7 ± 32.1

Pre-Intervention
Variable

Denotes mean, relative V̇O2 peak was significantly greater in males than females (p = 0.006), b Denotes mean
bench press 1RM was significantly greater in males than females (p < 0.001), and c Denotes mean back squat
1RM was significantly greater in males than females (p < 0.001).
a

Intervention-Related Outcomes
Mean, relative V̇O2 peak, and BP and BS 1RM values by time point, treatment, and sex
are presented in Table 21. There were no significant 3-way (time * treatment * sex) and 2-way
(time * sex, time * treatment, and treatment * sex) interactions with respect to mean, relative
V̇O2 peak and BP and BS 1RM values. A main effect of time was found with respect to mean,
relative V̇O2 peak and BS 1RM values. Overall mean, relative V̇O2 peak values decreased by 4%
(p = 0.035) and BS 1RM values increased by 5.4% (p = 0.027) by the end of intervention. A
main effect of sex was also found in which males had 18% higher overall mean, relative V̇O2
peak values, 80% higher overall mean BP 1RM values, and 45% higher overall mean BS 1RM
values than females (p = 0.003, < 0.001, and < 0.001, respectively).
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Table 21
Mean Relative Peak Oxygen Uptake, Bench Press One Repetition Maximum, and Back Squat One Repetition Maximum by Time,
Treatment, and Sex
Pre-Intervention

Post-Intervention

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Peak oxygen uptake
(V̇O2 peak)
(ml/min/kg)

49.3 ± 9.3
(12) a

40.4 ± 7.9
(12)

45.2 ± 7.6
(13) a

41.4 ± 7.5
(13)

47.8 ± 8.2
(12) a, d

38.9 ± 7.4
(12) d

46.2 ± 7.1
(10) a, d

39.8 ± 6.1
(13) d

Bench press
(1 repetition
maximum)
(BP 1RM) (kg)

91.9 ± 22.2
(11) b

39.2 ± 8.7
(12)

(12) b

41.3 ± 8.8
(13)

92.9 ± 21.8
(11) b

40.0 ± 9.2
(12)

96.7 ± 26.3
(12) b

40.8 ± 8.3
(13)

Bench squat
(1 repetition
maximum)
(BS 1RM) (kg)

113 ± 21.6
(11) c

72.2 ± 26.9
± (12)

112.7 ± 29
(12) c

68.4 ±19.7
(13)

116.4 ±22.8
(11) c, e

78.1 ± 24
(12) e

119.2 ± 22.6
(12) c, e

71.7 ± 19.6
(12) e

Variable

94.8 ± 27.2

Denotes mean, relative V̇O2 peak was significantly greater in males than females (p = 0.003), b Denotes mean bench press 1RM
was significantly greater in males than females (p < 0.001), c Denotes mean back squat 1RM was significantly greater in males than
females (p < 0.001), d Denotes post-intervention mean, relative V̇O2 peak values were significantly lower than pre-intervention
values (p = 0.035), and e Denotes post-intervention mean back squat 1RM values were significantly greater than pre-intervention
values (p = 0.027).
a
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Anaerobic Fitness Measures
Pre-Intervention Comparisons
Mean peak power (PP), mean power (MP), relative peak power (RPP), and relative mean
power (RMP) by sex and by treatment at the pre-intervention time point are presented in Tables
22 and 23, respectively. Overall mean PP ranged from 372.19 to 1147.73 W, MP ranged from
287.82 to 803.91 W, RPP ranged from 3.71 to 12.66 W/kg, RMP ranged from 2.85 to 8.37 W/kg,
and AF ranged from 54.40 to 71.35% when all groups were combined at the pre-intervention
time point. There was a significant sex-related difference in which males had 36% greater mean
PP (p < 0.001), 39% greater mean MP (p < 0.001), 21% greater mean RPP (p < 0.001), and 20%
greater mean RMP than females (p < 0.001). There were no significant sex-related differences
with respect to AF. When mean PP, MP, RPP, RMP, and AF were analyzed with a 2-way
ANOVA (treatment assignment * sex), no significant interactions were found on PP F(1, 44) =
1.067, p = 0.307, η2 = 0.024, MP F(1, 44) = 0.280, p = 0.600, η2 = 0.006, RPP F(1, 44) = 0.353, p
= 0.555, η2 = 0.008, RMP F(1, 44) = 0.001, p = 0.979, η2 = 0.000, and AF F(1, 44) = 0.574, p =
0.453, η2 = 0.013 (Table 24). There was a main effect of sex with respect to mean PP, MP, RPP,
and RMP where males had 39%, 39%, 22%, and 20% greater values than females (p < 0.001, p
<0.001, p <0.001, and p < 0.001, respectively).
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Table 22
Pre-Intervention Anaerobic Fitness Measures by Sex
± SD
Males
(n = 23)

Females
(n = 25)

Overall
(N = 48)

p

Cohen’s d

Peak power (PP) (W)

811.2 ± 135.1

549.4 ± 104.3

674.8 ± 177.7

< 0.001 a

2.180

Mean power (MP) (W)

573.2 ± 107.4

388.2 ± 63

476.8 ± 127.1

< 0.001 b

2.123

10.1 ± 1.3

8.2 ± 1.5

9.1 ± 1.7

< 0.001 c

1.294

Relative mean power (W/kg)

7.1 ± 1

5.8 ± 0.9

6.4 ± 1.2

< 0.001 d

1.275

Anaerobic fatigue (AF) (%)

54.4 ± 12.9

55.9 ± 6.9

55.2 ± 10.1

0.621

-0.144

Pre-Intervention Variable

Relative peak power
(W/kg)

a

Denotes mean PP was significantly greater in males than females, b Denotes mean MP was
significantly greater in males than females, c Denotes mean RPP was significantly greater in
males than females, and d Denotes mean RMP was significantly greater in males than females.
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Table 23
Pre-Intervention Anaerobic Fitness Measures by Treatment
± SD
Cannabidiol
Group (CG)
(n = 23)

Placebo
Group (PG)
(n = 25)

Overall
(N = 48)

p

Cohen’s d

Peak power (PP) (W)

672.4 ± 188.1

677.1 ± 171.5

675 ± 177

0.929

-0.026

Mean power (MP) (W)

477.1 ± 130.6

476.7 ± 126.6

476.9 ± 127.1

0.992

0.003

Relative peak power (RPP)
(W/kg)

9.1 ± 1.9

9.1 ± 1.7

9.2 ± 1.7

0.873

-0.046

Relative mean power
(RMP) (W/kg)

6.5 ± 1.3

6.4 ± 1.2

6.5 ± 1.2

0.937

0.023

Anaerobic fatigue (AF) (%)

56.6 ± 8.2

56 ± 5.9

56.3 ± 7.1

0.758

0.089

Pre-Intervention Variable

Note. There were no significant treatment differences.
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Table 24
Pre-Intervention Anaerobic Fitness Measures by Treatment and Sex
± SD

Cannabidiol
Group-Male
(CG-M)
(n = 11)

Cannabidiol
Group-Female
(CG-F)
(n =12)

Placebo
Group-Male
(PG-M)
(n = 12)

Placebo
GroupFemale
(PG-F)
(n = 13)

Overall
(N = 48)

828.7 ± 111.4 a

529.2 ± 112.5

795.2 ± 157 a

568.1 ± 96.9

674.9 ± 177.7

580 ± 102.2 b

381.8 ± 62.5

566.1 ± 116.1 b

394.1 ± 65.4

476.9 ± 127.1

Relative peak power
(RPP) (W/kg)

10.2 ± 1.4 c

8.1 ± 1.6

10.1 ± 1.4 c

8.4 ± 1.5

9.2 ± 1.7

Relative mean power
(RMP) (W/kg)

7.1 ± 1.2 d

5.8 ± 1

7.1 ± 1 d

5.8 ± 0.9

6.5 ± 1.2

57 ± 8.4

56.3 ± 8.4

56.3 ± 6.6

55.6 ± 5.5

56.3 ± 7.1

Pre-Intervention
Variable
Peak power (PP) (W)
Mean power (MP) (W)

Anaerobic fatigue (AF)
(%)
a

Denotes mean PP was significantly greater in males than females (p < 0.001), b Denotes mean MP was
significantly greater in male than females (p < 0.001), c Denotes mean RPP was significantly greater in males
than females (p < 0.001), and d Denotes mean RMP was significantly greater in males than females (p < 0.001).
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Intervention-Related Outcomes
Mean PP, RPP, MP, RMP, and AF by time point, treatment, and sex are presented in
Table 25. There were no significant 3-way interactions (time * treatment * sex) with respect to
PP, RPP, MP, RMP, and AF. A significant 2-way interaction (time * treatment) was found with
respect to mean PP (p = 0.013) and RPP (p = 0.006). A follow-up Bonferroni multiple
comparison confirmed that PG experienced a 9% decrease in mean PP (p = 0.006) and 3%
decrease in mean RPP compared to CG (p = 0.006) and CG experienced no changes in mean PP
and RPP after the 8-week intervention (Figures 3 and 4, respectively). A significant 2-way
interaction (time * sex) was also found with respect to mean MP and RMP (p = 0.017 and p =
0.036, respectively). Bonferroni post hoc testing confirmed that females experienced a 4.5%
decrease in mean MP (p = 0.021) and a 3.5% decrease in mean RMP compared to males (p =
0.018) while males experienced no changes in mean MP and RMP after the 8-week intervention
(Figures 5 and 6, respectively). A main effect of sex was found with respect to overall mean PP
and RPP in which males had 40% and 22% higher overall mean PP and RPP than females (p =
<0.001 and p = < 0.001, respectively). A main effect of sex was also found on overall MP and
RMP in which males had 41% and 22% higher overall mean MP and RMP than females (p =
<0.001 and p = < 0.001, respectively).
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Table 25
Mean Anaerobic Fitness Measures by Time, Treatment, and Sex
Pre-Intervention

Post-Intervention

± SD

± SD

Cannabidiol
GroupMale
(CG-M)
(n = 11)

Cannabidiol
GroupFemale
(CG-F)
(n = 12)

Placebo
GroupMale
(PG-M)
(n = 12)

Placebo
GroupFemale
(PG-F)
(n = 13)

Cannabidiol
GroupMale
(CG-M)
(n = 11)

Cannabidiol
GroupFemale
(CG-F)
(n = 12)

Placebo
GroupMale
(PG-M)
(n = 12)

Placebo
GroupFemale
(PG-F)
(n = 13)

828.7 ± 111.4 e

529.1 ± 112.5

795.1 ± 157 a, e

568.1 ± 96.8 a

852.4 ± 119.9 e

540.9 ± 107.8

724.6 ±
272.7 a, e

512.9 ±
133.6 a

10.2 ± 1.4 f

8 ± 1.6

10 ± 1.4 b, f

8.3 ± 1.51 b

10.4 ± 1.4 f

8.2 ± 1.8

9.5 ± 1.5 b, f

7.8 ± 1.4 b

Relative peak
power (RPP)
(W/kg)

580.9 ± 102.1 g

381.8 ± 62.5 c

566.7 ± 116.1 g

396.1 ± 54.4 c

593.1 ± 84.7 g

396.9 ± 65.5 c

571.3 ±
120.1 g

371.1 ± 73.9 c

Relative mean
power (RMP)
(W/kg)

7.1 ± 1.1 h

5.8 ± 1 d

7.1 ± 1 h

5.8 ± 0.9 d

7.2 ± 0.9 h

5.7 ± 1.2 d

7.1 ± 0.9 h

5.4 ± 0.9 d

Anaerobic fatigue
(AF) (%)

52.4 ± 17.6

56.3 ± 8.4

56.3 ± 6.5

55.6 ± 5.5

58.3 ± 7.34

61.3 ± 8.8

55.3 ± 8.6

60.2 ± 9.2

Variable
Peak power (PP)
(W)
Mean power (MP)
(W)

a

Denotes post-intervention mean PP was significantly lower in PG than CG (p = 0.013; Bonferroni: p = 0.006), b Denotes post-intervention mean RPP was
significantly lower in PG than CG (p = 0.006; Bonferroni: p = 0.006), c Denotes post-intervention mean MP was significantly lower in females than males (p =
0.017; Bonferroni: p = 0.021), d Denotes post-intervention mean RMP was significantly lower in females than males (p = 0.036; Bonferroni: p = 0.018), e
Denotes overall mean PP was significantly greater in males than females (p < 0.001), f Denotes overall mean RPP was significantly greater in males than
females (p < 0.001), g Denotes overall mean MP was significantly greater in males than females (p < 0.001), and h Denotes overall mean RMP was
significantly greater in males than in females (p < 0.001).
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Figure 3
Pre- and Post-Intervention Peak Power by Treatment
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* Denotes mean peak power at the post-intervention time point was significantly lower than the
pre-intervention time point for PG (p = 0.006).
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Figure 4
Pre- and Post-Intervention Relative Peak Power by Treatment
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* Denotes relative mean peak power at the post-intervention time point was significantly lower
than the pre-intervention time point for PG (p = 0.006).
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Figure 5
Pre- and Post-Intervention Mean Power by Sex
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* Denotes relative mean power at the post-intervention time point was significantly lower than
the pre-intervention time point for females (p = 0.021).
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Figure 6
Pre- and Post-Intervention Relative Mean Power by Sex
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* Denotes relative mean power at the post-intervention time point was significantly lower than
the pre-intervention time point for females (p = 0.018).

Psychological Wellbeing
Pre-Intervention Comparisons
Mean psychological wellbeing (PWB) scores for each of the 6 aspects (autonomy,
environmental mastery, personal growth, positive relation with others, purpose in life, and selfacceptance) by sex and by treatment at the pre-intervention time point are presented in Tables 26
and 27, respectively. Overall autonomy scores ranged from 8 to 21, environmental mastery
scores ranged from 7 to 21, personal growth scores ranged from 15 to 21, positive relation with
other scores ranged from 10 to 21, purpose in life scores ranged from 11 to 21, and selfacceptance scores ranged from 8 to 21. There was a significant sex-related difference with
respect to purpose in life scores in which females had 7.7% higher scores than males (p = 0.041).
There were no significant sex-related differences with respect to autonomy, environmental
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mastery, personal growth, positive relation with others, and self-acceptance. There were also no
significant treatment differences for and no 2-way (treatment assignment * sex) interactions or
main effects for all PWB aspects (F(1, 45) = 1.976, p = 0.167, η2 = 042, F(1, 45) = 0.303, p =
0.585, η2 = 0.007, F(1, 45) = 0.255, p = 0.616, η2 = 0.006, F(1, 45) = 0.151, p = 0.699, η2 =
0.003, F(1, 45) = 0.166, p = 0.686, η2 = 0.004, F(1, 45) = 0.237, p = 0.628, η2 = 0.005,
respectively; Table 28).

Table 26
Pre-Intervention Psychological Wellbeing by Sex
Pre-Intervention
Variable

Males
± SD (n)

Females
± SD (n)

Overall
± SD (N)

Autonomy

17 ± 3.1
(24)

16 ± 3
(25)

15.5 ± 3.1
(25)

Personal Growth

Positive Relation
with Others

p

Cohen’s d

16.5 ± 3
(49)

0.273

0.317

15.7 ± 3.4
(25)

15.6 ± 3.3
(50)

0.849

-0.055

20 ± 1.6
(24)

20.4 ± 0.9
(25)

20.2 ± 1.3
(49)

0.336

-0.280

17.5 ± 3
(24)

17.9 ± 3
(25)

17.7 ± 3
(49)

0.694

-0.113

Purpose in Life

16.9 ± 2.2
(24)

18.2 ± 2.2
(25)

17.6 ± 2.4
(49)

0.041 a

-0.600

Self-Acceptance

17.5 ± 3.2
(24)

17.9 ± 3.1
(25)

17.7 ± 3.1
(49)

0.612

-0.146

Environmental
Mastery

Note. Values represent participant scores for each aspect from a 7-point Likert scale of the Psychological
Wellbeing Scale.
a

Denotes mean purpose in life scores were significantly higher in females than males (p = 0.041).
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Table 27
Pre-Intervention Psychological Wellbeing by Treatment
± SD
Cannabidiol
Group (CG)
(n = 24)

Placebo
Group (PG)
(n = 25)

Overall
(N = 49)

p

Cohen’s d

17 ± 3

16 ± 3.1

16.5 ± 3

0.273

0.317

Environmental
Mastery

16.1 ± 2.8

15 ± 3.6

15.6 ± 3.3

0.307

0.295

Personal Growth

20.2 ± 1.2

20.2 ± 1.4

20.2 ± 1.3

0.929

-0.26

Positive Relation
with Others

17.3 ± 3.1

18.1 ± 2.8

17.7 ± 3

0.384

-0.251

Purpose in Life

17.5 ± 2.6

17.8 ± 2.1

17.6 ± 2.4

0.658

-0.127

Self-Acceptance

17.6 ± 2.7

17.8 ± 3.6

17.7 ± 3.1

0.812

-0.060

Pre-Intervention
Variable
Autonomy

Note. Values represent participant scores for each aspect from a 7-point Likert scale of the Psychological
Wellbeing Scale. There were no significant treatment differences.
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Table 28
Pre-Intervention Psychological Wellbeing by Treatment and Sex
± SD
Cannabidiol
Group-Male
(CG-M)
(n = 12)

Cannabidiol
Group-Female
(CG-F)
(n = 12)

Placebo
Group-Male
(PG-M)
(n = 12)

Placebo
Group-Female
(PG-F)
(n = 13)

Overall
(N = 49)

18.1 ± 3

16 ± 2.7

16 ± 2.8

16.2 ± 3.4

16.5 ± 3

Environmental
Mastery

16.3 ± 2.5

16.9 ± 3.2

14.8 ± 3.6

15.5 ± 3.8

15.6 ± 3.3

Personal Growth

20.1 ± 1.4

20.3 ± 0.9

20 ± 1.8

10.5 ± 0.9

20.2 ± 1.2

Positive Relation
with Others

17 ± 3.5

17.7 ± 2.9

18.1 ± 2.5

18.1 ± 3.2

17.7 ± 2.9

Purpose in Life

16.9 ± 2.5

18 ± 2.7

16.9 ± 2.1

18.5 ± 1.9

17.6 ± 2.4

Self-Acceptance

17.6 ± 2.7

17.5 ± 2.7

17.3 ± 3.7

18.2 ± 3.6

17.7 ± 3.1

Pre-Intervention
Variable
Autonomy

Note. Values represent participant scores for each aspect from a 7-point Likert scale of the Psychological
Wellbeing Scale. There were no significant interactions or main effects.

Intervention-Related Outcomes
Mean PWB scores for each aspect by each time point, treatment, and sex are presented in
Table 29. There were no significant 3-way (time * treatment * sex) and 2-way (time * sex, time *
treatment, and treatment * sex) interactions on mean PWB scores for each aspect. There was
main effect of time on mean personal growth, positive relation with others, purpose in life scores
in which each significantly decreased by 5%, 7%, and 7% by the end of the intervention (p <
0.001, p = 0.017, and p = 0.016, respectively). A main effect of sex was also found with respect
to mean purpose in life scores in which females had 11.7% scores than males (p = 0.008).
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Cognitive Function
Pre-Intervention Comparisons
Mean cognitive function T scores and cognitive function abilities T scores by sex and by
treatment at the pre-intervention time point are presented in Tables 30 and 31, respectively.
Overall cognitive function T scores ranged from 29.8 to 63.9 and cognitive function ability T
scores ranged from 36.9 to 67.1. There were no significant sex or treatment differences with
respect to cognitive function and cognitive function abilities T scores. When these outcomes
were analyzed by a 2-way ANOVA (treatment assignment * sex), there were no interactions or
main effects were with respect to cognitive function T score F(1, 45) = 0.923, p = 0.342, η2 =
0.020 and cognitive function abilities T scores F(1, 45) = 0.412, p = 0.542, η2 = 0.009 (Table 32).
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Table 29
Psychological Wellbeing by Time, Treatment, and Sex

Variable
Autonomy
Environmental
Mastery

Pre-Intervention

Post-Intervention

± SD

± SD

Cannabidiol
Group-Male
(CG-M)
(n = 11)

Cannabidiol
Group-Female
(CG-F)
(n = 12)

Placebo
Group-Male
(PG-M)
(n = 11)

Placebo
Group-Female
(PG-F)
(n = 13)

Cannabidiol
Group-Male
(CG-M)
(n = 11)

Cannabidiol
Group-Female
(CG-F)
(n = 12)

Placebo
Group-Male
(PG-M)
(n = 11)

Placebo
Group-Female
(PG-F)
(n = 13)

17.8 ± 3

15.9 ± 2.7

16.1 ± 2.9

16.1 ± 3.3

17.6 ± 2.3

15.7 ± 2.8

15.6 ± 3.6

15.9 ± 3.7

15.9 ± 3.2

15 ± 3.7

15.5 ± 3.8

15 ± 4.5

15.3 ± 3.1

14.9 ± 2.2

16 ± 4.5

16.3 ± 2.6

Personal Growth

20 ± 1.4

20.2 ± 0.9

20.1 ± 1.8

20.5 ± 0.8

18.7 ± 2.8 a

19.3 ± 1.5 a

18.6 ± 3 a

20.1 ± 1.3 a

Positive Relation
with Others

16.8 ± 3.6

17.7 ± 2.9

18.3 ± 2.5

18.1 ± 3.2

15.6 ± 3 b

17.9 ± 3 b

16 ± 3.1 b

17.5 ± 3 b

Purpose in Life

16.6 ± 2.4

18 ± 2.7 d

16.7 ± 2.1

18.5 ± 1.9 d

15.3 ± 3 c

17.3 ± 2.9 c, d

15.1 ± 4.3 c

17.9 ± 3.2 c, d

Self-Acceptance

17.4 ± 2.7

17.6 ± 2.7

17.5 ± 3.9

18.2 ± 3.6

17.5 ± 2.6

16.8 ± 2.3

16.9 ± 4.1

17.5 ± 3.2

Note. Values represent participant scores for each aspect from a 7-point Likert scale of the Psychological Wellbeing Scale.
a
Denotes post-intervention mean personal growth scores were significantly lower than pre-intervention scores (p < 0.001), b Denotes post-intervention mean
positive relation with other scores were significantly lower than pre-intervention scores (p = 0.017), c Denotes post-intervention mean purpose in life scores
were significantly lower than pre-intervention scores (p = 0.016), and d Denotes mean purpose in life scores were significantly higher in females than males (p
= 0.008).
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Table 30
Pre-Intervention Cognitive Function T Scores by Sex
± SD
Pre-Intervention
Variable

Males
(n = 24)

Females
(n = 25)

Overall
(N = 49)

p

Cohen’s d

Cognitive Function
T Scores

49.8 ± 7.4

48.5 ± 8.8

49.1 ± 8.1

0.588

0.156

Cognitive Abilities
T Scores

52.3 ± 8.6

51.1 ± 7.1

51.7 ± 7.8

0.616

0.144

Note. Values represent participant scores calculated from the 5-point Likert scale of each of the NIH PROMIS
Cognitive Function Questionnaires. There were no significant sex differences.

Table 31
Pre-Intervention Cognitive Function T Scores by Treatment
± SD
Cannabidiol
Group (CG)
(n = 24)

Placebo
Group (PG)
(n = 25)

Overall
(N = 49)

p

Cohen’s d

Cognitive Function
T Scores

50.1 ± 6.6

48.2 ± 9.4

49.1 ± 8.1

0.102

0.220

Cognitive Abilities
T Scores

51.8 ± 7.1

51.6 ± 8.7

51.7 ± 7.8

0.394

0.035

Pre-Intervention
Variable

Note. Values represent participant scores calculated from the 5-point Likert scale of each of the NIH PROMIS
Cognitive Function Questionnaires. There were no significant treatment differences.
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Table 32
Pre-Intervention Cognitive Function T Scores by Treatment and Sex
± SD
Cannabidiol
Group-Male
(CG-M)
(n = 11)

Cannabidiol
Group-Female
(CG-F)
(n = 12)

Placebo
Group-Male
(PG-M)
(n = 11)

Placebo
Group-Female
(PG-F)
(n = 13)

Overall
(N = 47)

Cognitive Function
T Scores

51.7 ± 7.2

48.3 ± 6.0

47.9 ± 8.0

48.7 ± 11.1

4.0 ± 8.1

Cognitive Abilities
T Scores

53.0 ± 9.1

50.5 ± 5.1

51.3 ± 9.2

51.7 ± 8.8

51.6 ± 8.0

Pre-Intervention
Variable

Note. Values represent participant scores calculated from the 5-point Likert scale of each of the NIH PROMIS
Cognitive Function Questionnaires. There were no significant group differences.

Intervention-Related Outcomes
Mean cognitive function T scores and cognitive function abilities T scores by each time
point, treatment, and sex are presented in Table 33. There were no significant 3-way interactions
(time * treatment * sex), 2-way interactions (time * sex, time * treatment, and treatment * sex),
and main effects (time, treatment, and sex) with respect to both cognitive function T scores and
cognitive function abilities T scores.
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Table 33
Mean Cognitive Function T Scores by Time, Treatment, and Sex
Pre-Intervention

Post-Intervention

± SD

± SD

Cannabidiol
Group-Male
(CG-M)
(n = 11)

Cannabidiol
Group-Female
(CG-F)
(n = 12)

Placebo
Group-Male
(PG-M)
(n = 11)

Placebo
Group-Female
(PG-F)
(n = 13)

Cannabidiol
Group-Male
(CG-M)
(n = 11)

Cannabidiol
Group-Female
(CG-F)
(n = 12)

Placebo
Group-Male
(PG-M)
(n = 11)

Placebo
Group-Female
(PG-F)
(n = 13)

Cognitive Function
T Scores

51.7 ± 7.2

48.3 ± 6.0

47.9 ± 8.0

48.7 ± 11.1

49.8 ± 6.5

48.4 ± 7.2

49.6 ± 9.7

46.2 ± 13.4

Cognitive Abilities
T Scores

53.0 ± 9.1

50.5 ± 5.1

51.3 ± 9.2

51.7 ± 8.8

51.1 ± 8.8

52.7 ± 8.0

52.7 ± 9.1

50.0 ± 14.5

Variable

Note. Values represent participant scores calculated from the 5-point Likert scale of each of the NIH PROMIS Cognitive Function Questionnaires. There were
no significant interactions or main effects.
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Resting Concentrations of C-Reactive Protein
Pre-Intervention Comparisons
Mean concentrations of C-reactive protein (CRP) by sex and by treatment at the preintervention time point are presented in Tables 34 and 35, respectively. Overall concentrations of
CRP ranged from 0.1 to 8.8 mg/L when all groups were combined at the pre-intervention time
point and there were no significant differences between sex and treatment. A 2-way ANOVA
(treatment assignment * sex) found no interactions or main effects with respect to concentrations
of CRP at the pre-intervention time point; however, a medium effect size was detected F(1, 42) =
4.089, p = 0.050, η2 = 0.089 showing that CG-F had 81% higher concentrations of CRP than PGF (Table 36). The inter- and intra-assay CVs for serum concentrations of CRP were 11.78% and
3.5%, respectively, and both were within manufacturer ranges.
Intervention-Related Outcomes
Mean concentrations of CRP at the pre- and post-intervention time points are presented in
Figure 7. Mean concentrations of CRP by time point, treatment, and sex are presented in Table
37. There were no significant 3-way interactions (time * treatment * sex) with respect to CRP. A
significant 2-way interaction (treatment * sex) was found with respect to resting concentrations
of CRP (p = 0.006). Bonferroni post hoc testing showed that CG-F had 92% higher
concentrations of CRP than PG-F (p = 0.026), and CG-F had 115% higher concentrations of
CRP than CG-M (p = 0.012; Figure 8).
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Table 34
Pre-Intervention Resting Concentrations of C-Reactive Protein by Sex
Pre-Intervention
Variable

Males
± SD (n)

Females
± SD (n)

Overall
± SD (N)

C-reactive protein (CRP)
(mg/L)

1.1 ± 1.5
(22)

1.9 ± 2.1
(24)

1.5 ± 1.9
(46)

p

Cohen’s d

0.150

-0.432

Note. There were no significant sex differences.

Table 35
Pre-Intervention Resting Concentrations of C-Reactive Protein by Treatment

Pre-Intervention
Variable
C-reactive protein (CRP)
(mg/L)

Cannabidiol
Group (CG)
± SD (n)

Placebo
Group (PG)
± SD (n)

Overall
± SD (N)

1.7 ± 2.1
(23)

1.3 ± 1.6
(23)

1.5 ± 1.8
(46)

p

Cohen’s d

0.494

0.204

Note. There were no significant treatment differences.

Table 36
Pre-Intervention Resting Concentrations of C-Reactive Protein by Treatment and Sex

Pre-Intervention
Variable
C-reactive protein (CRP)
(mg/L)

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Overall
± SD (N)

0.73 ± 0.7
(11)

2.6 ± 2.6
(12)

1.5 ± 2
(11)

1.2 ± 1.2
(12)

1.5 ± 1.9
(46)

Note. There were no significant interactions or main effects.
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Figure 7
Pre- and Post-Intervention Concentrations of C-Reactive Protein

7.00

C-Reactive Protein Concentration (mg/L)

6.00

5.00

4.00

3.00

2.00

1.00

0.00
Pre-Intervention

Post-Intervention

P1

P2

P3

P6

P7

P8

P9

P10

P11

P13

P14

P15

P16

P17

P18

P19

P20

P22

P24

P25

P27

P28

P29

P32

P34

P35

P42

P44

P45

P46

P47

P50

P51

P53

P54

P55

P56

P57

P58

P60

P61

P64

Note. P = participant number.
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Table 37
Resting Concentrations of C-Reactive Protein by Time, Treatment, and Sex
Pre-Intervention

Variable
C-reactive protein
(CRP) (mg/L)

Post-Intervention

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

0.7 ± 0.7
(11)

2.6 ± 2.6
(12) a, b

1.5 ± 2
(11)

1.2 ± 1.2
(12

0.6 ± 0.7
(11)

2.5 ± 2.7
(12) a, b

2.6 ± 2.7
(11)

0.6 ± 0.5
(12)

Note. a Denotes overall mean CRP concentrations were significantly greater in CG-F than PG-F (p = 0.026) and b Denotes overall mean CRP concentrations
were significantly greater in CG-F than CG-M (p = 0.012).
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Figure 8

Mean C-Reactive Protein (CRP) (mg/L)

Mean C-Reactive Protein Concentrations by Treatment and Sex
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Note. Data are presented as mean ± standard error (SE). CG-M = CBD male group, CG-F = CBD
female group, PG-M = placebo male group, PG-F = placebo female group.
#

Denotes overall mean CRP concentrations were significantly greater in CG-F than CG-M (p =
0.012) and * Denotes overall mean CRP concentrations were significantly greater in CG-F than
PG-F (p = 0.026).

Resting Concentrations of Brain-Derived Neurotrophic
Factor
Pre-Intervention Comparisons
Mean concentrations of brain-derived neurotrophic factor (BDNF) by sex and by
treatment at the pre-intervention time point are presented in Tables 38 and 39, respectively.
Overall concentrations of BDNF ranged from 5 to 87 ng/ml when all groups were combined at
the pre-intervention time point. There was a significant sex difference in which females had 38%
higher BDNF concentrations than males at the pre-intervention time point (p = 0.025). There
were no treatment differences, no 2-way interactions (treatment assignment * sex), and no main
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effects with respect to concentrations of BDNF at the pre-intervention time point. However, a
medium effect size was detected in treatment F(1, 34) = 3.504, p = 0.070, η2 = 0.093 showing
that PG had 43% higher concentrations of BDNF than CG, and in sex F(1, 34) = 3.366, p =
0.075, η2 = 0.090 showing that females had 28% higher concentrations of BDNF than males
(Table 40). The inter- and intra-assay CVs for serum concentrations of BDNF were 2.5% and
5%, respectively, and both were within manufacturer ranges.
Intervention-Related Outcomes
Mean concentrations of CRP at the pre- and post-intervention time points are presented in
Figure 9. Mean concentrations of BDNF by time point, treatment, and sex are presented in Table
41. There were no significant 3-way interactions (time * treatment * sex) with respect to BDNF
concentrations. A significant 2-way interaction (treatment * sex) was found with respect to
overall resting concentrations of BDNF (p = 0.009). Bonferroni post hoc testing showed
overall mean BDNF concentrations in PG-F were 43% greater than CG-F (p = 0.014) and 39%
greater than PG-M (p = 0.008; Figure 10).

Table 38
Pre-Intervention Resting Concentrations of Brain-Derived Neurotrophic Factor by Sex

Pre-Intervention Variable

Males
± SD (n)

Females
± SD (n)

Overall
± SD (N)

Brain-derived neurotrophic
factor (BDNF) (ng/mL)

28.5 ± 10
(15)

41.4 ± 20
(22)

36 ± 1.7
(37)

p

Cohen’s d

0.025 a

-0.787

Note. a Denotes mean BDNF concentrations in females were significantly greater than males.
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Table 39
Pre-Intervention Resting Concentrations of Brain-Derived Neurotrophic Factor by Treatment

Pre-Intervention Variable
Brain-derived neurotrophic
factor (BDNF) (ng/mL)

Cannabidiol
Group (CG)
± SD (n)

Placebo
Group (PG)
± SD (n)

Overall
± SD (N)

31.4 ± 11
(19)

41.2 ± 22
(19)

3 ± 17.4
(38)

p

Cohen’s d

0.089

-0.575

Note. There were no significant treatment differences.

Table 40
Pre-Intervention Resting Concentrations of Brain-Derived Neurotrophic Factor by Treatment
and Sex

Pre-Intervention Variable
Brain-derived neurotrophic
factor (BDNF) (ng/mL)

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Overall
± SD (N)

30 ± 1.3
(8)

33 ± 0.9
(11)

33 ± 1.7
(8)

50 ± 2.4
(11)

37 ± 1.8
(38)

Note. There were no significant interactions or main effects.
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Figure 9
Pre- and Post-Intervention Concentrations of Brain-Derived Neurotrophic Factor
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Table 41
Resting Brain-Derived Neurotrophic Factor by Time, Treatment, and Sex
Pre-Intervention

Variable
Brain-derived
neurotrophic factor
(BDNF) (ng/mL)

Post-Intervention

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

Cannabidiol
Group-Male
(CG-M)
± SD (n)

Cannabidiol
Group-Female
(CG-F)
± SD (n)

Placebo
Group-Male
(PG-M)
± SD (n)

Placebo
Group-Female
(PG-F)
± SD (n)

33 ± 9.7
(7)

32.8 ± 9.2
(11)

27 ± 3.6
(7)

46.3 ± 21.4
(10) a, b

41.8 ± 14.2
(7)

30.2 ± 9.8
(10)

29.7 ± 9.2
(7)

42.5 ± 19.2
(10) a, b

Note. a Denotes overall mean BDNF concentrations in PG-F were significantly greater than CG-F (p = 0.014) and b Denotes overall mean BDNF
concentrations in PG-F were significantly greater than PG-M (p = 0.008).
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Figure 10
Mean Brain-Derived Neurotrophic Factor Concentrations by Treatment and Sex
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Note. Data are presented as mean ± SE. BDNF = Brain-derived neurotrophic factor, CG-M =
CBD male group, CG-F = CBD female group, PG-M = placebo male group, PG-F = placebo
female group.
#

Denotes overall mean BDNF concentrations in PG-F were significantly greater than CG-F (p =
0.014) and * Denotes overall mean BDNF concentrations in PG-F were significantly greater than
PG-M (p = 0.008).
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CHAPTER V
DISCUSSION
There is a great need to clarify and understand the potential health effects of long-term
cannabidiol (CBD) use given false medical claims and increasing accessibility of the product to
consumers. Previous research shows inconclusive results due to lack of healthy volunteers,
length of CBD administration (acute vs chronic administration), imbalanced samples (unequal
numbers of men and women, exclusion of women; Bhattacharyya et al., 2010; Crane, Schuster,
& Gonzalez, 2013; Martin-Santos et al., 2012; Solowij et al., 2018), contamination of CBD
products (presence of THC and/or heavy metals, lack of CBD purity testing; Crane, Schuster, &
Gonzalez, 2013; Lisano et al., 2020; Solowij et al., 2018), and the variability of testing protocols
used for determining health-related fitness (Arndt & de Wit, 2017; Babalonis et al., 2017; Haney
et al., 2016). The current study was the first randomized placebo-controlled clinical trial with
parallel design to explore the effects of 50 mg of daily CBD for 8 weeks in a population of
healthy males and females. The main objectives of this study were to investigate overall sex or
treatment assignment differences with respect to physical activity patterns, health-related fitness,
mental and cognitive health before an 8-week CBD intervention and to explore whether CBD
will significantly affect these outcomes. Furthermore, this study sought to explore whether CBD
will significantly alter concentrations of C-reactive protein (CRP) and brain-derived neurotrophic
factor (BDNF).
The first aim examined overall differences, by sex, treatment, and treatment by sex in all
physical and mental health outcomes at the pre-intervention time point. With respect to sex
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differences, it was specifically hypothesized that females would have lower average daily step
counts and distance traveled, lower muscular strength, relative peak oxygen uptake (V̇O2 peak)
values, and anaerobic fitness test scores, higher body fat percentage (BF%) and resting
concentrations of CRP, and similar resting concentrations of BDNF, measures of psychological
wellbeing (PWB), and cognitive function when compared with males at the pre-intervention time
point. In the present study, there were sex differences in self-reported time spent engaged in
vigorous physical activity, mean resting systolic blood pressure (RSBP) and resting diastolic
blood pressure (RDBP), height, body mass (BM), lean body mass (LBM), BF%, relative V̇O2
peak values, bench press and back squat one repetition maximum (BP 1RM and BS 1RM,
respectively) performance, absolute and relative peak and mean anaerobic power output, the
purpose in life aspect of the PWB, and resting concentrations of BDNF at the pre-intervention
time point. However, there were no sex differences in average daily step counts and distance
traveled, cognitive function, and CRP concentrations at the pre-intervention time point.
With respect to treatment, it was specifically hypothesized that there would be no
differences between males and females consuming CBD and males and females consuming
placebo in all physical and mental health outcomes at the pre-intervention time point. In the
present study, there was one treatment difference with respect to days spent walking in which
placebo group (PG) reported 19% more days walking than CBD group (CG) at the preintervention time point. There were no other treatment differences in all other physical and
mental health outcomes, and there were no treatment by sex interactions in all of the physical
and mental health outcomes at the pre-intervention time. However, there was a main effect of sex
with respect to self-reported physical activity in days spent walking, height, BM, LBM, BF%,
relative V̇O2 peak values, BP and BS 1RM performance, absolute and relative peak and mean
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anaerobic power output, the purpose of life aspect in PWB, and resting BDNF concentrations at
the pre-intervention time point. Overall, there were sex differences with respect to self-reported
physical activity, body size and composition, measures of cardiorespiratory fitness, muscular
strength, and anaerobic fitness, PWB, and resting concentrations of BDNF, but no sex
differences in average daily steps and distance traveled, cognitive function, and resting
concentrations of CRP.
The final aim examined whether 8 weeks of CBD affected all physical and mental health
outcomes in those consuming CBD with a hypothesis specifically stating that both males and
females consuming CBD would experience increases in average daily step counts and distance
traveled, improvements in relative V̇O2 peak, bench press and back squat 1RM performance,
absolute and relative peak and mean power outputs, measures of cognitive function and PWB,
reduced CRP concentrations, and increased BDNF concentrations over the course of the
intervention period when compared with males and females consuming placebo. In the present
study, the analyses revealed no treatment differences with respect to all physical and mental
health outcomes over the course of the intervention. However, there was a significant time by
treatment interaction with respect to absolute and relative peak power in which PG experienced a
9% and 3% decline in absolute and relative peak power compared with CG, which experienced
no changes in either absolute or relative peak power, over the course of the intervention.
It was also hypothesized that females in the CBD group (CG-F) would experience a
greater increase in average daily step counts and distance traveled, greater improvements in
BF%, relative V̇O2 peak, measures of cognitive function and PWB, a greater reduction in CRP
concentrations, and a greater increase in BDNF concentrations when compared with males in the
CBD group (CG-M) over the course of the intervention. In the present study, the analyses
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revealed no differences between CG-M and CG-F with respect to these physical and mental
health outcomes. However, there was a significant time by sex interaction with respect to
absolute and relative mean power in which females experienced a 4.5% and 3.5% decline in
absolute and relative mean power compared with males, which experienced no changes in either
absolute or relative mean power, over the course of the intervention. There was a main effect of
sex in which males had 7% higher overall mean RSBP, 9 % higher overall mean RDBP, 18%
higher overall BM, 28% higher overall LBM, 55% lower overall BF%, 40% and 22% higher
overall mean peak and relative peak power (PP and RPP, respectively), and 41% and 22% higher
overall mean and relative mean power (MP and RMP, respectively) than females. Interestingly,
there was significant treatment by sex interaction for overall CRP concentrations in which
overall mean CRP concentrations in CG-F were 92% and 115% greater than overall mean CRP
concentrations in females in the placebo group (PG-F) and CG-M, respectively. Another
treatment by sex interaction was also found for overall BDNF concentrations in which overall
mean BDNF concentrations in PG-F were 43% and 39% greater than overall mean BDNF
concentrations in CG-F and males in the placebo group (PG-M), respectively. Overall, 8 weeks
of CBD supplementation did not affect physical and mental health and biomarkers of
inflammation and neural health over the course of the intervention.
Resting Heart Rate and Blood Pressure
At the pre-intervention time point, mean RHR, RSBP, and RDBP were all within normal
ranges when all groups were combined (N = 47; RHR: 67.4 ± 9.6 bpm, RSBP: 118 ± 10.3
mmHg, RDBP: 75.1 ± 8). There were no sex differences in RHR which was somewhat surprising
as females typically have smaller hearts and left ventricular size which are often linked to higher
heart rates when compared with males (Wingate, 1997). At the pre-intervention time point and
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when all males were grouped together, their average blood pressure (RSBP: 121.5 ± 9.5 mmHg;
RDBP: 77.7 ± 6.9 mmHg) placed them in the elevated risk category (120-129 mmHg and less
than 80 mmHg) as defined by the American Heart Association (Vaduganathan et al., 2018).
When all females were grouped together, their average blood pressure (RSBP: 114.9 ± 10.1
mmHg; RDBP: 72.8 ± 8.2 mmHg) placed them in the normal category (less than 120 SBP and
less than 80 mmHg DBP; Vaduganathan et al., 2018). Although these sex differences in RSBP
and RDBP were observed at the pre-intervention time point, no differences were found as a
result of the intervention. There was a significant time by treatment interaction (p = 0.047), but
the multiple comparisons failed to identify which time points and treatments were different.
When RHR, RSBP, and RDBP were compared between treatments, there were no differences
between CG and PG. Overall, these findings suggest that 8 weeks of daily, low dose CBD does
not have long-term effects on RHR, RSBP, and RDBP in males and females.
The lack of a CBD-mediated change in RHR, RSBP, and RDBP is supported by a few
other related studies using healthy volunteers. One study found no differences between oral CBD
(600 mg) and placebo with respect to RHR after three, separate administrations over the course
of a one-month time frame in healthy men. This study concluded that oral CBD was not
associated with an increase in RHR (Martin-Santos et al., 2012). Another study revealed no
changes in RHR, RSBP, and RDBP after 7 days of vaporized CBD inhalation (13.75 mg) in
cannabis-using (using < 2 times per week) males (n = 21) and females (n = 19; Arkell et al.,
2022). In one randomized placebo-controlled, double blind study with parallel design exploring
the effects of oral CBD (600 mg) on hemodynamics in healthy males (n = 13), CBD acutely
reduced resting mean arterial pressure (-2 mmHg), but did not alter RSBP and RDBP after 7
consecutive days of consumption (Sultan et al., 2020). However, when both groups completed a
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3-minute isometric handgrip exercise on day 1 and 7, oral CBD attenuated increases in RSBP (-6
to -5.7 mmHg) within 2-3 minutes of acute CBD ingestion on day 1, and repeated oral CBD
attenuated increases in RSBP (-8mmHg) within 1 minute of finishing the handgrip exercise on
day 7, suggesting that CBD may only act on RSBP in response to acute stress (Sultan et al.,
2020). These results are fascinating because mean arterial pressure is calculated as the sum of
systolic blood pressure and 2 times diastolic blood pressure, and in the current study, there were
no significant group differences with respect to RDBP although a medium effect size (p = 0.070,
η2 = 0.078) was observed at a confidence interval of 95% [-.32, 7.77]. It is important to note that
the results of the present study and those of the aforementioned projects provide a glimpse into
the potential effects of cannabis compounds and CBD on RHR, RSBP, RDBP, but this area is
still largely unexplored.
Physical Activity Patterns
Self-reported physical activity within the last 7 days revealed that participants were
below the recommendations set forth by the American College of Sports Medicine (ACSM) and
the American Heart Association for physical activity guidelines for moderate intensity aerobic
physical activity which is at least 30 minutes for 5 days per week (150 minutes per week)
(Haskell et al., 2007). However, mean responses placed participants within guidelines for
vigorous intensity aerobic physical activity which is at least 20 minutes for 3 days per week (60
mins per week; Haskell et al., 2007). Compared to these guidelines, participants engaged in 92%
less and 2% more moderate and vigorous intensity aerobic physical activity (53.3 ± 36.1
minutes, 61.2 ± 44.8 minutes), respectively. Though participants did not meet the moderate
intensity aerobic physical activity guidelines, they fit within the national average in which 53.3%
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of adults ages 18 years and older meet the total physical activity guidelines (Centers for Disease
Control, 2022).
When comparing sex, time spent engaged in moderate physical activity was not different
between males and females; however, males engaged in 45% more vigorous physical activity (74
± 47.5 minutes) than females (47.8 ± 38.4 minutes; p = 0.044), and females spent 24% more days
walking than males (p = 0.001). These findings are similar to a study evaluating gender
differences in physical activity and sedentary behavior using the IPAQ from 2002 to 2009 which
found that males engaged in more vigorous physical activity than females from 2002-2009 (p <
0.05), males had significantly higher moderate physical activity than females in 2003-2004 (p =
0.001) and females had higher moderate physical activity than males in 2005-2006 (p = 0.03),
and females spent significantly more time walking than males in 2002, and 2005-2006 (p < 0.001
and p = 0.005, respectively; Dagmar et al., 2011). It is important to note that self-reported
physical activity was collected only at the pre-intervention time point to determine subject health
status and whether the subject had the potential to exercise safely.
The Fitbit wrist accelerometer was used at both pre– and post-intervention time points to
provide a more objective measure of physical activity. It is well established that individuals tend
to underestimate sedentary time (time spent sitting) and overestimate moderate to vigorous
physical activity (MVPA). In one study that compared IPAQ responses to Actigraph
accelerometry data collected in 1,751 adults ages 19 years and older, results showed that males
underestimated sedentary time (131 minutes lower) and overestimated MVPA when compared
with accelerometer data (Dyrstad et al., 2014), and that this overestimation of MVPA resulted in
incorrect sex differences of MVPA which suggested males engaged in 47% more MVPA when
compared with females (Dyrstad et al., 2014). However, researchers concluded that IPAQ
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responses may not accurately reflect physical activity and that more objective measures of
physical activity should be used (Dyrstad et al., 2014). Although participants in the current study
may have incorrectly reported moderate aerobic physical activity on the IPAQ, they compared
favorably to national averages of accelerometry data. Mean steps per day was 9,676 in a sample
of 3,744 Americans ages 20 years and older (Tudor-Locke et al., 2009) which is 17% lower than
the 7-day average from participants in the present study (11,495 ± 4,193 steps per day), placing
them in the active category (10,000 to 12,499 steps per day; Tudor-Locke & Bassett, 2004).
Additionally, one study determined that an average of 8,000 steps per day translated to an
average of 30 minutes of MVPA per day in a sample of 3,523 healthy adult males (n = 1,782)
and females (n = 1,742) ages 20 and older who wore an Actigraph accelerometer for one full day
(Tudor-Locke et al., 2011). By this definition, the participants in the present study met the 150minute requirement of moderate aerobic physical activity due to their 7-day average of mean
steps per day.
To date, there are no studies examining the effect of daily CBD use and physical activity
using accelerometry. In the current study, no differences between CG and PG with respect to
accelerometer-based steps per day and distance traveled at both the pre- and post-intervention
time points were observed. However, the IPAQ revealed that PG reported spending 19% more
days walking than CG (p <0.0001) at the pre-intervention time point. It is possible that the
variability in days spent walking between groups may be due to poor subjective perceptions of
physical activity which is a highlighted limitation of the IPAQ (Sember et al., 2020). There are
also no studies which have explored the potential for CBD-related sex differences in physical
activity. One recent cross-sectional study of 387 CBD-using adult males (n = 150) and females
(n = 237) found that most users were female (61%). Additionally, the same study found that a
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disproportionate number of users consumed CBD for post-workout muscle soreness (14% males,
7% females), general health and wellbeing (47% males, 31% females), and self-perceived
anxiety (48% females, 34% males; Moltke & Hindocha, 2021). These results imply that in a
sample of CBD users, only some individuals may be physically active and may be taking CBD
as a post-workout recovery aid. Despite these findings and other cross-sectional studies
describing CBD users (Corroon & Phillips, 2018; Fedorova et al., 2021; Wheeler, Merten, et al.,
2020), it is surprising that there are no longitudinal studies to date which explore physical
activity in CBD users with accelerometry.
Body Size and Composition Measures
At the pre-intervention time point, there were sex differences with respect to height, BM,
LBM, and BF%, but no sex differences in BMI. Males were 7.6% taller than females (p =
<0.001), 16.5% heavier than females (p < 0.001), had 32% more LBM than females (p =
<0.001), and had 53% less BF% than females (p < 0.001). Although males and females did not
differ with respect to BMI at the pre-intervention time point, overall mean BMI of participants
was 24.8 kg/m2 and categorized participants in the upper tier of “normal or healthy” (18.5 to 24.9
kg/m2) according to ACSM BMI standards (D. Riebe et al., 2018). Overall male and female BMI
ranged from 20 to 33 kg/m2 and 19.6 to 30 kg/m2, respectively, which reveals a large variance
within both sexes (11 and 9, respectively). In total, 14 individuals were in the “overweight”
category (25 to 29.9 kg/m2), and 4 individuals were in the “obese” category (greater than 30
kg/m2). However, it is important to note that BMI does not account for age, sex, bone structure,
fat distribution and LBM. When comparing mean BF% at the pre-intervention time point to
ACSM body composition norms, males in the current study were within the 50th to 40th
percentiles, categorizing them as “average” and “slightly below average,” and females were
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within the 30th to 20th percentiles for BF%, categorizing them as “below average.” There were no
treatment-related differences observed with respect to any of the outcome variables in this study.
There were no time by treatment by sex interactions with respect to all body size and
composition outcomes. However, a main effect of sex showed that similar sex differences in
BM, LBM, and BF% were still present at the end of the intervention. This suggests that 8 weeks
of daily, low dose CBD may not alter body composition, regardless of sex, in an otherwise
healthy, non-clinical population. The lack of CBD-related change in mean LBM is supported by
one randomized, placebo-controlled, double blind study with parallel design in overweight males
(n = 65) in which 6 weeks of 60 mg/d of CBD hemp oil extract (15 mg of hemp-derived CBD)
resulted in no changes in LBM and fat free mass when compared with the placebo group (Lopez
et al., 2020). However, another randomized study with a crossover design investigating CBD
pharmacokinetics found that the time it took for CBD (30 mg) to reach maximum concentration
after of acute ingestion in healthy men (n = 9) and women (n = 6) was significantly dependent on
fat free mass (Williams et al., 2021). These studies suggested that, although CBD may not alter
LBM, its absorption was affected by LBM and it was possible that larger doses of CBD were
needed in order to observe an effect on LBM.
Interestingly, no changes in BF% were observed after 8 weeks of CBD. Other preclinical
and cell culture studies suggested that CBD increased BF% through increased feeding patterns
(Farrimond et al., 2012) and may decrease BF% through increasing metabolism in white
adipocytes (Parray & Yun, 2016). However, these findings were not confirmed in clinical trials.
In fact, the closest human studies were survey based. Results from 2 national surveys in adults 18
and over (n = 50,000) revealed that prevalence of obesity was 14% to 17% lower in cannabis
users who used cannabis at least 3 days per week compared to 22% to 25% of nonusers (Le Strat
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& Le Foll, 2011) suggesting that cannabinoids and their derivatives may affect body
composition. It is important to note that the CBD content of the products that these individuals
used was not specified. This made it difficult to determine whether changes in BF% were
associated with tetrahydrocannabinol (THC), CBD, or a combination of both.
Cardiorespiratory Fitness
At the pre-intervention point, there were sex differences, but no treatment differences
with respect to any of the outcome variables in the present study. Overall, males had higher
mean, relative V̇O2 peak values than females. According to ACSM V̇O2 max standards, mean,
relative V̇O2 peak values placed males in the “good” category (44.3 to 48.2 ml/kg/min) for men
20 to 29 years old and mean, relative V̇O2 peak values placed females in the “good” category
(36.8 to 41.0 ml/kg/min) for women 20 to 29 years old (D. Riebe et al., 2018). Mean, relative
V̇O2 peak values are not the same as true V̇O2 max due to the specific criteria that must be met;
however, these values provide a good evaluation of the cardiorespiratory fitness in all study
participants. It is important to note that V̇O2 peak was reported because all study participants did
not reach the appropriate criteria for a V̇O2 max. More specifically, because this study was
focused on capturing the effects of CBD in a healthy, non-elite, recreationally active population,
and one that is representative of surveyed CBD users, the need to use the term V̇O2 peak, instead
of V̇O2 max, was not unexpected (BrightfieldGroup, 2017; Corroon & Phillips, 2018; Fedorova
et al., 2021; Wheeler, Merten, et al., 2020).
There were no V̇O2 peak-related time by treatment by sex interactions in this study.
However, there was a main effect of time where overall relative V̇O2 peak values decreased by
4% (p = 0.035) over the course of the intervention. This decrease in V̇O2 peak may be attributed
to the fact that data were collected during the COVID pandemic and participants were more
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stressed and may have been more likely to change their dietary habits. Also, there were no
significant differences in V̇O2 peak between treatments to suggest that CG was significantly
different than PG. Currently, no other study has evaluated effects of longer term, low dose, CBD
on V̇O2 in similar populations. However, the findings from the present study are contrary to one
recent randomized, double-blind pilot study that evaluated the effects of an acute oral CBD (300
mg) dose on aerobic performance in endurance-trained men (n = 9) on two, separate occasions
(Sahinovic et al., 2022). Researchers found that acute administration of CBD increased V̇O2 max
(+ 0.1 ± 0.2 L/min) without increasing heart rate or rate of perceived exertion, leading the
authors to speculate that a high dose of CBD taken just before aerobic activity may increase
tissue vasodilation (Sahinovic et al., 2022). Although the aforementioned pilot study assessed the
acute effects of a high dose, it also suggests that CBD may enhance aerobic performance. Other
similar studies are more focused on exploring chronic cannabis consumption on V̇O2 max
performance (Lisano et al., 2018, 2019), and cannabis administration before a V̇O2 test (Avakian
et al., 1979; Renaud & Cormier, 1986). Despite these intriguing findings, more research which
addresses the effects of both acute and long-term CBD treatments on V̇O2 max and
cardiorespiratory fitness are needed in the future.
Muscular Strength Measures
At the pre-intervention time point, there were sex differences in BP and BS 1RM and no
treatment differences. Generally, males had higher BP and BS 1RM values when compared to
females. When considering relative strength, males lifted, on average, 1.2-times their bodyweight
for BP and 1.4-times their bodyweight for BS, while females lifted, on average, 0.6-times their
bodyweight for BP and 1-times their bodyweight for BS. Compared to other healthy and
recreationally-trained males (n = 15) and females (n = 15; Seo et al., 2012), the males in the
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present study had 3% lower BP 1RM values and 2.5% higher BS 1RM values, and the females in
the present study had 5% higher BP 1RM values and 30% higher BS 1RM values. Given these
findings, it was clear that the males and females in this study were similar and, even slightly
stronger than other recreationally active males and the females.
No differences were found with respect to measures of muscular strength between CG
and PG as the result of the intervention, and there was no time by treatment by sex interaction.
The findings of the present study are in agreement with a recent randomized, placebo-controlled,
double-blind study with crossover design that found no effect of acute oral CBD (150 mg) on
maximal voluntary isomeric contraction after a damaging eccentric protocol in the elbow flexors
of untrained males (n = 13; Cochrane-Snyman et al., 2021). While the findings from the present
study are interesting, this general area of inquiry is confounded by the type of strength measure,
acute vs. chronic CBD administration, and a lack of female study participants.
In the current study, CG-M and CG-F did not experience significant changes in both
bench press and back squat 1RMs. Though these increases were not statistically significant, CGM experienced a 1% and 2.6% increase in bench press and back squat 1RM values, respectively
and CG-F experienced a 2.5% and 8% increase in bench press and back squat 1RM values,
respectively. Given these responses, it is plausible that CBD may be acting on downstream
targets in a manner that preserves skeletal muscle with chronic resistance training. This idea was
observed in one preclinical study (Langer et al., 2021), and is supported by one human study
examining changes in concentrations of creatine kinase and myoglobin (Isenmann et al., 2021).
However, it is important to note that biological sex may play a role in this response. In the
current study, PG-M experienced a 2% and 5% increase in both BP and BS 1RM, respectively,
and PG-F experienced a 1.2% decrease in bench press 1RM and 4% increase in back squat 1RM,

127
and these changes were not significantly different from CG-M and CG-F. A main effect of time
was also observed in which back squat 1RM values for all groups increased by 5.4% by the postintervention time point. Thus, it is unknown whether molecular targets of CBD are only
stimulated during strenuous training sessions and whether biological sex plays a role in this
response.
It is also unknown whether the CBD response, if any, to strenuous resistance training is
similar in all skeletal muscle fiber types in both sexes. The current study found a main effect of
sex on both strength measures, but no time by treatment by sex interactions, suggesting that sex
influences upper and lower body strength measures regardless of long-term CBD use. Sex
differences are documented in animal studies. One study showed that after an acute bout of
eccentric exercise, female rats had less pronounced skeletal muscle fiber damage compared with
male rats (Komulainen et al., 1999), and after a unilateral hindlimb muscle injury exercise,
female mice experienced less leukocyte activation into damaged myofibers compared with males
(St. Pierre Schneider et al., 1999). Human research also shows less leukocyte invasion after acute
damaging eccentric exercise in females compared with males (Stupka et al., 2000). Thus, more
research focused on understanding how CBD might influence the sex-related differences in
strength measures and muscle physiology are necessary.
Anaerobic Fitness Measures
At the pre-intervention time point, all anerobic power outputs except anaerobic fatigue
(AF) were significantly different between males and females and no differences in treatment
were found. Sex differences in anaerobic fitness are typical in previous and current normative
data (Borgert-Poepping et al., 2008; Maud & Shultz, 1986). Compared to previous normative
data, male and female mean PP placed both groups in the 85-90th percentile (Above Average),
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MP in the 60-70th percentile (Average), RPP placed both in the 60-70th percentile (Average),
RMP placed males in the 60-80th percentile (Average) and females in the 5-10th percentile (Well
Below Average), and AF placed both groups in the 5-10th percentile (Well Below Average;
Maud & Shultz, 1986) Compared with updated normative data from other college-age
individuals (unspecified number of participants per sex), males and females in the current study
had 5% lower PP and 7.8% higher PP, respectively (Borgert-Poepping et al., 2008). Compared
with 18–25-year-old intercollegiate athletes, males and females in the current study had 16% and
9% lower PP, 18% and 14% lower MP, 15% and 16% lower RPP, and 17% and 21% lower
RMP, respectively (Zupan et al., 2009). This classified male mean PP as “below average,” MP as
“below average,” RPP as “below average” and RMP as “poor” (Zupan et al., 2009). This also
classified female mean PP as “below average,” MP as “below average,” RPP as “below
average,” and RMP as “poor” (Zupan et al., 2009). The AF for the males and females in the
present study placed them in the 5th percentile (Well Below Average; Maud & Shultz, 1986).
Mean PP, RPP, MP, RMP, and AF in CG and PG did not significantly change over the
course of the intervention period, and there were no time by treatment by sex interactions.
However, a time by treatment effect was found in which PG experienced a 9% decrease in mean
PP (p = 0.006) and a 3% decrease in mean RPP compared to CG (p = 0.006). After 8 weeks, CG
experienced a 2.5% increase in mean PP whereas PG experienced a 9% decrease in mean PP.
These translated to a 2% and 2.5% increase in mean RPP for CG-M and CG-F, but a 9% and
10% decrease in mean RPP for PG-M and PG-F, respectively. Participants were instructed to
maintain their physical activity and the accelerometry data from this study supports this claim.
These results suggest that it is possible for long-term CBD supplementation to attenuate
decreases in peak anaerobic power over time.
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A time by sex effect was also found in which females experienced a 4.5% decrease in
mean MP (p = 0.021) and a 3.5% decrease in mean RMP compared to males (p = 0.018). With
respect to mean MP, CG and PG experienced a 0.2% and 10% decrease in MP over the course of
the intervention, respectively; however, these changes were not significant. Within CG, mean
MP changes over time were different for males and females. In fact, CG-M and CG-F
experienced a 2% and 4% increase in mean MP, respectively, and these increases translated to a
1.4% increase in mean RMP for CG-M, but a 12% decrease in mean RMP for CG-F over the
course of the intervention. Within PG, PG-M experienced a 1% increase in mean MP and PG-F
experienced a 7% decrease in mean MP and these changes translated to no change in mean RMP
for PG-M, but a 7% decrease in mean RMP for PG-F, respectively. In summary, females
experienced a significant decrease in MP by the end of the study, regardless of CBD use.
Additionally, a medium effect size of time for AF% was observed (p = 0.067, η2 = 0.078) at 95%
[-1, .09], but no other large, main effects of time were found.
The intervention suggests that the effect of CBD on mean PP and the influence of sex on
mean MP may depend on the duration of the intervention. It is plausible that long-term CBD
supplementation may not impair anaerobic power output but rather, act to maintain anaerobic
power output during times of stress. These results also suggest that males and females may
respond differently to anaerobic testing over time and this response may be influenced by longterm CBD supplementation. This is the first study to explore the effect of chronic, low dose CBD
over the course of 8 weeks on anerobic power output and there is currently no literature to use
for comparison.
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Mental Health and Cognition Surveys
Given the gender gap in mental health (Green et al., 2019; Riecher-Rössler, 2017;
Terlizzi & Norris, 2021) and the potential of CBD to affect mental health and wellbeing, scores
were obtained at both pre-intervention and post-intervention time points to determine mental
health status with a specific focus on eudaimonic wellbeing which refers to self-recognition as
the full functioning of the person (Di Fabio & Palazzeschi, 2015). At the pre-intervention time
point, there were no treatment differences. However, sex differences were observed in one of the
6 aspects of PWB at the pre-intervention time point in which females had higher scores in
purpose for life aspect when compared with males. No significant differences were found with
respect to all other aspects of the PWB scale at the pre-intervention time point. These findings
are similar to one study that found gender differences in Filipino, college-age males (n = 110)
and females (n = 478) in which females had a significantly higher purpose in life scores than
males (p < 0.001; Perez, 2012). The findings in the current study are also similar to another
investigation of Westernized college-age males (n = 40) and females (n = 91) and found that
females also had significantly higher purpose in life scores score than males (p = 0.002; Ludban
& Gitimu, 2015).
No sex or treatment differences with respect to cognitive function and cognitive function
abilities T scores were found at the pre-intervention time point. These findings are similar to
others that have compared cognitive function in normal, general populations. The mean cognitive
function T score categorizes participants from the current study as typical (T score range from
25-75), with males 3% below the male T score mean, and females 1% above the female mean in
a sample of healthy males (n = 493) and females (n = 516) without neuropsychiatric disorders
(Iverson et al., 2021). Cognitive function abilities T scores were similar to another study that
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found no gender differences in healthy controls that were compared with a medical outpatient
population (Saffer et al., 2015). Mean cognitive function abilities T scores from participants in
this study were 1.8% and 2% lower than those healthy, non-depressed adult controls (n = 134)
and non-anxious adult controls (n = 130; Saffer et al., 2015).
No time by treatment by sex interactions were found for all 6 aspects of the PWB aspects
and both cognitive scale T scores. However, there was main effect of time on three of the six
PWB aspects. Mean personal growth, positive relation with others, purpose in life scores in
significantly decreased by 5%, 7%, and 7% over the course of the intervention (p < 0.001, p =
0.017, and p = 0.016, respectively). A main effect of sex was also found with respect to mean
purpose in life scores in which females had 11.7% overall higher scores than males (p = 0.008).
This finding could be attributed to timing of data collection which began January 2021 and
ended March 2022. Decreased PWB and potentially overall retention and attrition rates may have
been impacted by local (campus and community) and global events during this 17-month period
of data collection. These events included economic and financial consequences from the
coronavirus-19 pandemic, and major social and cultural events such as a controversial
presidential election, the Tokyo Summer Olympics, and the Russia-Ukraine War. Other
researchers agree that these types of disruptions significantly altered mental health and wellbeing
(Moreno et al., 2020; Pfefferbaum & North, 2020).
It was hypothesized that positive changes in PWB and cognition would be observed from
long-term CBD use in this study due to evidence highlighting its protective effects against
induced psychosis (Bhattacharyya et al., 2010; Bloomfield et al., 2020) and anxiety (Crippa et
al., 2004). Compared to these previous acute CBD models in healthy men completing MRI
analyses and cognitive function tasks, the current study results suggest that CBD may not
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provide improvements or a resistance to decrements in cognition. Animal research already
demonstrates that acute and chronic CBD administration improves measures of cognitive
function and mental health (Barichello et al., 2012; Campos et al., 2015; Mori et al., 2017;
Osborne, Solowij, Babic, et al., 2017; Sales et al., 2020; Schiavon et al., 2016). This finding has
yet to be consistently shown in the literature. It is also necessary to include females in these
studies. In fact, other studies have found that men and women perform cognitive tasks differently
after consuming acute oral and vaporized CBD (Schoedel et al., 2018; Spindle et al., 2020).
Biomarkers of Inflammation and Neural Health
There were no sex differences in concentrations of CRP at the pre-intervention time
point, and no interactions or main effects of time, treatment, or sex in the 3-way mixed ANOVA.
Mean concentrations of CRP for total participants were 18% lower than concentrations of CRP
of other healthy and active individuals (males: n = 405, females: n = 454) ages 25-75 years old
(Pischon et al., 2003). When biological sex was taken into account, males and females in the
current study had 53% and 9% lower concentrations of CRP compared to healthy men and
women, respectively (Pischon et al., 2003). According to the CVD risk stratification literature
(Lee et al., 2019; Ridker, 2003), individual CRP concentrations at the pre-intervention time point
placed half of the participants in the present study (50%; males: n = 16, females: n = 12) in the
low-risk category (serum CRP < 1 mg/L) for cardiovascular disease (CVD), while individual
CRP values placed almost 24% of participants in the present study (22% males: n = 4 , females:
n = 7) in the moderate-risk category for CVD (serum CRP 1-3 mg/L). Only a few (15%, males: n
= 2, females: n = 5) CRP values placed individuals into the high-risk for CVD category (serum
CRP >3 mg/L). Prior research shows that sex differences in concentrations of CRP are most
attributed to differences in adiposity and BMI (Khera et al., 2009; Rexrode et al., 2003; Thorand
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et al., 2006). An additional bivariate correlational analysis confirmed this association in the
present study; concentrations of CRP were directly correlated with BF% (r = 0.571, p = 0.004),
BMI (r = 0.448, p = 0.018), and BM (r = 0.649, p < 0.001) in females, but not in males.
Additionally, concentrations of CRP were also inversely correlated with relative V̇O2 peak (r =
-0.493, p = 0.014) only in females at the pre-intervention time point.
The relationship of adiposity and CRP may also explain why a treatment by sex
interaction was found with respect to total concentrations of CRP in which CG-F had greater
mean concentrations of serum CRP when compared to both CG-M and PG-F. It is important to
note that these values are the average concentrations of CRP from both pre- and postintervention time points and comparisons reflect the interaction of between-group factors as there
were no main effect or interactions of time. Therefore, this finding suggests that the effect of 8
weeks of CBD on concentrations of serum CRP depends on whether the user is male or female.
This finding complements the aforementioned CBD survey-based studies which identified
females as common CBD users who may not be meeting in ACSM physical activity
recommendations (BrightfieldGroup, 2017; Corroon & Phillips, 2018; Fedorova et al., 2021;
Wheeler, Merten, et al., 2020). The body size and composition measurements of the females in
the present study are correlated with CRP concentrations and their IPAQ responses match this
profile of typical CBD users. Interestingly, two interactions (time * sex and time * treatment *
sex) were observed to have a medium effect size at a 95% confidence interval (time * sex: p =
0.086, η2 = 0.069; time * treatment * sex: p = 0.086, η2 = 0.068); however, these interactions did
not reach significance. This presents a fascinating finding and highlights the need for more
research exploring chronic CBD administration on serum concentrations in CRP in males and
females, as well as exploring the molecular underpinnings related to this change.
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In the present study, mean concentrations of BDNF in males and females at the
pre-intervention time point were all within normal ranges of reported serum concentrations of
BDNF for healthy adults (8 to 46 ng/mL and 18 to 26 ng/mL; Dong et al., 2021; Elsner et al.,
2020; Kallies et al., 2019; Lisano et al., 2020; Szuhany & Otto, 2020; Toll et al., 2020;
Trajkovska et al., 2007). A significant sex difference was found with respect to concentrations of
BDNF in which females were 38% higher than males at the pre-intervention time point (p =
0.025). This sex difference is supported in a large body of research that shows that circulating
concentrations of BDNF are higher in women than in men (Collins et al., 2021; Glud et al.,
2019), with others suggesting that age, body composition, and mental and cognitive health affect
the degree of change between males and females (Bus et al., 2011; Dong et al., 2021; Ihara et al.,
2016). However, a bivariate correlational analysis revealed that there were no significant
relationships between resting concentrations of BDNF and age, BM, LBM, BF%, PWB aspects,
and cognitive function scale T scores in the present study, at the pre-intervention time point, for
both males and females. Overall, participants had normal, healthy ranges of resting
concentrations of peripheral, serum BDNF. There were no additional treatment or treatment by
sex interactions and main effects at the pre-intervention time point.
Interestingly, there was a significant treatment by sex interaction in which overall mean
concentrations of BDNF in PG-F were 43% greater than CG-F (p = 0.014) and 39% greater than
PG-M (p = 0.008). It is important to note that overall BDNF concentrations are the total of both
pre- and post-intervention time points. Thus, this suggests that the effect of CBD may be more
pronounced in females compared with males. This is an interesting finding because mean
concentrations of BDNF were 28% higher in males and 13% lower in females over the course of
the intervention, but these were not significant, suggesting that CBD may not maintain or
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attenuate losses in concentrations of BDNF in females. However, clinical studies with
psychiatric populations suggest that CBD may have therapeutic effects in females that is
correlated with improvements in concentrations of BDNF (Campos et al., 2016, 2017). It is
possible that during times of stress, CBD has protective properties that may be more pronounced
in females. This is demonstrated in animal models showing the agonistic effects of CBD on the
inhibitory G-protein coupled receptor known as 5-beta hydroxytryptamine receptor 1, resulting
in antiepileptic, antidepressant, and anti-anxiolytic effects (Campos et al., 2016; Sartim et al.,
2016). Although this suggests that females may experience positive changes in concentrations of
BDNF with acute CBD, the current study did not observe this phenomenon and this underlying
CBD mechanism is not confirmed in healthy, human females. It is possible that the
concentrations of BDNF in CG-F reflect some degree of stress or mental health condition.
However, there were no positive relationships with PWB aspects and concentrations of BDNF
when bivariate correlational analyses were carried out by treatment and sex, and there were no
indications of current psychiatric stress from the medical health questionnaire. Overall, the
difference in total concentrations of BDNF between CG-F, PG-F, and PG-M present another
fascinating finding which suggests that CBD may affect this neural health biomarker in both
sexes differently.
Limitations and Advantages
The results of this study should be interpreted with caution due to several limitations.
First and foremost, as this analysis was exploratory in nature, sample sizes were specifically
powered by concentrations of CRP in individuals who underwent an exercise intervention. It was
not specifically powered to detect sex differences nor differences in any other outcome. The
resulting smaller sample size limits the generalizability of the study to other similar populations.
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A second limitation is linked to the CBD intervention duration. This study involved 8
weeks of daily CBD ingestion in healthy individuals and is similar to other long-term studies
investigating CBD responses for 4 to 6 weeks in patients with schizophrenia (200 to 1,000 mg/d;
Boggs et al., 2018; Leweke et al., 2012; McGuire et al., 2018), 13 weeks in patients with type 2
diabetes and dyslipidemia (200 mg/d; Jadoon et al., 2016), 8 weeks in patients with Crohn’s
disease (20 mg/d; Naftali et al., 2017), and for 10 weeks in patients with ulcerative colitis (50 to
250 mg/d; Irving et al., 2018). Although the present study was similar in length to these clinical
populations, it is unknown whether non-clinical populations respond in the same way.
Neuropsychiatric populations also show improvements after 6-8 weeks, but with a possible need
to combine additional cannabinoids for treatment of some neuropsychiatric disorders (Boggs et
al., 2018; Leweke et al., 2012; McGuire et al., 2018). It is possible that the individuals in the
current study adjusted to the 50 mg of CBD within the 8 weeks, and as a result, may have
become desensitized or may have needed additional supplement compounds to experience
changes in physical or mental health outcomes. It is also possible that the time was not long
enough for CBD to be influential in the system due to low potency from low absorption rate;
however, the current study had participants consume CBD (which was combined with MCT oil)
after dinner to increase its bioavailability. Future plans to explore intervention lengths in healthy
individuals should include assessing outcomes at more than two time points.
The final limitation to this study was CBD dose, which may have been too small to
observe a change in all physical and mental health outcomes. A CBD dose of 50 mg was chosen
as it more closely resembles products available to (and used by) the general population. There is
a wide range of doses used in other studies depending on neurological condition with an average
CBD dose ranging anywhere from 1-5 mg/kg/d to 20 mg/kg/d (Silva et al., 2020). For example,
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when considering a 67 kg female and 80 kg male (mean BM of both sexes in the current study), a
CBD dose of 15 mg/kg/d, which is 5 mg/kg/d less than an experimental trial of CBD in Dravet
Syndrome (Devinsky et al., 2017), would be equivalent to 1,005 mg (67 kg * 15 mg/kg/d) and
1,200 mg (80 kg * 15 mg/kg/d) of CBD for each, respectively. Additionally, the BM of
participants in the current study ranged from 49 to 106 kg, which would have resulted in uneven
dosages from 750 mg to 1,250 mg, dosing similar to clinical trials in children and young adults
that showed 20 mg/kg/d significantly reduced seizures (Devinsky et al., 2014, 2017, 2018).
Although CBD has not demonstrated a potential for abuse and is well tolerated (Huestis et al.,
2019; Schoedel et al., 2018), there is limited information and inconclusive findings from human
pharmacokinetic studies of healthy and patient populations, males and females, and cannabis
naïve participants (Cooper & Craft, 2018; Nadulski et al., 2005; Williams et al., 2021). Thus,
more dose-response trials are needed in healthy, non-clinical populations to better provide
support for CBD doses.
This study has a few strengths that should be noted. The results of this study add to the
limited knowledge from randomized controlled trials in CBD-related research in recreationally
active adult males and females. This study also provides critical knowledge for public health
officials and healthcare professionals regarding the effects of CBD and its potential sex-related
differences on anaerobic fitness and resting concentrations of CRP and BDNF. Lastly, this study
also provides information on the effects of CBD on females, which is an important addition as
many current CBD surveys show CBD users are predominantly female (Fedorova et al., 2021;
Moltke & Hindocha, 2021; Wheeler, Merten, et al., 2020).
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Conclusions and Future Directions
This study suggests that 8 weeks of CBD consumption does not alter body composition,
cardiovascular measures, cardiorespiratory fitness, and muscular strength. However, results from
this study suggest it may serve as a potential aid in preventing decreases in anerobic power
output with respect to mean PP and MP, and that its effect on resting concentrations of CRP and
BDNF are different between males and females.
Given the wide variety of CBD compounds, modes of delivery, and the very little that is
known about the effects of CBD on the mental and physical status of otherwise healthy people,
there is room for future high quality randomized, controlled clinical trials. Additionally, there is
very little information about the potential for sex to influence the effects of CBD. This area of
research is growing, and future funding may help support studies which expand our knowledge
in the area.

139

REFERENCES
Abd El-Kader, S. M., & Al-Jiffri, O. H. (2019). Aerobic exercise modulates cytokine profile and
sleep quality in elderly. African Health Sciences, 19(2), 2198-2207.
https://doi.org/10.4314/ahs.v19i2.45
Abd El-Kader, S. M., & Al-Shreef, F. M. (2018). Inflammatory cytokines and immune system
modulation by aerobic versus resisted exercise training for elderly. African Health
Sciences, 18(1), 120-131. https://doi.org/10.4314/ahs.v18i1.16
Ali, E. T., Jabbar, A. S., & Mohammed, A. N. (2019). A comparative study of interleukin 6,
inflammatory markers, ferritin, and hematological profile in rheumatoid arthritis patients
with anemia of chronic disease and iron deficiency anemia. Anemia, 2019, Article
3457347. https://doi.org/10.1155/2019/3457347
Alonso, M., Medina, J. H., & Pozzo-Miller, L. (2004). Erk1/2 activation is necessary for bdnf to
increase dendritic spine density in hippocampal ca1 pyramidal neurons. Learning &
Memory, 11(2), 172-178. https://doi.org/10.1101/lm.67804
Angelucci, F., Ricci, V., Spalletta, G., Pomponi, M., Tonioni, F., Caltagirone, C., & Bria, P.
(2008). Reduced serum concentrations of nerve growth factor, but not brain-derived
neurotrophic factor, in chronic cannabis abusers. European Neuropsychopharmacology:
The Journal of the European College of Neuropsychopharmacology, 18(12), 882-887.
https://doi.org/10.1016/j.euroneuro.2008.07.008

140
Arkell, T. R., Kevin, R. C., Vinckenbosch, F., Lintzeris, N., Theunissen, E., Ramaekers, J. G., &
McGregor, I. S. (2022). Sex differences in acute cannabis effects revisited: Results from
two randomized, controlled trials. Addiction Biology, 27(2), e13125.
https://doi.org/10.1111/adb.13125
Arndt, D. L., & de Wit, H. (2017). Cannabidiol does not dampen responses to emotional stimuli
in healthy adults. Cannabis Cannabinoid Res, 2(1), 105-113.
https://doi.org/10.1089/can.2017.0014
Ativie, F., Komorowska, J. A., Beins, E., Albayram, Ö., Zimmer, T., Zimmer, A., Tejera, D.,
Heneka, M., & Bilkei-Gorzo, A. (2018). Cannabinoid 1 receptor signaling on
hippocampal gabaergic neurons influences microglial activity. Frontiers in Molecular
Neuroscience, 11, 295. https://doi.org/10.3389/fnmol.2018.00295
Autry, A. E., Adachi, M., Cheng, P., & Monteggia, L. M. (2009). Gender-specific impact of
brain-derived neurotrophic factor signaling on stress-induced depression-like behavior.
Biological Psychiatry, 66(1), 84-90. https://doi.org/10.1016/j.biopsych.2009.02.007
Avakian, E. V., Horvath, S. M., Michael, E. D., & Jacobs, S. (1979). Effect of marihuana on
cardiorespiratory responses to submaximal exercise. Clinical Pharmacology and
Therapeutics, 26(6), 777-781. https://doi.org/10.1002/cpt1979266777
Babalonis, S., Haney, M., Malcolm, R. J., Lofwall, M. R., Votaw, V. R., Sparenborg, S., &
Walsh, S. L. (2017). Oral cannabidiol does not produce a signal for abuse liability in
frequent marijuana smokers. Drug and Alcohol Dependence, 172, 9-13.
https://doi.org/10.1016/j.drugalcdep.2016.11.030
Baechle, T. R., & Earle, R. W. (2008). Essentials of strength training and conditioning (3 ed.).
Human Kinetics.

141
Barcellos, F. C., Del Vecchio, F. B., Reges, A., Mielke, G., Santos, I. S., Umpierre, D., Bohlke,
M., & Hallal, P. C. (2018). Exercise in patients with hypertension and chronic kidney
disease: A randomized controlled trial. Journal of Human Hypertension, 32(6), 397-407.
https://doi.org/10.1038/s41371-018-0055-0
Barichello, T., Ceretta, R. A., Generoso, J. S., Moreira, A. P., Simões, L. R., Comim, C. M.,
Quevedo, J., Vilela, M. C., Zuardi, A. W., Crippa, J. A., & Teixeira, A. L. (2012).
Cannabidiol reduces host immune response and prevents cognitive impairments in wistar
rats submitted to pneumococcal meningitis. European Journal of Pharmacology, 697(13), 158-164. https://doi.org/10.1016/j.ejphar.2012.09.053
Bar-Or, O. (1987). The wingate anaerobic test. An update on methodology, reliability and
validity. Sports Medicine, 4(6), 381-394. https://doi.org/10.2165/00007256-19870406000001
Beavers, K. M., Hsu, F. C., Isom, S., Kritchevsky, S. B., Church, T., Goodpaster, B., Pahor, M.,
& Nicklas, B. J. (2010). Long-term physical activity and inflammatory biomarkers in
older adults. Medicine and Science in Sports and Exercise, 42(12), 2189-2196.
https://doi.org/10.1249/MSS.0b013e3181e3ac80
Beltz, N. M., Gibson, A. L., Janot, J. M., Kravitz, L., Mermier, C. M., & Dalleck, L. C. (2016).
Graded exercise testing protocols for the determination of vo(2)max: Historical
perspectives, progress, and future considerations. Journal of Sports Medicine, 2016,
Article 3968393. https://doi.org/10.1155/2016/3968393

142
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., De Oliveira, D. C. G., De Martinis,
B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., & Nardi, A. E. (2011).
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive
social phobia patients. Neuropsychopharmacology, 36(6), 1219-1226.
https://doi.org/10.1038/npp.2011.6
Bermudez, E. A., Rifai, N., Buring, J., Manson, J. E., & Ridker, P. M. (2002). Interrelationships
among circulating interleukin-6, c-reactive protein, and traditional cardiovascular risk
factors in women. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(10), 16681673. https://doi.org/10.1161/01.atv.0000029781.31325.66
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., WintonBrown, T., Nosarti, C., O'Carroll, C. M., Seal, M., & Allen, P. (2010). Opposite effects of
δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Neuropsychopharmacology, 35(3), 764-774. https://doi.org/10.1038/npp.2009.184
Bhattacharyya, S., Wilson, R., Appiah-Kusi, E., O’Neill, A., Brammer, M., Perez, J., Murray, R.,
Allen, P., Bossong, M. G., & McGuire, P. (2018). Effect of cannabidiol on medial
temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: A
randomized clinical trial. JAMA Psychiatry, 75(11), 1107-1117.
https://doi.org/10.1001/jamapsychiatry.2018.2309
Bidwell, A. J., Fairchild, T. J., Redmond, J., Wang, L., Keslacy, S., & Kanaley, J. A. (2014).
Physical activity offsets the negative effects of a high-fructose diet. Medicine and Science
in Sports and Exercise, 46(11), 2091-2098.
https://doi.org/10.1249/mss.0000000000000343

143
Bilbo, S. D., Smith, S. H., & Schwarz, J. M. (2012). A lifespan approach to neuroinflammatory
and cognitive disorders: A critical role for glia. Journal of Neuroimmune Pharmacology,
7(1), 24-41. https://doi.org/10.1007/s11481-011-9299-y
Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S.,
Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001). Molecular targets for cannabidiol
and its synthetic analogues: Effect on vanilloid vr1 receptors and on the cellular uptake
and enzymatic hydrolysis of anandamide. Br J Pharmacol, 134(4), 845-852.
https://doi.org/10.1038/sj.bjp.0704327
Bloomfield, M. A., Green, S. F., Hindocha, C., Yamamori, Y., Yim, J. L. L., Jones, A. P.,
Walker, H. R., Tokarczuk, P., Statton, B., & Howes, O. D. (2020). The effects of acute
cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin
labelling magnetic resonance imaging study. Journal of Psychopharmacology, 34(9),
981-989. https://doi.org/10.1177/0269881120936419
Boggs, D. L., Surti, T., Gupta, A., Gupta, S., Niciu, M., Pittman, B., Schnakenberg Martin, A.
M., Thurnauer, H., Davies, A., D’Souza, D. C., & Ranganathan, M. (2018). The effects
of cannabidiol (cbd) on cognition and symptoms in outpatients with chronic
schizophrenia a randomized placebo controlled trial. Psychopharmacology, 235(7), 19231932. https://doi.org/10.1007/s00213-018-4885-9
Bollinger, J. L., Bergeon Burns, C. M., & Wellman, C. L. (2016). Differential effects of stress on
microglial cell activation in male and female medial prefrontal cortex. Brain Behav
Immun, 52, 88-97. https://doi.org/https://doi.org/10.1016/j.bbi.2015.10.003

144
Bonini, S. A., Premoli, M., Tambaro, S., Kumar, A., Maccarinelli, G., Memo, M., & Mastinu, A.
(2018). Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal
plant with a long history. Journal of Ethnopharmacology, 227, 300-315.
https://doi.org/10.1016/j.jep.2018.09.004
Borg, G. A. (1982). Psychophysical bases of perceived exertion. Medicine and Science in Sports
and Exercise, 14(5), 377-381.
Borgert-Poepping, M., Gressick, B., & Bredle, D. (2008). Updated wingate anaerobic power test
norms. University of Wisconsin-Eu Claire.
https://minds.wisconsin.edu/bitstream/handle/1793/30629/BorgertPoeppingSpr08.pdf?sequence=1&isAllowed=y
Borson, S., Scanlan, J. M., Chen, P., & Ganguli, M. (2003). The mini‐cog as a screen for
dementia: Validation in a population‐based sample. J Am Geriatr Soc, 51(10), 14511454. https://doi.org/10.1046/j.1532-5415.2003.51465.x
Boyne, P., Meyrose, C., Westover, J., Whitesel, D., Hatter, K., Reisman, D. S., Cunningham, D.,
Carl, D., Jansen, C., Khoury, J. C., Gerson, M., Kissela, B., & Dunning, K. (2019).
Exercise intensity affects acute neurotrophic and neurophysiological responses
poststroke. Journal of Applied Physiology, 126(2), 431-443.
https://doi.org/10.1152/japplphysiol.00594.2018
Brigadski, T., & Leßmann, V. (2020). The physiology of regulated bdnf release. Cell and Tissue
Research, 382(1), 15-45. https://doi.org/10.1007/s00441-020-03253-2

145
BrightfieldGroup, H. (2017). Understanding cannabidiol (cbd), industry expert report.
BrightfieldGroup.
https://daks2k3a4ib2z.cloudfront.net/595e80a3d32ef41bfa200178/59946dd86c6b200001
c5b9cb_CBD_-_HelloMD_Brightfield_Study_-_Expert_Report_-_FINAL.pdf
Briken, S., Rosenkranz, S. C., Keminer, O., Patra, S., Ketels, G., Heesen, C., Hellweg, R., Pless,
O., Schulz, K.-H., & Gold, S. M. (2016). Effects of exercise on irisin, bdnf and il-6 serum
levels in patients with progressive multiple sclerosis. Journal of Neuroimmunology, 299,
53-58. https://doi.org/10.1016/j.jneuroim.2016.08.007
Britch, S. C., Goodman, A. G., Wiley, J. L., Pondelick, A. M., & Craft, R. M. (2020).
Antinociceptive and immune effects of delta-9-tetrahydrocannabinol or cannabidiol in
male versus female rats with persistent inflammatory pain. The Journal of Pharmacology
and Experimental Therapeutics, 373(3), 416-428.
https://doi.org/10.1124/jpet.119.263319
Britch, S. C., Wiley, J. L., Yu, Z., Clowers, B. H., & Craft, R. M. (2017). Cannabidiol-delta(9)tetrahydrocannabinol interactions on acute pain and locomotor activity. Drug and
Alcohol Dependence, 175, 187-197. https://doi.org/10.1016/j.drugalcdep.2017.01.046
Bus, B. A., Molendijk, M. L., Penninx, B. J., Buitelaar, J. K., Kenis, G., Prickaerts, J., Elzinga,
B. M., & Voshaar, R. C. (2011). Determinants of serum brain-derived neurotrophic
factor. Psychoneuroendocrinology, 36(2), 228-239.
https://doi.org/10.1016/j.psyneuen.2010.07.013

146
Cabral-Santos, C., Castrillón, C. I., Miranda, R. A., Monteiro, P. A., Inoue, D. S., Campos, E. Z.,
Hofmann, P., & Lira, F. S. (2016). Inflammatory cytokines and bdnf response to highintensity intermittent exercise: Effect the exercise volume. Frontiers in Physiology, 7,
509. https://doi.org/10.3389/fphys.2016.00509
Calignano, A., La Rana, G., Giuffrida, A., & Piomelli, D. (1998). Control of pain initiation by
endogenous cannabinoids. Nature, 394(6690), 277-281. https://doi.org/10.1038/28393
Campos, A. C., Brant, F., Miranda, A. S., Machado, F. S., & Teixeira, A. L. (2015). Cannabidiol
increases survival and promotes rescue of cognitive function in a murine model of
cerebral malaria. Neuroscience, 289, 166-180.
https://doi.org/10.1016/j.neuroscience.2014.12.051
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego,
A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017). Plastic and
neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in
psychiatric disorders. Frontiers in Pharmacology, 8, 269.
https://doi.org/10.3389/fphar.2017.00269
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016). Cannabidiol,
neuroprotection and neuropsychiatric disorders. Pharmacol Res, 112, 119-127.
https://doi.org/10.1016/j.phrs.2016.01.033
Carlini, E. A., & Cunha, J. M. (1981). Hypnotic and antiepileptic effects of cannabidiol. Journal
of Clinical Pharmacology, 21(S1), 417S-427S. https://doi.org/10.1002/j.15524604.1981.tb02622.x

147
Castellano, V., & White, L. J. (2008). Serum brain-derived neurotrophic factor response to
aerobic exercise in multiple sclerosis. Journal of the Neurological Sciences, 269(1-2), 8591. https://doi.org/10.1016/j.jns.2007.12.030
Centers for Disease Control. (2022). Physical activity guidelines and recommendations. U.S.
Department of Health & Human Services.
https://www.cdc.gov/physicalactivity/resources/recommendations.html
Chen, M. H., Hsu, J. W., Huang, K. L., Tsai, S. J., Su, T. P., Li, C. T., Lin, W. C., Tu, P. C., &
Bai, Y. M. (2021). Role of obesity in systemic low-grade inflammation and cognitive
function in patients with bipolar i disorder or major depressive disorder. CNS Spectrums,
26(5), 521-527. https://doi.org/10.1017/S1092852920001534
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang,
B., Ding, J., & Li, F. (2020). Detectable serum severe acute respiratory syndrome
coronavirus 2 viral load (rnaemia) is closely correlated with drastically elevated
interleukin 6 level in critically ill patients with coronavirus disease 2019. Clinical
Infectious Diseases, 71(8), 1937-1942. https://doi.org/10.1093/cid/ciaa449
Chiarlone, A., Bellocchio, L., Blázquez, C., Resel, E., Soria-Gómez, E., Cannich, A., Ferrero, J.
J., Sagredo, O., Benito, C., Romero, J., Sánchez-Prieto, J., Lutz, B., Fernández-Ruiz, J.,
Galve-Roperh, I., & Guzmán, M. (2014). A restricted population of cb1 cannabinoid
receptors with neuroprotective activity. Proc Natl Acad Sci U S A, 111(22), 8257-8262.
https://doi.org/10.1073/pnas.1400988111
Cipryan, L., Svagera, Z., & Vala, R. (2015). Il-6 and crp response to maximal exercise
intervention. Journal of Sports Medicine and Physical Fitness, 55(7-8), 813-823.
https://pubmed.ncbi.nlm.nih.gov/25678206/

148
Cochrane-Snyman, K. C., Cruz, C., Morales, J., & Coles, M. (2021). The effects of cannabidiol
oil on noninvasive measures of muscle damage in men. Medicine and Science in Sports
and Exercise, 53(7), 1460-1472. https://doi.org/10.1249/mss.0000000000002606
Colbert, L. H., Visser, M., Simonsick, E. M., Tracy, R. P., Newman, A. B., Kritchevsky, S. B.,
Pahor, M., Taaffe, D. R., Brach, J., & Rubin, S. (2004). Physical activity, exercise, and
inflammatory markers in older adults: Findings from the health, aging and body
composition study. J Am Geriatr Soc, 52(7), 1098-1104. https://doi.org/10.1111/j.15325415.2004.52307.x
Collins, J. M., Hill, E., Bindoff, A., King, A. E., Alty, J., Summers, M. J., & Vickers, J. C.
(2021). Association between components of cognitive reserve and serum bdnf in healthy
older adults. Frontiers in Aging Neuroscience, 13, 725914.
https://doi.org/10.3389/fnagi.2021.725914
Consroe, P., Sandyk, R., & Snider, S. R. (1986). Open label evaluation of cannabidiol in
dystonic movement disorders. International Journal of Neuroscience, 30(4), 277-282.
https://doi.org/10.3109/00207458608985678
Cooper, Z. D., & Craft, R. M. (2018). Sex-dependent effects of cannabis and cannabinoids: A
translational perspective. Neuropsychopharmacology, 43(1), 34-51.
https://doi.org/10.1038/npp.2017.140
Corroon, J., & Phillips, J. A. (2018). A cross-sectional study of cannabidiol users. Cannabis
Cannabinoid Research, 3(1), 152-161. https://doi.org/10.1089/can.2018.0006
Couch, D. G., Tasker, C., Theophilidou, E., Lund, J. N., & O'Sullivan, S. E. (2017). Cannabidiol
and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon.
Clinical Science, 131(21), 2611-2626. https://doi.org/10.1042/cs20171288

149
Crane, N. A., Schuster, R. M., Fusar-Poli, P., & Gonzalez, R. (2013). Effects of cannabis on
neurocognitive functioning: Recent advances, neurodevelopmental influences, and sex
differences. Neuropsychology Review, 23(2), 117-137. https://doi.org/10.1007/s11065012-9222-1
Crane, N. A., Schuster, R. M., & Gonzalez, R. (2013). Preliminary evidence for a sex-specific
relationship between amount of cannabis use and neurocognitive performance in young
adult cannabis users. Journal of the International Neuropsychological Society, 19(9),
1009-1015. https://doi.org/10.1017/s135561771300088x
Crane, N. A., Schuster, R. M., Mermelstein, R. J., & Gonzalez, R. (2015). Neuropsychological
sex differences associated with age of initiated use among young adult cannabis users.
Journal of Clinical and Experimental Neuropsychology, 37(4), 389-401.
https://doi.org/10.1080/13803395.2015.1020770
Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L.,
Azevedo-Marques, P. M., Hallak, J. E., McGuire, P. K., & Filho Busatto, G. (2004).
Effects of cannabidiol (cbd) on regional cerebral blood flow. Neuropsychopharmacology,
29(2), 417-426. https://doi.org/10.1038/sj.npp.1300340
Cuñetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., & Orihuela, S. (2018). Chronic pain
treatment with cannabidiol in kidney transplant patients in uruguay. Transplantation
Proceedings, 50(2), 461-464. https://doi.org/10.1016/j.transproceed.2017.12.042
Dagmar, S., Erik, S., Karel, F., & Aleš, S. (2011). Gender differences in physical activity,
sedentary behavior and bmi in the liberec region: The ipaq study in 2002-2009. Journal
of Human Kinetics, 28, 123-131. https://doi.org/10.2478/v10078-011-0029-6

150
De la Rosa, A., Solana, E., Corpas, R., Bartrés-Faz, D., Pallàs, M., Vina, J., Sanfeliu, C., &
Gomez-Cabrera, M. C. (2019). Long-term exercise training improves memory in middleaged men and modulates peripheral levels of bdnf and cathepsin b. Scientific Reports,
9(1), 3337. https://doi.org/10.1038/s41598-019-40040-8
Dempster, P., & Aitkens, S. (1995). A new air displacement method for the determination of
human body composition. Medicine and Science in Sports and Exercise, 27(12), 16921697. https://pubmed.ncbi.nlm.nih.gov/8614327/
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di
Marzo, V., Jutras‐Aswad, D., & Notcutt, W. G. (2014). Cannabidiol: Pharmacology and
potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia,
55(6), 791-802. https://doi.org/10.1111/epi.12631
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E.
A., & Wright, S. (2017). Trial of cannabidiol for drug-resistant seizures in the dravet
syndrome. New England Journal of Medicine, 376(21), 2011-2020.
https://doi.org/10.1056/NEJMoa1611618
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood,
S. M., Roberts, C., Checketts, D., & VanLandingham, K. E. (2018). Effect of cannabidiol
on drop seizures in the lennox–gastaut syndrome. New England Journal of Medicine,
378(20), 1888-1897. https://doi.org/10.1056/NEJMoa1714631

151
Dieli-Conwright, C. M., Parmentier, J. H., Sami, N., Lee, K., Spicer, D., Mack, W. J., Sattler, F.,
& Mittelman, S. D. (2018). Adipose tissue inflammation in breast cancer survivors:
Effects of a 16-week combined aerobic and resistance exercise training intervention.
Breast Cancer Research and Treatment, 168(1), 147-157.
https://doi.org/10.1007/s10549-017-4576-y
Di Fabio, A., & Palazzeschi, L. (2015). Hedonic and eudaimonic well-being: The role of
resilience beyond fluid intelligence and personality traits. Frontiers in Psychology, 6,
1367. https://doi.org/10.3389/fpsyg.2015.01367
Di Marzo, V. (2018). New approaches and challenges to targeting the endocannabinoid system.
Nature Reviews Drug Discovery, 17(9), 623-639. https://doi.org/10.1038/nrd.2018.115
Di Marzo, V., & De Petrocellis, L. (2012). Why do cannabinoid receptors have more than one
endogenous ligand? Philosophical Transactions of the Royal Society of London. Series B,
Biological Sciences, 367(1607), 3216-3228. https://doi.org/10.1098/rstb.2011.0382
Ding, H., Chen, J., Su, M., Lin, Z., Zhan, H., Yang, F., Li, W., Xie, J., Huang, Y., Liu, X., Liu,
B., & Zhou, X. (2020). Bdnf promotes activation of astrocytes and microglia contributing
to neuroinflammation and mechanical allodynia in cyclophosphamide-induced cystitis.
Journal of Neuroinflammation, 17(1), 19. https://doi.org/10.1186/s12974-020-1704-0
Dong, R., Zhao, N. O., Wu, H. E., Yu, L., & Zhang, X. Y. (2021). Sex differences in the
association between serum bdnf and cognitive impairment in schizophrenia patients using
various antipsychotics. Journal of Psychiatric Research, 138, 492-499.
https://doi.org/10.1016/j.jpsychires.2021.04.026

152
Dow-Edwards, D. (2020). Sex differences in the interactive effects of early life stress and the
endocannabinoid system. Neurotoxicology and Teratology, 80, 106893.
https://doi.org/10.1016/j.ntt.2020.106893
Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T.,
Tarsish, E., & Lotan, C. (2007). Cannabidiol, a nonpsychoactive cannabis constituent,
protects against myocardial ischemic reperfusion injury. American Journal of
Physiology-Heart and Circulatory Physiology, 293(6), H3602-3607.
https://doi.org/10.1152/ajpheart.00098.2007
Dyrstad, S. M., Hansen, B. H., Holme, I. M., & Anderssen, S. A. (2014). Comparison of selfreported versus accelerometer-measured physical activity. Medicine and Science in
Sports and Exercise, 46(1), 99-106. https://doi.org/10.1249/MSS.0b013e3182a0595f
Edwards, K. M., Burns, V. E., Ring, C., & Carroll, D. (2006). Sex differences in the interleukin6 response to acute psychological stress. Biological Psychology, 71(3), 236-239.
https://doi.org/10.1016/j.biopsycho.2005.06.006
Eggers, S., Ohnesorg, T., & Sinclair, A. (2014). Genetic regulation of mammalian gonad
development. Nature Reviews Endocrinology, 10(11), 673.
https://doi.org/10.1038/nrendo.2014.163
Elms, L., Shannon, S., Hughes, S., & Lewis, N. (2019). Cannabidiol in the treatment of posttraumatic stress disorder: A case series. Journal of Integrative and Complementary
Medicine, 25(4), 392-397. https://doi.org/10.1089/acm.2018.0437

153
Elsner, V. R., Dorneles, G. P., Santos, M. A., da Silva, I. M., Romão, P., & Peres, A. (2020).
Exercise-induced bdnf production by mononuclear cells of sedentary and physically
active obese men. Journal of Sports Medicine and Physical Fitness, 60(3), 435-441.
https://doi.org/10.23736/s0022-4707.19.10113-2
Enns, D. L., & Tiidus, P. M. (2008). Estrogen influences satellite cell activation and proliferation
following downhill running in rats. Journal of Applied Physiology, 104(2), 347-353.
https://doi.org/10.1152/japplphysiol.00128.2007
Enns, D. L., & Tiidus, P. M. (2010). The influence of estrogen on skeletal muscle. Sports
Medicine, 40(1), 41-58. https://doi.org/10.2165/11319760-000000000-00000
Erickson, K. I., Voss, M. W., Prakash, R. S., Basak, C., Szabo, A., Chaddock, L., Kim, J. S.,
Heo, S., Alves, H., White, S. M., Wojcicki, T. R., Mailey, E., Vieira, V. J., Martin, S. A.,
Pence, B. D., Woods, J. A., McAuley, E., & Kramer, A. F. (2011). Exercise training
increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A, 108(7),
3017-3022. https://doi.org/10.1073/pnas.1015950108
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M.,
Carratù, M. R., Iuvone, T., & Steardo, L. (2011). Cannabidiol reduces aβ-induced
neuroinflammation and promotes hippocampal neurogenesis through pparγ involvement.
PLoS One, 6(12), e28668. https://doi.org/10.1371/journal.pone.0028668
Evert, D. L., & Oscar-Berman, M. (1995). Alcohol-related cognitive impairments: An overview
of how alcoholism may affect the workings of the brain. Alcohol Health and Research
World, 19(2), 89-96. https://pubmed.ncbi.nlm.nih.gov/31798082/

154
Fanaei, H., Karimian, S. M., Sadeghipour, H. R., Hassanzade, G., Kasaeian, A., Attari, F.,
Khayat, S., Ramezani, V., & Javadimehr, M. (2014). Testosterone enhances functional
recovery after stroke through promotion of antioxidant defenses, bdnf levels and
neurogenesis in male rats. Brain Research 1558, 74-83.
https://doi.org/10.1016/j.brainres.2014.02.028
Farrimond, J. A., Whalley, B. J., & Williams, C. M. (2012). Cannabinol and cannabidiol exert
opposing effects on rat feeding patterns. Psychopharmacology (Berl), 223(1), 117-129.
https://doi.org/10.1007/s00213-012-2697-x
Fattore, L., & Fratta, W. (2010). How important are sex differences in cannabinoid action? Br J
Pharmacol, 160(3), 544-548. https://doi.org/10.1111/j.1476-5381.2010.00776.x
Fedorova, E. V., Wong, C. F., Ataiants, J., Iverson, E., Conn, B. M., & Lankenau, S. E. (2021).
Cannabidiol (cbd) and other drug use among young adults who use cannabis in los
angeles. Drug and Alcohol Dependence, 221, 108648.
https://doi.org/10.1016/j.drugalcdep.2021.108648
Fernandez-Real, J.-M., Vayreda, M., Richart, C., Gutierrez, C., Broch, M., Vendrell, J., & Ricart,
W. (2001). Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in
apparently healthy men and women. Journal of Clinical Endocrinology and Metabolism,
86(3), 1154-1159. https://doi.org/10.1210/jcem.86.3.7305
Festa, A., D'Agostino, R., Jr., Williams, K., Karter, A., Mayer-Davis, E., Tracy, R., & Haffner,
S. (2001). The relation of body fat mass and distribution to markers of chronic
inflammation. International Journal of Obesity and Related Metabolic Disorders, 25(10),
1407-1415. https://doi.org/10.1038/sj.ijo.0801792

155
Fine, P. G., & Rosenfeld, M. J. (2013). The endocannabinoid system, cannabinoids, and pain.
Rambam Maimonides Medical Journal, 4(4), e0022.
https://doi.org/10.5041/RMMJ.10129
Fioranelli, M., Bottaccioli, A. G., Bottaccioli, F., Bianchi, M., Rovesti, M., & Roccia, M. G.
(2018). Stress and inflammation in coronary artery disease: A review
psychoneuroendocrineimmunology-based. Frontiers in Immunology, 9, 2031.
https://doi.org/10.3389/fimmu.2018.02031
Fischer, C. P. (2006). Interleukin-6 in acute exercise and training: What is the biological
relevance? Exercise Immunology Review, 12, 6-33.
http://www.ncbi.nlm.nih.gov/pubmed/17201070
Food and Drug Administration. (2020, November 19). Scientific conference: Cbd and other
cannabinoids: Sex and gender differences in use and responses [virtual meeting]. Office
of Women's Health Research. https://www.fda.gov/science-research/womens-healthresearch/scientific-conference-cbd-and-other-cannabinoids-sex-and-gender-differencesuse-and-responses
Forti, L. N., Van Roie, E., Njemini, R., Coudyzer, W., Beyer, I., Delecluse, C., & Bautmans, I.
(2017). Effects of resistance training at different loads on inflammatory markers in young
adults. European Journal of Applied Physiology, 117(3), 511-519.
https://doi.org/10.1007/s00421-017-3548-6
Fortress, A. M., Kim, J., Poole, R. L., Gould, T. J., & Frick, K. M. (2014). 17β-estradiol
regulates histone alterations associated with memory consolidation and increases bdnd
promoter acetylation in middle-aged female mice. Learning & Memory, 21(9), 457-467.
https://doi.org/10.1101/lm.034033.113

156
Frazzitta, G., Maestri, R., Ghilardi, M. F., Riboldazzi, G., Perini, M., Bertotti, G., Boveri, N.,
Buttini, S., Lombino, F. L., Uccellini, D., Turla, M., Pezzoli, G., & Comi, C. (2014).
Intensive rehabilitation increases bdnf serum levels in parkinsonian patients: A
randomized study. Neurorehabilitation & Neural Repair, 28(2), 163-168.
https://doi.org/10.1177/1545968313508474
Fujimura, H., Altar, C. A., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J., Sun, B., &
Tandon, N. N. (2002). Brain-derived neurotrophic factor is stored in human platelets and
released by agonist stimulation. Journal of Thrombosis and Haemostasis, 87(4), 728-734.
Fumagalli, F., Racagni, G., & Riva, M. (2006). The expanding role of bdnf: A therapeutic target
for alzheimer's disease? Pharmacogenomics Journal, 6(1), 8-15.
https://doi.org/10.1038/sj.tpj.6500337
Gabay, C., & Kushner, I. (1999). Acute-phase proteins and other systemic responses to
inflammation. New England Journal of Medicine, 340(6), 448-454.
https://doi.org/10.1056/NEJM199902113400607
Gáll, Z., Farkas, S., Albert, Á., Ferencz, E., Vancea, S., Urkon, M., & Kolcsár, M. (2020).
Effects of chronic cannabidiol treatment in the rat chronic unpredictable mild stress
model of depression. Biomolecules, 10(5), 801. https://doi.org/10.3390/biom10050801
Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active
constituent of hashish. Journal of the American Chemical Society, 86(8), 1646-1647.
Gillman, A. S., Hutchison, K. E., & Bryan, A. D. (2015). Cannabis and exercise science: A
commentary on existing studies and suggestions for future directions. Sports Medicine,
45(10), 1357-1363. https://doi.org/10.1007/s40279-015-0362-3

157
Glud, M., Christiansen, T., Larsen, L. H., Richelsen, B., & Bruun, J. M. (2019). Changes in
circulating bdnf in relation to sex, diet, and exercise: A 12-week randomized controlled
study in overweight and obese participants. Journal of Obesity, 2019, 4537274.
https://doi.org/10.1155/2019/4537274
Gold, S. M., Schulz, K.-H., Hartmann, S., Mladek, M., Lang, U. E., Hellweg, R., Reer, R.,
Braumann, K.-M., & Heesen, C. (2003). Basal serum levels and reactivity of nerve
growth factor and brain-derived neurotrophic factor to standardized acute exercise in
multiple sclerosis and controls. Journal of Neuroimmunology, 138(1), 99-105.
https://doi.org/10.1016/s0165-5728(03)00121-8
Goldstein, B. I., Collinger, K. A., Lotrich, F., Marsland, A. L., Gill, M. K., Axelson, D. A., &
Birmaher, B. (2011). Preliminary findings regarding proinflammatory markers and brainderived neurotrophic factor among adolescents with bipolar spectrum disorders. Journal
of Child and Adolescent Psychopharmacology, 21(5), 479-484.
https://doi.org/10.1089/cap.2011.0009
Gomarasca, M., Banfi, G., & Lombardi, G. (2020). Myokines: The endocrine coupling of
skeletal muscle and bone. Advances in Clinical Chemistry, 94, 155-218.
https://doi.org/10.1016/bs.acc.2019.07.010
Gomes, C., Ferreira, R., George, J., Sanches, R., Rodrigues, D. I., Gonçalves, N., & Cunha, R. A.
(2013). Activation of microglial cells triggers a release of brain-derived neurotrophic
factor (bdnf) inducing their proliferation in an adenosine a2a receptor-dependent manner:
A2a receptor blockade prevents bdnf release and proliferation of microglia. Journal of
Neuroinflammation, 10(1), 16. https://doi.org/10.1186/1742-2094-10-16

158
Gratacos, J., Collado, A., Filella, X., Sanmarti, R., Canete, J., Llena, J., Molina, R., Ballesta, A.,
& Muñoz-Gómez, J. (1994). Serum cytokines (il-6, tnf-α, il-1β and ifn-γ) in ankylosing
spondylitis: A close correlation between serum il-6 and disease activity and severity.
British Journal of Rheumatology, 33(10), 927-931.
https://doi.org/10.1093/rheumatology/33.10.927
Green, T., Flash, S., & Reiss, A. L. (2019). Sex differences in psychiatric disorders: What we can
learn from sex chromosome aneuploidies. Neuropsychopharmacology, 44(1), 9-21.
https://doi.org/10.1038/s41386-018-0153-2
Greenwald, A. G., McGhee, D. E., & Schwartz, J. L. (1998). Measuring individual differences in
implicit cognition: The implicit association test. Journal of Personality and Social
Psychology, 74(6), 1464. https://doi.org/10.1037//0022-3514.74.6.1464
Guo, L., Ren, L., & Zhang, C. (2018). Relationship between depression and inflammatory factors
and brain-derived neurotrophic factor in patients with perimenopause syndrome.
Experimental and Therapeutic Medicine, 15(5), 4436-4440.
https://doi.org/10.3892/etm.2018.5985
Hackett, R. A., Hamer, M., Endrighi, R., Brydon, L., & Steptoe, A. (2012). Loneliness and
stress-related inflammatory and neuroendocrine responses in older men and women.
Psychoneuroendocrinology, 37(11), 1801-1809.
https://doi.org/10.1016/j.psyneuen.2012.03.016

159
Hallak, J. E., Machado-de-Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C., Chaves,
C., Bernardo, S. A., Regalo, S. C., & Zuardi, A. W. (2010). Performance of schizophrenic
patients in the stroop color word test and electrodermal responsiveness after acute
administration of cannabidiol (cbd). Brazilian Journal of Psychiatry, 32(1), 56-61.
https://doi.org/10.1590/s1516-44462010000100011
Han, Y. X., Tao, C., Gao, X. R., Wang, L. L., Jiang, F. H., Wang, C., Fang, K., Chen, X. X.,
Chen, Z., & Ge, J. F. (2018). Bdnf-related imbalance of copine 6 and synaptic plasticity
markers couples with depression-like behavior and immune activation in cums rats.
Frontiers in Neuroscience, 12, 731. https://doi.org/10.3389/fnins.2018.00731
Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M.,
McRae-Clark, A., Lofwall, M. R., Sparenborg, S., & Walsh, S. L. (2016). Oral
cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked
cannabis. Neuropsychopharmacology, 41(8), 1974-1982.
https://doi.org/10.1038/npp.2015.367
Hardee, J. P., Fix, D. K., Wang, X., Goldsmith, E. C., Koh, H. J., & Carson, J. A. (2018).
Systemic il-6 regulation of eccentric contraction-induced muscle protein synthesis.
American Journal of Physiology-Cell Physiology, 315(1), C91-c103.
https://doi.org/10.1152/ajpcell.00063.2018
Haskell, W. L., Lee, I. M., Pate, R. R., Powell, K. E., Blair, S. N., Franklin, B. A., Macera, C. A.,
Heath, G. W., Thompson, P. D., & Bauman, A. (2007). Physical activity and public
health: Updated recommendation for adults from the american college of sports medicine
and the american heart association. Medicine and Science in Sports and Exercise, 39(8),
1423-1434. https://doi.org/10.1249/mss.0b013e3180616b27

160
He, J. Y., Wei, X. H., Li, S. J., Liu, Y., Hu, H. L., Li, Z. Z., Kuang, X. H., Wang, L., Shi, X.,
Yuan, S. T., & Sun, L. (2018). Adipocyte-derived il-6 and leptin promote breast cancer
metastasis via upregulation of lysyl hydroxylase-2 expression. Cell Communication and
Signaling, 16(1), 100. https://doi.org/10.1186/s12964-018-0309-z
Herder, C., Schneitler, S., Rathmann, W., Haastert, B., Schneitler, H., Winkler, H., Bredahl, R.,
Hahnloser, E., & Martin, S. (2007). Low-grade inflammation, obesity, and insulin
resistance in adolescents. Journal of Clinical Endocrinology & Metabolism, 92(12),
4569-4574. https://doi.org/10.1210/jc.2007-0955
Hofer, M., Pagliusi, S. R., Hohn, A., Leibrock, J., & Barde, Y. A. (1990). Regional distribution
of brain-derived neurotrophic factor mrna in the adult mouse brain. EMBO Journal, 9(8),
2459-2464. https://doi.org/10.1002/j.1460-2075.1990.tb07423.x
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019).
Cannabidiol adverse effects and toxicity. Curr Neuropharmacol, 17(10), 974-989.
https://doi.org/10.2174/1570159x17666190603171901
Hughto, J. M., Quinn, E. K., Dunbar, M. S., Rose, A. J., Shireman, T. I., & Jasuja, G. K. (2021).
Prevalence and co-occurrence of alcohol, nicotine, and other substance use disorder
diagnoses among us transgender and cisgender adults. JAMA Network Open, 4(2),
e2036512. https://doi.org/10.1001/jamanetworkopen.2020.36512
Hurel, I., Muguruza, C., Redon, B., Marsicano, G., & Chaouloff, F. (2021). Cannabis and
exercise: Effects of delta(9)-tetrahydrocannabinol on preference and motivation for
wheel-running in mice. Prog Neuropsychopharmacol Biol Psychiatry, 105, 110117.
https://doi.org/10.1016/j.pnpbp.2020.110117

161
Ihara, K., Yoshida, H., Jones, P. B., Hashizume, M., Suzuki, Y., Ishijima, H., Kim, H. K.,
Suzuki, T., & Hachisu, M. (2016). Serum bdnf levels before and after the development of
mood disorders: A case–control study in a population cohort. Translational Psychiatry
6(4), e782-e782. https://doi.org/10.1038/tp.2016.47
Irving, P. M., Iqbal, T., Nwokolo, C., Subramanian, S., Bloom, S., Prasad, N., Hart, A., Murray,
C., Lindsay, J. O., & Taylor, A. (2018). A randomized, double-blind, placebo-controlled,
parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic
treatment of ulcerative colitis. Inflammatory Bowel Disease, 24(4), 714-724.
https://doi.org/10.1093/ibd/izy002
Isenmann, E., Veit, S., Starke, L., Flenker, U., & Diel, P. (2021). Effects of cannabidiol
supplementation on skeletal muscle regeneration after intensive resistance training.
Nutrients, 13(9). https://doi.org/10.3390/nu13093028
Iverson, G. L., Marsh, J. M., Connors, E. J., & Terry, D. P. (2021). Normative reference values,
reliability, and item-level symptom endorsement for the promis® v2.0 cognitive
function-short forms 4a, 6a and 8a. Archives of Clinical Neuropsychology, 36(7), 13411349. https://doi.org/10.1093/arclin/acaa128
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S.
E., & Tan, G. D. (2016). Efficacy and safety of cannabidiol and tetrahydrocannabivarin
on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, doubleblind, placebo-controlled, parallel group pilot study. Diabetes Care, 39(10), 1777-1786.
Javadi-Paydar, M., Nguyen, J. D., Kerr, T. M., Grant, Y., Vandewater, S. A., Cole, M., & Taffe,
M. A. (2018). Effects of δ9-thc and cannabidiol vapor inhalation in male and female rats.
Psychopharmacology, 235(9), 2541-2557. https://doi.org/10.1007/s00213-018-4946-0

162
Jehn, C. F., Becker, B., Flath, B., Nogai, H., Vuong, L., Schmid, P., & Lüftner, D. (2015).
Neurocognitive function, brain-derived neurotrophic factor (bdnf) and il-6 levels in
cancer patients with depression. Journal of Neuroimmunology, 287, 88-92.
https://doi.org/https://doi.org/10.1016/j.jneuroim.2015.08.012
Jimenez Naranjo, C., Osborne, A. L., & Weston-Green, K. (2019). Effect of cannabidiol on
muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly i:C
rat model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 94, 109640.
https://doi.org/https://doi.org/10.1016/j.pnpbp.2019.109640
Jovanović, V. (2015). Structural validity of the mental health continuum-short form: The bifactor
model of emotional, social and psychological well-being. Personality and Individual
Differences, 75, 154-159. https://doi.org/10.1016/j.paid.2014.11.026
Kaczkurkin, A. N., Raznahan, A., & Satterthwaite, T. D. (2019). Sex differences in the
developing brain: Insights from multimodal neuroimaging. Neuropsychopharmacology,
44(1), 71-85. https://doi.org/10.1038/s41386-018-0111-z
Kallies, G., Rapp, M. A., Fydrich, T., Fehm, L., Tschorn, M., Terán, C., Schwefel, M., Pietrek,
A., Henze, R., Hellweg, R., Ströhle, A., Heinzel, S., & Heissel, A. (2019). Serum brainderived neurotrophic factor (bdnf) at rest and after acute aerobic exercise in major
depressive disorder. Psychoneuroendocrinology, 102, 212-215.
https://doi.org/10.1016/j.psyneuen.2018.12.015
Kang, H. J., Kim, J. M., Kim, S. Y., Kim, S. W., Shin, I. S., Kim, H. R., Park, M. H., Shin, M.
G., Yoon, J. H., & Yoon, J. S. (2015). A longitudinal study of bdnf promoter methylation
and depression in breast cancer. Psychiatry Investigation, 12(4), 523-531.
https://doi.org/10.4306/pi.2015.12.4.523

163
Karlović, D., Serretti, A., Vrkić, N., Martinac, M., & Marčinko, D. (2012). Serum concentrations
of crp, il-6, tnf-α and cortisol in major depressive disorder with melancholic or atypical
features. Psychiatric Research, 198(1), 74-80.
https://doi.org/10.1016/j.psychres.2011.12.007
Karmaus, P. W., Wagner, J. G., Harkema, J. R., Kaminski, N. E., & Kaplan, B. L. (2013).
Cannabidiol (cbd) enhances lipopolysaccharide (lps)-induced pulmonary inflammation in
c57bl/6 mice. Journal of Immunotoxicology, 10(3), 321-328.
https://doi.org/10.3109/1547691X.2012.741628
Karsenty, G., & Ferron, M. (2012). The contribution of bone to whole-organism physiology.
Nature, 481(7381), 314-320. https://doi.org/10.1038/nature10763
Karsenty, G., & Mera, P. (2018). Molecular bases of the crosstalk between bone and muscle.
Bone, 115, 43-49.
Kasapis, C., & Thompson, P. D. (2005). The effects of physical activity on serum c-reactive
protein and inflammatory markers: A systematic review. Journal of the American College
of Cardiology, 45(10), 1563-1569. https://doi.org/10.1016/j.jacc.2004.12.077
Kasper, A. M., Sparks, S. A., Hooks, M., Skeer, M., Webb, B., Nia, H., Morton, J. P., & Close,
G. L. (2020). High prevalence of cannabidiol use within male professional rugby union
and league players: A quest for pain relief and enhanced recovery. International Journal
of Sport Nutrition and Exercise Metabolism, 30(5), 315-322.
https://doi.org/10.1123/ijsnem.2020-0151
Kennedy, M. C. (2017). Cannabis: Exercise performance and sport. A systematic review.
Journal of Science and Medicine in Sport, 20(9), 825-829.
https://doi.org/10.1016/j.jsams.2017.03.012

164
Kerschensteiner, M., Gallmeier, E., Behrens, L., Leal, V. V., Misgeld, T., Klinkert, W. E.,
Kolbeck, R., Hoppe, E., Oropeza-Wekerle, R. L., Bartke, I., Stadelmann, C., Lassmann,
H., Wekerle, H., & Hohlfeld, R. (1999). Activated human t cells, b cells, and monocytes
produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A
neuroprotective role of inflammation? Journal of Experimental Medicine, 189(5), 865870. https://doi.org/10.1084/jem.189.5.865
Khan, A. A., Shekh-Ahmad, T., Khalil, A., Walker, M. C., & Ali, A. B. (2018). Cannabidiol
exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal
lobe epilepsy model. Br J Pharmacol, 175(11), 2097-2115.
https://doi.org/10.1111/bph.14202
Khera, A., Vega, G. L., Das, S. R., Ayers, C., McGuire, D. K., Grundy, S. M., & de Lemos, J. A.
(2009). Sex differences in the relationship between c-reactive protein and body fat. The
Journal of Clinical Endocrinology & Metabolism, 94(9), 3251-3258.
https://doi.org/10.1210/jc.2008-2406
Khreiss, T., József, L., Hossain, S., Chan, J. S., Potempa, L. A., & Filep, J. G. (2002). Loss of
pentameric symmetry of c-reactive protein is associated with delayed apoptosis of human
neutrophils. Journal of Biological Chemistry, 277(43), 40775-40781.
https://doi.org/10.1074/jbc.M205378200
Kim, Y., Ryu, J., Ryu, M. S., Lim, S., Han, K. O., Lim, I. K., & Han, K. H. (2014). C-reactive
protein induces g2/m phase cell cycle arrest and apoptosis in monocytes through the
upregulation of b-cell translocation gene 2 expression. FEBS Letters, 588(4), 625-631.
https://doi.org/10.1016/j.febslet.2014.01.008

165
Komulainen, J., Koskinen, S., Kalliokoski, R., Takala, T., & Vihko, V. (1999). Gender
differences in skeletal muscle fibre damage after eccentrically biased downhill running in
rats. Acta Psychiatrica Scandinavica 165(1), 57-63. https://doi.org/10.1046/j.1365201x.1999.00481.x
Krebs-Kraft, D. L., Hill, M. N., Hillard, C. J., & McCarthy, M. M. (2010). Sex difference in cell
proliferation in developing rat amygdala mediated by endocannabinoids has implications
for social behavior. Proceedings of the National Academy of Sciences, 107(47), 2053520540. https://doi.org/10.1073/pnas.1005003107
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016). Role of interleukin-6 in cancer
progression and therapeutic resistance. Tumour Biol, 37(9), 11553-11572.
https://doi.org/10.1007/s13277-016-5098-7
Laczkovics, C., Kothgassner, O. D., Felnhofer, A., & Klier, C. M. (2020). Cannabidiol treatment
in an adolescent with multiple substance abuse, social anxiety and depression.
Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der
Gesellschaft Osterreichischer Nervenarzte und Psychiater, 35(1), 31-34.
https://doi.org/10.1007/s40211-020-00334-0
Landers, M. R., Navalta, J. W., Murtishaw, A. S., Kinney, J. W., & Pirio Richardson, S. (2019).
A high-intensity exercise boot camp for persons with parkinson disease: A phase ii,
pragmatic, randomized clinical trial of feasibility, safety, signal of efficacy, and disease
mechanisms. Journal of Neurologic Physical Therapy, 43(1), 12-25.
https://doi.org/10.1097/npt.0000000000000249

166
Lang, U. E., Hellweg, R., & Gallinat, J. (2004). Bdnf serum concentrations in healthy volunteers
are associated with depression-related personality traits. Neuropsychopharmacology,
29(4), 795-798.
Langer, H. T., Mossakowski, A. A., Pathak, S., Mascal, M., & Baar, K. (2021). Cannabidiol does
not impair anabolic signaling following eccentric contractions in rats. International
Journal of Sport Nutrition and Exercise Metabolism, 31(2), 98-100.
https://doi.org/10.1123/ijsnem.2020-0270
Laprairie, R. B., Bagher, A. M., Kelly, M. E., & Denovan-Wright, E. M. (2015). Cannabidiol is a
negative allosteric modulator of the cannabinoid cb1 receptor. Br J Pharmacol, 172(20),
4790-4805. https://doi.org/10.1111/bph.13250
Lear, S. A., Chen, M. M., Birmingham, C. L., & Frohlich, J. J. (2003). The relationship between
simple anthropometric indices and c-reactive protein: Ethnic and gender differences.
Metabolism, 52(12), 1542-1546.
https://doi.org/https://doi.org/10.1016/j.metabol.2003.07.005
Lee, Y., McKechnie, T., Doumouras, A. G., Handler, C., Eskicioglu, C., Gmora, S., Anvari, M.,
& Hong, D. (2019). Diagnostic value of c-reactive protein levels in postoperative
infectious complications after bariatric surgery: A systematic review and meta-analysis.
Obesity Surgery, 29(7), 2022-2029. https://doi.org/10.1007/s11695-019-03832-5
Lentini, E., Kasahara, M., Arver, S., & Savic, I. (2013). Sex differences in the human brain and
the impact of sex chromosomes and sex hormones. Cerebral Cortex, 23(10), 2322-2336.
https://doi.org/10.1093/cercor/bhs222
Lenz, K. M., & McCarthy, M. M. (2015). A starring role for microglia in brain sex differences.
Neuroscientist, 21(3), 306-321. https://doi.org/10.1177/1073858414536468

167
Lenz, K. M., & Nelson, L. H. (2018). Microglia and beyond: Innate immune cells as regulators
of brain development and behavioral function. Frontiers in Immunology, 9, 698.
https://doi.org/10.3389/fimmu.2018.00698
Le Strat, Y., & Le Foll, B. (2011). Obesity and cannabis use: Results from 2 representative
national surveys. American journal of epidemiology, 174(8), 929-933.
https://doi.org/10.1093/aje/kwr200
Leweke, F., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C., Hoyer, C., Klosterkötter, J.,
Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and
alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94-e94.
https://doi.org/10.1038/tp.2012.15
Li, G., Shang, Z., Liu, Y., Yan, H., & Ou, T. (2020). The diagnostic values of pretreatment
serum inflammation markers and lipoprotein in men with total prostate-specific antigen
between 4 and 10 ng/ml. Frontiers in Medicine, 7, 576812.
https://doi.org/10.3389/fmed.2020.576812
Libardi, C. A., De Souza, G. V., Cavaglieri, C. R., Madruga, V. A., & Chacon-Mikahil, M. P. T.
(2012). Effect of resistance, endurance, and concurrent training on tnf-α, il-6, and crp.
Medicine and Science in Sports and Exercise, 44(1), 50-56.
https://doi.org/10.1249/MSS.0b013e318229d2e9
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016). From phytocannabinoids to cannabinoid
receptors and endocannabinoids: Pleiotropic physiological and pathological roles through
complex pharmacology. Physiological Reviews, 96(4), 1593-1659.
https://doi.org/10.1152/physrev.00002.2016

168
Linher-Melville, K., Zhu, Y. F., Sidhu, J., Parzei, N., Shahid, A., Seesankar, G., Ma, D., Wang,
Z., Zacal, N., Sharma, M., Parihar, V., Zacharias, R., & Singh, G. (2020). Evaluation of
the preclinical analgesic efficacy of naturally derived, orally administered oil forms of
δ9-tetrahydrocannabinol (thc), cannabidiol (cbd), and their 1:1 combination. PLoS One,
15(6), e0234176-e0234176. https://doi.org/10.1371/journal.pone.0234176
Lisano, J. K., Kisiolek, J. N., Smoak, P., Phillips, K. T., & Stewart, L. K. (2020). Chronic
cannabis use and circulating biomarkers of neural health, stress, and inflammation in
physically active individuals. Applied Physiology, Nutrition, and Metabolism, 45(3), 258263. https://doi.org/10.1139/apnm-2019-0300
Lisano, J. K., Phillips, K. T., Smith, J. D., Barnes, M. J., & Stewart, L. K. (2018). Patterns and
perceptions of cannabis use with physical activity. bioRxiv, 328732.
https://doi.org/10.1101/328732
Lisano, J. K., Smith, J. D., Mathias, A. B., Christensen, M., Smoak, P., Phillips, K. T., Quinn, C.
J., & Stewart, L. K. (2019). Performance and health-related characteristics of physically
active males using marijuana. Journal of Strength & Conditioning Research, 33(6), 16581668. https://doi.org/10.1519/jsc.0000000000002238
Littlefield, A. M., Setti, S. E., Priester, C., & Kohman, R. A. (2015). Voluntary exercise
attenuates lps-induced reductions in neurogenesis and increases microglia expression of a
proneurogenic phenotype in aged mice. Journal of Neuroinflammation, 12, 138.
https://doi.org/10.1186/s12974-015-0362-0

169
Liu, C. H., Abrams, N. D., Carrick, D. M., Chander, P., Dwyer, J., Hamlet, M. R. J.,
Macchiarini, F., PrabhuDas, M., Shen, G. L., Tandon, P., & Vedamony, M. M. (2017).
Biomarkers of chronic inflammation in disease development and prevention: Challenges
and opportunities. Nat Immunol, 18(11), 1175-1180. https://doi.org/10.1038/ni.3828
Liu, L. L., Li, J. M., Su, W. J., Wang, B., & Jiang, C. L. (2019). Sex differences in depressivelike behaviour may relate to imbalance of microglia activation in the hippocampus. Brain
Behav Immun, 81, 188-197. https://doi.org/10.1016/j.bbi.2019.06.012
Liu, Q. R., Pan, C. H., Hishimoto, A., Li, C. Y., Xi, Z. X., Llorente-Berzal, A., Viveros, M. P.,
Ishiguro, H., Arinami, T., Onaivi, E. S., & Uhl, G. R. (2009). Species differences in
cannabinoid receptor 2 (cnr2 gene): Identification of novel human and rodent cb2
isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.
Genes, Brain and Behavior, 8(5), 519-530. https://doi.org/10.1111/j.1601183X.2009.00498.x
Lobo-Silva, D., Carriche, G. M., Castro, A. G., Roque, S., & Saraiva, M. (2016). Balancing the
immune response in the brain: Il-10 and its regulation. Journal of Neuroinflammation,
13(1), 297. https://doi.org/10.1186/s12974-016-0763-8
Lockwood, K. G., Marsland, A. L., Cohen, S., & Gianaros, P. J. (2016). Sex differences in the
association between stressor-evoked interleukin-6 reactivity and c-reactive protein. Brain
Behav Immun, 58, 173-180. https://doi.org/10.1016/j.bbi.2016.07.001

170
Lopez, H. L., Cesareo, K. R., Raub, B., Kedia, A. W., Sandrock, J. E., Kerksick, C. M., &
Ziegenfuss, T. N. (2020). Effects of hemp extract on markers of wellness, stress
resilience, recovery and clinical biomarkers of safety in overweight, but otherwise
healthy subjects. J Diet Suppl, 17(5), 561-586.
https://doi.org/10.1080/19390211.2020.1765941
Lovejoy, J., Sainsbury, A., & Group, S. C. W. (2009). Sex differences in obesity and the
regulation of energy homeostasis. Obesity Reviews, 10(2), 154-167.
https://doi.org/10.1111/j.1467-789X.2008.00529.x
Luchicchi, A., & Pistis, M. (2012). Anandamide and 2-arachidonoylglycerol: Pharmacological
properties, functional features, and emerging specificities of the two major
endocannabinoids. Mol Neurobiol, 46(2), 374-392. https://doi.org/10.1007/s12035-0128299-0
Ludban, M., & Gitimu, P. (2015). Psychological well-being of college students.
https://www.kon.org/urc/v14/ludban.html
Maachi, M., Pieroni, L., Bruckert, E., Jardel, C., Fellahi, S., Hainque, B., Capeau, J., & Bastard,
J. (2004). Systemic low-grade inflammation is related to both circulating and adipose
tissue tnf α, leptin and il-6 levels in obese women. International Journal of Obesity and
Related Metabolic Disorders, 28(8), 993-997. https://doi.org/10.1038/sj.ijo.0802718
MacNeil, L. G., Baker, S. K., Stevic, I., & Tarnopolsky, M. A. (2011). 17β-estradiol attenuates
exercise-induced neutrophil infiltration in men. American Journal of PhysiologyRegulatory, Integrative and Comparative Physiology, 300(6), R1443-1451.
https://doi.org/10.1152/ajpregu.00689.2009

171
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of
the association between the level of cannabis use and risk of psychosis. Schizophrenia
Bulletin 42(5), 1262-1269. https://doi.org/10.1093/schbul/sbw003
Maroon, J., & Bost, J. (2018). Review of the neurological benefits of phytocannabinoids. Surg
Neurol Int, 9, 91. https://doi.org/10.4103/sni.sni_45_18
Martin-Santos, R., a Crippa, J., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen,
P., Seal, M., Langohr, K., & Farre, M. (2012). Acute effects of a single, oral dose of d9tetrahydrocannabinol (thc) and cannabidiol (cbd) administration in healthy volunteers.
Current pharmaceutical design, 18(32), 4966-4979.
https://doi.org/10.2174/138161212802884780
Marzolini, C., Stader, F., Stoeckle, M., Franzeck, F., Egli, A., Bassetti, S., Hollinger, A., Osthoff,
M., Weisser, M., Gebhard, C. E., Baettig, V., Geenen, J., Khanna, N., Tschudin-Sutter,
S., Mueller, D., Hirsch, H. H., Battegay, M., & Sendi, P. (2020). Effect of systemic
inflammatory response to sars-cov-2 on lopinavir and hydroxychloroquine plasma
concentrations. Antimicrobial Agents and Chemotherapy, 64(9).
https://doi.org/10.1128/aac.01177-20
Matheson, J., Sproule, B., Di Ciano, P., Fares, A., Le Foll, B., Mann, R. E., & Brands, B. (2020).
Sex differences in the acute effects of smoked cannabis: Evidence from a human
laboratory study of young adults. Psychopharmacology (Berl), 237(2), 305-316.
https://doi.org/10.1007/s00213-019-05369-y
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure
of a cannabinoid receptor and functional expression of the cloned cdna. Nature,
346(6284), 561-564. https://doi.org/10.1038/346561a0

172
Matthews, V. B., Aström, M. B., Chan, M. H., Bruce, C. R., Krabbe, K. S., Prelovsek, O.,
Akerström, T., Yfanti, C., Broholm, C., Mortensen, O. H., Penkowa, M., Hojman, P.,
Zankari, A., Watt, M. J., Bruunsgaard, H., Pedersen, B. K., & Febbraio, M. A. (2009).
Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to
contraction and enhances fat oxidation via activation of amp-activated protein kinase.
Diabetologia, 52(7), 1409-1418. https://doi.org/10.1007/s00125-009-1364-1
Mattusch, F., Dufaux, B., Heine, O., Mertens, I., & Rost, R. (2000). Reduction of the plasma
concentration of c-reactive protein following nine months of endurance training.
International Journal of Sports Medicine 21(1), 21-24. https://doi.org/10.1055/s-20008852
Maud, P. J., & Shultz, B. B. (1986). Gender comparisons in anaerobic power and anaerobic
capacity tests. British Journal of Sports Medicine, 20(2), 51-54.
https://doi.org/10.1136/bjsm.20.2.51
McCartney, D., Benson, M. J., Desbrow, B., Irwin, C., Suraev, A., & McGregor, I. S. (2020).
Cannabidiol and sports performance: A narrative review of relevant evidence and
recommendations for future research. Sports Medicine - Open, 6(1), 1-18.
https://doi.org/10.1186/s40798-020-00251-0
McDowell, I., Kristjansson, B., Hill, G., & Hebert, R. (1997). Community screening for
dementia: The mini mental state exam (mmse) and modified mini-mental state exam
(3ms) compared. Journal of Clinical Epidemiology, 50(4), 377-383.
McEwen, B. S., & Milner, T. A. (2017). Understanding the broad influence of sex hormones and
sex differences in the brain. Journal of Neuroscience Research, 95(1-2), 24-39.
https://doi.org/10.1002/jnr.23809

173
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., &
Wright, S. (2018). Cannabidiol (cbd) as an adjunctive therapy in schizophrenia: A
multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225231. https://doi.org/10.1176/appi.ajp.2017.17030325
McLean, C. P., Asnaani, A., Litz, B. T., & Hofmann, S. G. (2011). Gender differences in anxiety
disorders: Prevalence, course of illness, comorbidity and burden of illness. Journal of
Psychiatric Research, 45(8), 1027-1035. https://doi.org/10.1016/j.jpsychires.2011.03.006
Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454(7203), 428435. https://doi.org/10.1038/nature07201
Mendham, A. E., Donges, C. E., Liberts, E. A., & Duffield, R. (2011). Effects of mode and
intensity on the acute exercise-induced il-6 and crp responses in a sedentary, overweight
population. European Journal of Applied Physiology, 111(6), 1035-1045.
https://doi.org/10.1007/s00421-010-1724-z
Mogil, J. S. (2012). Sex differences in pain and pain inhibition: Multiple explanations of a
controversial phenomenon. Nature Reviews Neuroscience, 13(12), 859-866.
https://doi.org/10.1038/nrn3360
Moltke, J., & Hindocha, C. (2021). Reasons for cannabidiol use: A cross-sectional study of cbd
users, focusing on self-perceived stress, anxiety, and sleep problems. Journal of
Cannabis Research, 3(1), 5. https://doi.org/10.1186/s42238-021-00061-5
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis,
G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A
systematic review. Lancet, 370(9584), 319-328. https://doi.org/10.1016/s01406736(07)61162-3

174
Moreno, C., Wykes, T., Galderisi, S., Nordentoft, M., Crossley, N., Jones, N., Cannon, M.,
Correll, C. U., Byrne, L., & Carr, S. (2020). How mental health care should change as a
consequence of the covid-19 pandemic. Lancet Psychiatry, 7(9), 813-824.
https://doi.org/10.1016/S2215-0366(20)30307-2
Mori, M. A., Meyer, E., Soares, L. M., Milani, H., Guimarães, F. S., & de Oliveira, R. M. W.
(2017). Cannabidiol reduces neuroinflammation and promotes neuroplasticity and
functional recovery after brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry,
75, 94-105. https://doi.org/10.1016/j.pnpbp.2016.11.005
Mörs, K., Braun, O., Wagner, N., Auner, B., Voth, M., Störmann, P., Wutzler, S., Marzi, I., &
Relja, B. (2016). Influence of gender on systemic il-6 levels, complication rates and
outcome after major trauma. Immunobiology, 221(8), 904-910.
https://doi.org/10.1016/j.imbio.2016.03.005
Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation.
Nature Reviews Immunology, 8(12), 958-969. https://doi.org/10.1038/nri2448
Moy, M. L., Teylan, M., Weston, N. A., Gagnon, D. R., Danilack, V. A., & Garshick, E. (2014).
Daily step count is associated with plasma c-reactive protein and il-6 in a us cohort with
copd. Chest, 145(3), 542-550. https://doi.org/10.1378/chest.13-1052
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral
receptor for cannabinoids. Nature, 365(6441), 61. https://doi.org/10.1038/365061a0
Murphy, K., & Weaver, C. (2017). Janeway's immunobiology (9th ed.). Garland Science/Taylor
& Francis.

175
Muthumalage, T., & Rahman, I. (2019). Cannabidiol differentially regulates basal and lpsinduced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts.
Toxicology and Applied Pharmacology, 382, 114713.
https://doi.org/10.1016/j.taap.2019.114713
Nadulski, T., Pragst, F., Weinberg, G., Roser, P., Schnelle, M., Fronk, E.-M., & Stadelmann, A.
M. (2005). Randomized, double-blind, placebo-controlled study about the effects of
cannabidiol (cbd) on the pharmacokinetics of δ9-tetrahydrocannabinol (thc) after oral
application of thc verses standardized cannabis extract. Therapeutic Drug Monitoring,
27(6), 799-810. https://doi.org/10.1097/01.ftd.0000177223.19294.5c
Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., Laish, I.,
Benjaminov, F., & Konikoff, F. M. (2017). Low-dose cannabidiol is safe but not effective
in the treatment for crohn’s disease, a randomized controlled trial. Digestive Diseases and
Sciences, 62(6), 1615-1620. https://doi.org/10.1007/s10620-017-4540-z
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I.,
Cummings, J. L., & Chertkow, H. (2005). The montreal cognitive assessment, moca: A
brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 53(4), 695-699.
https://doi.org/10.1111/j.1532-5415.2005.53221.x
Navarrete, F., García-Gutiérrez, M. S., Jurado-Barba, R., Rubio, G., Gasparyan, A., AustrichOlivares, A., & Manzanares, J. (2020). Endocannabinoid system components as potential
biomarkers in psychiatry. Frontiers in Psychiatry, 11, 315.
https://doi.org/10.3389/fpsyt.2020.00315

176
Nishida, Y., Higaki, Y., Taguchi, N., Hara, M., Nakamura, K., Nanri, H., Imaizumi, T.,
Sakamoto, T., Horita, M., Shinchi, K., & Tanaka, K. (2014). Objectively measured
physical activity and inflammatory cytokine levels in middle-aged japanese people.
Preventive Medicine, 64, 81-87. https://doi.org/10.1016/j.ypmed.2014.04.004
Nofuji, Y., Suwa, M., Moriyama, Y., Nakano, H., Ichimiya, A., Nishichi, R., Sasaki, H., Radak,
Z., & Kumagai, S. (2008). Decreased serum brain-derived neurotrophic factor in trained
men. Neuroscience Letters, 437(1), 29-32. https://doi.org/10.1016/j.neulet.2008.03.057
Norden, D. M., Trojanowski, P. J., Villanueva, E., Navarro, E., & Godbout, J. P. (2016).
Sequential activation of microglia and astrocyte cytokine expression precedes increased
iba-1 or gfap immunoreactivity following systemic immune challenge. Glia, 64(2), 300316. https://doi.org/10.1002/glia.22930
Nygaard, H., Falch, G. S., Whist, J. E., Hollan, I., Ellefsen, S., Holmboe-Ottesen, G., Rønnestad,
B. R., & Høstmark, A. T. (2017). Acute effects of post-absorptive and postprandial
moderate exercise on markers of inflammation in hyperglycemic individuals. European
Journal of Applied Physiology, 117(4), 787-794. https://doi.org/10.1007/s00421-0173576-2
Oberbach, A., Lehmann, S., Kirsch, K., Krist, J., Sonnabend, M., Linke, A., Tönjes, A.,
Stumvoll, M., Blüher, M., & Kovacs, P. (2008). Long-term exercise training decreases
interleukin-6 (il-6) serum levels in subjects with impaired glucose tolerance: Effect of the
-174g/c variant in il-6 gene. European Journal of Endocrinology, 159(2), 129-136.
https://doi.org/10.1530/eje-08-0220

177
O'Callaghan, A., Harvey, M., Houghton, D., Gray, W. K., Weston, K. L., Oates, L. L., Romano,
B., & Walker, R. W. (2020). Comparing the influence of exercise intensity on brainderived neurotrophic factor serum levels in people with parkinson's disease: A pilot
study. Aging - Clinical and Experimental Research, 32(9), 1731-1738.
https://doi.org/10.1007/s40520-019-01353-w
Osborne, A. L., Solowij, N., Babic, I., Huang, X.-F., & Weston-Green, K. (2017). Improved
social interaction, recognition and working memory with cannabidiol treatment in a
prenatal infection (poly i:C) rat model. Neuropsychopharmacology, 42(7), 1447-1457.
https://doi.org/10.1038/npp.2017.40
Osborne, A. L., Solowij, N., Babic, I., Lum, J. S., Huang, X. F., Newell, K. A., & Weston-Green,
K. (2019). Cannabidiol improves behavioural and neurochemical deficits in adult female
offspring of the maternal immune activation (poly i:C) model of neurodevelopmental
disorders. Brain Behav Immun, 81, 574-587. https://doi.org/10.1016/j.bbi.2019.07.018
Osborne, A. L., Solowij, N., & Weston-Green, K. (2017). A systematic review of the effect of
cannabidiol on cognitive function: Relevance to schizophrenia. Neuroscience &
Biobehavioral Reviews, 72, 310-324. https://doi.org/10.1016/j.neubiorev.2016.11.012
Ostrowski, K., Rohde, T., Asp, S., Schjerling, P., & Pedersen, B. K. (1999). Pro- and antiinflammatory cytokine balance in strenuous exercise in humans. Journal of Physiology,
515 (287-291. https://doi.org/10.1111/j.1469-7793.1999.287ad.x
Paller, C. J., Campbell, C. M., Edwards, R. R., & Dobs, A. S. (2009). Sex-based differences in
pain perception and treatment. Pain Medicine, 10(2), 289-299.
https://doi.org/10.1111/j.1526-4637.2008.00558.x

178
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998). Transport of brainderived neurotrophic factor across the blood-brain barrier. Neuropharmacology, 37(12),
1553-1561. https://doi.org/10.1016/s0028-3908(98)00141-5
Parbo, P., Ismail, R., Hansen, K. V., Amidi, A., Mårup, F. H., Gottrup, H., Brændgaard, H.,
Eriksson, B. O., Eskildsen, S. F., & Lund, T. E. (2017). Brain inflammation accompanies
amyloid in the majority of mild cognitive impairment cases due to alzheimer’s disease.
Brain, 140(7), 2002-2011.
Parray, H. A., & Yun, J. W. (2016). Cannabidiol promotes browning in 3t3-l1 adipocytes.
Molecular and Cellular Biochemistry, 416(1-2), 131-139.
https://doi.org/10.1007/s11010-016-2702-5
Patanella, A. K., Zinno, M., Quaranta, D., Nociti, V., Frisullo, G., Gainotti, G., Tonali, P. A.,
Batocchi, A. P., & Marra, C. (2010). Correlations between peripheral blood mononuclear
cell production of bdnf, tnf‐alpha, il‐6, il‐10 and cognitive performances in multiple
sclerosis patients. Journal of Neuroscience Research, 88(5), 1106-1112.
https://doi.org/10.1002/jnr.22276
Patas, K., Penninx, B. W., Bus, B. A., Vogelzangs, N., Molendijk, M. L., Elzinga, B. M., Bosker,
F. J., & Oude Voshaar, R. C. (2014). Association between serum brain-derived
neurotrophic factor and plasma interleukin-6 in major depressive disorder with
melancholic features. Brain Behav Immun, 36, 71-79.
https://doi.org/10.1016/j.bbi.2013.10.007
Pedersen, B. K., & Febbraio, M. A. (2012). Muscles, exercise and obesity: Skeletal muscle as a
secretory organ. Nature Reviews Endocrinology, 8(8), 457-465.
https://doi.org/10.1038/nrendo.2012.49

179
Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A., Silva, R. H., & Abílio, V. C. (2018).
Cannabidiol as a promising strategy to treat and prevent movement disorders? Frontiers
in Pharmacology, 9, 482-482. https://doi.org/10.3389/fphar.2018.00482
Perez, J. A. (2012). Gender difference in psychological well-being among filipino college
student samples. International Journal of Humanities and Social Science, 2(13), 84-93.
Perrin, J. S., Hervé, P.-Y., Leonard, G., Perron, M., Pike, G. B., Pitiot, A., Richer, L., Veillette,
S., Pausova, Z., & Paus, T. (2008). Growth of white matter in the adolescent brain: Role
of testosterone and androgen receptor. Journal of Neuroscience, 28(38), 9519-9524.
https://doi.org/10.1523/jneurosci.1212-08.2008
Pertwee, R. G. (1997). Pharmacology of cannabinoid cb1 and cb2 receptors. Pharmacology &
Therapeutics, 74(2), 129-180. https://doi.org/https://doi.org/10.1016/S01637258(97)82001-3
Pescatello, L., Arena, R., Riebe, D., & Thompson, P. (2014). Health-related physical fitness
testing and interpretation. In Acsm's guidelines for exercise testing and prescription (9
ed., pp. 73-76). Wolters Kluwer/Lippincott Williams & Wilkins.
Petersen, A. M., & Pedersen, B. K. (2005). The anti-inflammatory effect of exercise. Journal of
Applied Physiology, 98(4), 1154-1162. https://doi.org/10.1152/japplphysiol.00164.2004
Petrosino, S., Verde, R., Vaia, M., Allarà, M., Iuvone, T., & Di Marzo, V. (2018). Antiinflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental
allergic contact dermatitis. Journal of Pharmacology and Experimental Therapeutics,
365(3), 652-663. https://doi.org/10.1124/jpet.117.244368
Pfefferbaum, B., & North, C. S. (2020). Mental health and the covid-19 pandemic. New England
Journal of Medicine, 383(6), 510-512. https://doi.org/10.1056/NEJMp2008017

180
Pischon, T., Hankinson, S. E., Hotamisligil, G. S., Rifai, N., & Rimm, E. B. (2003). Leisure‐time
physical activity and reduced plasma levels of obesity‐related inflammatory markers.
Obesity Research, 11(9), 1055-1064. https://doi.org/10.1038/oby.2003.145
Pollock, M. L., Bohannon, R. L., Cooper, K. H., Ayres, J. J., Ward, A., White, S. R., &
Linnerud, A. C. (1976). A comparative analysis of four protocols for maximal treadmill
stress testing. American Heart Journal, 92(1), 39-46. https://doi.org/10.1016/s00028703(76)80401-2
Prather, A. A., Carroll, J. E., Fury, J. M., McDade, K. K., Ross, D., & Marsland, A. L. (2009).
Gender differences in stimulated cytokine production following acute psychological
stress. Brain Behav Immun, 23(5), 622-628.
https://doi.org/https://doi.org/10.1016/j.bbi.2008.11.004
Premoli, M., Aria, F., Bonini, S. A., Maccarinelli, G., Gianoncelli, A., Pina, S. D., Tambaro, S.,
Memo, M., & Mastinu, A. (2019). Cannabidiol: Recent advances and new insights for
neuropsychiatric disorders treatment. Life Sci, 224, 120-127.
https://doi.org/10.1016/j.lfs.2019.03.053
Radin, D. P., & Patel, P. (2017). Bdnf: An oncogene or tumor suppressor? Anticancer Research,
37(8), 3983-3990. https://doi.org/10.21873/anticanres.11783
Ramos-Arellano, L. E., Matia-Garcia, I., Marino-Ortega, L. A., Castro-Alarcón, N., MuñozValle, J. F., Salgado-Goytia, L., Salgado-Bernabé, A. B., & Parra-Rojas, I. (2020).
Obesity, dyslipidemia, and high blood pressure are associated with cardiovascular risk,
determined using high-sensitivity c-reactive protein concentration, in young adults.
Journal of International Medical Research, 48(12), 300060520980596.
https://doi.org/10.1177/0300060520980596

181
Rasmussen, P., Brassard, P., Adser, H., Pedersen, M. V., Leick, L., Hart, E., Secher, N. H.,
Pedersen, B. K., & Pilegaard, H. (2009). Evidence for a release of brain-derived
neurotrophic factor from the brain during exercise. Experimental Physiology, 94(10),
1062-1069. https://doi.org/10.1113/expphysiol.2009.048512
Renaud, A. M., & Cormier, Y. (1986). Acute effects of marihuana smoking on maximal exercise
performance. Medicine and Science in Sports and Exercise, 18(6), 685-689.
https://pubmed.ncbi.nlm.nih.gov/3097453/
Renault, K., Carlsen, E., Haedersdal, S., Nilas, L., Secher, N., Eugen-Olsen, J., Cortes, D., Olsen,
S., Halldorsson, T., & Nørgaard, K. (2017). Impact of lifestyle intervention for obese
women during pregnancy on maternal metabolic and inflammatory markers.
International journal of obesity, 41(4), 598-605. https://doi.org/10.1038/ijo.2017.9
Reuben, D. B., Judd‐Hamilton, L., Harris, T. B., & Seeman, T. E. (2003). The associations
between physical activity and inflammatory markers in high‐functioning older persons:
Macarthur studies of successful aging. J Am Geriatr Soc, 51(8), 1125-1130.
https://doi.org/10.1046/j.1532-5415.2003.51380.x
Rexrode, K. M., Pradhan, A., Manson, J. E., Buring, J. E., & Ridker, P. M. (2003). Relationship
of total and abdominal adiposity with crp and il-6 in women. Annals of epidemiology,
13(10), 674-682. https://doi.org/10.1016/s1047-2797(03)00053-x
Ribeiro, A., Almeida, V., Costola-de-Souza, C., Ferraz-de-Paula, V., Pinheiro, M., Vitoretti, L.,
Gimenes-Junior, J., Akamine, A., Crippa, J., & Tavares-de-Lima, W. (2015). Cannabidiol
improves lung function and inflammation in mice submitted to lps-induced acute lung
injury. Immunopharmacology and Immunotoxicology, 37(1), 35-41.
https://doi.org/10.3109/08923973.2014.976794

182
Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M. L., Vitoretti, L. B., Mariano-Souza, D. P.,
Quinteiro-Filho, W. M., Akamine, A. T., Almeida, V. I., Quevedo, J., & Dal-Pizzol, F.
(2012). Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases
inflammation in a murine model of acute lung injury: Role for the adenosine a2a
receptor. European Journal of Pharmacology, 678(1-3), 78-85.
https://doi.org/10.1016/j.ejphar.2011.12.043
Ridker, P. M. (2003). Clinical application of c-reactive protein for cardiovascular disease
detection and prevention. Circulation, 107(3), 363-369.
https://doi.org/10.1161/01.cir.0000053730.47739.3c
Riebe, C. J. N., Hill, M. N., Lee, T. T. Y., Hillard, C. J., & Gorzalka, B. B. (2010). Estrogenic
regulation of limbic cannabinoid receptor binding. Psychoneuroendocrinology, 35(8),
1265-1269. https://doi.org/https://doi.org/10.1016/j.psyneuen.2010.02.008
Riebe, D., Ehrman, J., Liguori, G., & Magal, M. (2018). Acsm's guidelines for exercise testing
and prescription (10 ed.). Wolters Kluwer.
Riecher-Rössler, A. (2017). Sex and gender differences in mental disorders. Lancet Psychiatry,
4(1), 8-9. https://doi.org/10.1016/s2215-0366(16)30348-0
Robbins, T. W. (2011). Cognition: The ultimate brain function. Neuropsychopharmacology,
36(1), 1-2. https://doi.org/10.1038/npp.2010.171
Rothrock, N. E., Amtmann, D., & Cook, K. F. (2020). Development and validation of an
interpretive guide for promis scores. Journal of Patient-Reported Outcomes, 4(1), 16.
https://doi.org/10.1186/s41687-020-0181-7

183
Ruehle, S., Rey, A. A., Remmers, F., & Lutz, B. (2012). The endocannabinoid system in anxiety,
fear memory and habituation. Journal of Psychopharmacology, 26(1), 23-39.
https://doi.org/10.1177/0269881111408958
Ryff, C. D., & Keyes, C. L. M. (1995). The structure of psychological well-being revisited.
Journal of Personality and Social Psychology, 69(4), 719. https://doi.org/10.1037//00223514.69.4.719
Saffer, B. Y., Lanting, S. C., Koehle, M. S., Klonsky, E. D., & Iverson, G. L. (2015). Assessing
cognitive impairment using promis(®) applied cognition-abilities scales in a medical
outpatient sample. Psychiatry Research, 226(1), 169-172.
https://doi.org/10.1016/j.psychres.2014.12.043
Sahinovic, A., Irwin, C., Doohan, P. T., Kevin, R. C., Cox, A. J., Lau, N. S., Desbrow, B.,
Johnson, N. A., Sabag, A., & Hislop, M. (2022). Effects of cannabidiol on exercise
physiology and bioenergetics: A randomised controlled pilot trial. Sports Medicine Open, 8(1), 1-18. https://doi.org/10.1186/s40798-022-00417-y
Sales, A. J., Fogaça, M. V., Sartim, A. G., Pereira, V. S., Wegener, G., Guimarães, F. S., & Joca,
S. R. L. (2019). Cannabidiol induces rapid and sustained antidepressant-like effects
through increased bdnf signaling and synaptogenesis in the prefrontal cortex. Mol
Neurobiol, 56(2), 1070-1081. https://doi.org/10.1007/s12035-018-1143-4
Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2020). Cbd modulates DNA methylation in the
prefrontal cortex and hippocampus of mice exposed to forced swim. Behavioural Brain
Research, 388, 112627. https://doi.org/10.1016/j.bbr.2020.112627

184
Sardeli, A. V., Tomeleri, C. M., Cyrino, E. S., Fernhall, B., Cavaglieri, C. R., & ChaconMikahil, M. P. T. (2018). Effect of resistance training on inflammatory markers of older
adults: A meta-analysis. Experimental Gerontology, 111, 188-196.
https://doi.org/10.1016/j.exger.2018.07.021
Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2016). Antidepressant-like effect of
cannabidiol injection into the ventral medial prefrontal cortex—possible involvement of
5-ht1a and cb1 receptors. Behavioural Brain Research, 303, 218-227.
https://doi.org/10.1016/j.bbr.2016.01.033
Scharfman, H. E., Goodman, J. H., & Sollas, A. L. (1999). Actions of brain-derived neurotrophic
factor in slices from rats with spontaneous seizures and mossy fiber sprouting in the
dentate gyrus. Journal of Neuroscience, 19(13), 5619-5631.
https://doi.org/10.1523/jneurosci.19-13-05619.1999
Scharfman, H. E., & MacLusky, N. J. (2006). Estrogen and brain-derived neurotrophic factor
(bdnf) in hippocampus: Complexity of steroid hormone-growth factor interactions in the
adult cns. Frontiers in Neuroendocrinology, 27(4), 415-435.
https://doi.org/10.1016/j.yfrne.2006.09.004
Schiavon, A. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M.
(2016). Influence of single and repeated cannabidiol administration on emotional
behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog
Neuropsychopharmacol Biol Psychiatry, 64, 27-34.
https://doi.org/10.1016/j.pnpbp.2015.06.017

185
Schiffer, T., Schulte, S., Hollmann, W., Bloch, W., & Strüder, H. K. (2009). Effects of strength
and endurance training on brain-derived neurotrophic factor and insulin-like growth
factor 1 in humans. Hormone and Metabolic Research, 41(3), 250-254.
https://doi.org/10.1055/s-0028-1093322
Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S. C., & Dinarello, C. A. (1990).
Correlations and interactions in the production of interleukin-6 (il-6), il-1, and tumor
necrosis factor (tnf) in human blood mononuclear cells: Il-6 suppresses il-1 and tnf.
Blood, 75(1), 40-47. https://doi.org/10.1182/blood.V75.1.40.40
Schoedel, K. A., Szeto, I., Setnik, B., Sellers, E. M., Levy-Cooperman, N., Mills, C., Etges, T.,
& Sommerville, K. (2018). Abuse potential assessment of cannabidiol (cbd) in
recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy &
Behavior 88, 162-171. https://doi.org/10.1016/j.yebeh.2018.07.027
Schräder, N. H. B., Duipmans, J. C., Molenbuur, B., Wolff, A. P., & Jonkman, M. F. (2019).
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: A
report of three cases. Epilepsy & Behavior, 180(4), 922-924.
https://doi.org/10.1111/bjd.17341
Schulz, P., Hryhorowicz, S., Rychter, A. M., Zawada, A., Słomski, R., Dobrowolska, A., &
Krela-Kaźmierczak, I. (2021). What role does the endocannabinoid system play in the
pathogenesis of obesity? Nutrients, 13(2), 373.
Sember, V., Meh, K., Sorić, M., Starc, G., Rocha, P., & Jurak, G. (2020). Validity and reliability
of the ipaq for adults across eu countries: Systematic review and meta analysis.
International Journal of Environmental Research and Public Health, 17(19).
https://doi.org/10.3390/ijerph17197161

186
Seo, D. I., Kim, E., Fahs, C. A., Rossow, L., Young, K., Ferguson, S. L., Thiebaud, R., Sherk, V.
D., Loenneke, J. P., Kim, D., Lee, M. K., Choi, K. H., Bemben, D. A., Bemben, M. G., &
So, W. Y. (2012). Reliability of the one-repetition maximum test based on muscle group
and gender. Journal of Sports Science and Medicine, 11(2), 221-225.
https://pubmed.ncbi.nlm.nih.gov/24149193/
Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in anxiety and sleep: A large
case series. Permanente Journal, 23, 18-041. https://doi.org/10.7812/TPP/18-041
Shbiro, L., Hen-Shoval, D., Hazut, N., Rapps, K., Dar, S., Zalsman, G., Mechoulam, R., Weller,
A., & Shoval, G. (2019). Effects of cannabidiol in males and females in two different rat
models of depression. Physiology & Behavior, 201, 59-63.
https://doi.org/10.1016/j.physbeh.2018.12.019
Shoval, G., & Weizman, A. (2005). The possible role of neurotrophins in the pathogenesis and
therapy of schizophrenia. European College of Neuropsychopharmacology, 15(3), 319329. https://doi.org/10.1016/j.euroneuro.2004.12.005
Silote, G., Reinert, L., Hasselstrøm, J., Joca, S., & Wegener, G. (2020). P. 212 cannabidiol effect
on genes related to bdnf-trkb and glutamatergic neurotransmission in the flinders
sensitive line rat. European Neuropsychopharmacology, 31(1), S27-S28.
https://doi.org/10.1016/j.euroneuro.2019.12.038
Silote, G. P., Sartim, A., Sales, A., Eskelund, A., Guimaraes, F. S., Wegener, G., & Joca, S.
(2019). Emerging evidence for the antidepressant effect of cannabidiol and the
underlying molecular mechanisms. J Chem Neuroanat, 98, 104-116.
https://doi.org/10.1016/j.jchemneu.2019.04.006

187
Silva, G. D., Del Guerra, F. B., de Oliveira Lelis, M., & Pinto, L. F. (2020). Cannabidiol in the
treatment of epilepsy: A focused review of evidence and gaps. Front Neurol, 11, 531939.
https://doi.org/10.3389/fneur.2020.531939
Skriver, K., Roig, M., Lundbye-Jensen, J., Pingel, J., Helge, J. W., Kiens, B., & Nielsen, J. B.
(2014). Acute exercise improves motor memory: Exploring potential biomarkers.
Neurobiology of Learning and Memory, 116, 46-58.
https://doi.org/10.1016/j.nlm.2014.08.004
Smith, J. K., Dykes, R., Douglas, J. E., Krishnaswamy, G., & Berk, S. (1999). Long-term
exercise and atherogenic activity of blood mononuclear cells in persons at risk of
developing ischemic heart disease. JAMA, 281(18), 1722-1727.
https://doi.org/10.1001/jama.281.18.1722
Sohrabji, F., & Lewis, D. K. (2006). Estrogen–bdnf interactions: Implications for
neurodegenerative diseases. Frontiers in Neuroendocrinology, 27(4), 404-414.
https://doi.org/10.1016/j.yfrne.2006.09.003
Sokka, T., & Pincus, T. (2009). Erythrocyte sedimentation rate, c-reactive protein, or rheumatoid
factor are normal at presentation in 35%–45% of patients with rheumatoid arthritis seen
between 1980 and 2004: Analyses from finland and the united states. Journal of
Rheumatology, 36(7), 1387. https://doi.org/10.3899/jrheum.080770
Solowij, N., Broyd, S. J., Beale, C., Prick, J. A., Greenwood, L. M., van Hell, H., Suo, C.,
Galettis, P., Pai, N., Fu, S., Croft, R. J., Martin, J. H., & Yucel, M. (2018). Therapeutic
effects of prolonged cannabidiol treatment on psychological symptoms and cognitive
function in regular cannabis users: A pragmatic open-label clinical trial. Cannabis
Cannabinoid Res, 3(1), 21-34. https://doi.org/10.1089/can.2017.0043

188
Spillane, J., & McAllister, W. B. (2003). Keeping the lid on: A century of drug regulation and
control. Drug and Alcohol Dependence, 70(3 Suppl), S5-12.
https://doi.org/10.1016/s0376-8716(03)00096-6
Spindle, T. R., Cone, E. J., Goffi, E., Weerts, E. M., Mitchell, J. M., Winecker, R. E., Bigelow,
G. E., Flegel, R. R., & Vandrey, R. (2020). Pharmacodynamic effects of vaporized and
oral cannabidiol (cbd) and vaporized cbd-dominant cannabis in infrequent cannabis users.
Drug and Alcohol Dependence, 211, 107937.
https://doi.org/10.1016/j.drugalcdep.2020.107937
Sproston, N. R., & Ashworth, J. J. (2018). Role of c-reactive protein at sites of inflammation and
infection. Frontiers in Immunology, 9, 754. https://doi.org/10.3389/fimmu.2018.00754
Steadward, R. D., & Singh, M. (1975). The effects of smoking marihuana on physical
performance. Medicine and Science in Sports, 7(4), 309-311.
https://pubmed.ncbi.nlm.nih.gov/1235156/
Steensberg, A., Fischer, C. P., Keller, C., Møller, K., & Pedersen, B. K. (2003). Il-6 enhances
plasma il-1ra, il-10, and cortisol in humans. American Journal of Physiology Endocrinology and Metabolism, 285(2), E433-E437.
https://doi.org/10.1152/ajpendo.00074.2003
Stempel, A. V., Stumpf, A., Zhang, H. Y., Özdoğan, T., Pannasch, U., Theis, A. K., Otte, D. M.,
Wojtalla, A., Rácz, I., Ponomarenko, A., Xi, Z. X., Zimmer, A., & Schmitz, D. (2016).
Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus.
Neuron, 90(4), 795-809. https://doi.org/10.1016/j.neuron.2016.03.034

189
Steptoe, A., Owen, N., Kunz-Ebrecht, S., & Mohamed-Ali, V. (2002). Inflammatory cytokines,
socioeconomic status, and acute stress responsivity. Brain Behav Immun, 16(6), 774-784.
https://doi.org/10.1016/S0889-1591(02)00030-2
Stetz, M. C., Thomas, M. L., Russo, M. B., Stetz, T. A., Wildzunas, R. M., McDonald, J. J.,
Wiederhold, B. K., & Romano, J. A. (2007). Stress, mental health, and cognition: A brief
review of relationships and countermeasures. Aviation, Space, and Environmental
Medicine, 78(5), B252-B260.
Stewart, L. K., Flynn, M. G., Campbell, W. W., Craig, B. A., Robinson, J. P., Timmerman, K.
L., McFarlin, B. K., Coen, P. M., & Talbert, E. (2007). The influence of exercise training
on inflammatory cytokines and c-reactive protein. Medicine and Science in Sports and
Exercise, 39(10), 1714. https://doi.org/10.1249/mss.0b013e31811ece1c
St. Pierre Schneider, B., Correia, L. A., & Cannon, J. G. (1999). Sex differences in leukocyte
invasion in injured murine skeletal muscle. Research in Nursing & Health, 22(3), 243250. https://doi.org/10.1002/(sici)1098-240x(199906)22:3<243::aid-nur6>3.0.co;2-x
Stupka, N., Lowther, S., Chorneyko, K., Bourgeois, J., Hogben, C., & Tarnopolsky, M. (2000).
Gender differences in muscle inflammation after eccentric exercise. Journal of Applied
Physiology, 89(6), 2325-2332. https://doi.org/10.1152/jappl.2000.89.6.2325
Su, Q., Cheng, Y., Jin, K., Cheng, J., Lin, Y., Lin, Z., Wang, L., & Shao, B. (2016). Estrogen
therapy increases bdnf expression and improves post-stroke depression in ovariectomytreated rats. Experimental and Therapeutic Medicine, 12(3), 1843-1848.
https://doi.org/10.3892/etm.2016.3531

190
Sugiura, T., Kobayashi, Y., Oka, S., & Waku, K. (2002). Biosynthesis and degradation of
anandamide and 2-arachidonoylglycerol and their possible physiological significance.
Prostaglandins, Leukotrienes & Essential Fatty Acids, 66(2-3), 173-192.
https://doi.org/10.1054/plef.2001.0356
Sultan, S. R., O'Sullivan, S. E., & England, T. J. (2020). The effects of acute and sustained
cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised
controlled trial. Br J Clin Pharmacol, 86(6), 1125-1138.
https://doi.org/10.1111/bcp.14225
Sung, Y. H., Kim, S. C., Hong, H. P., Park, C. Y., Shin, M. S., Kim, C. J., Seo, J. H., Kim, D. Y.,
Kim, D. J., & Cho, H. J. (2012). Treadmill exercise ameliorates dopaminergic neuronal
loss through suppressing microglial activation in parkinson's disease mice. Life Sci,
91(25-26), 1309-1316. https://doi.org/10.1016/j.lfs.2012.10.003
Szuhany, K. L., & Otto, M. W. (2020). Assessing bdnf as a mediator of the effects of exercise on
depression. Journal of Psychiatric Research, 123, 114-118.
https://doi.org/10.1016/j.jpsychires.2020.02.003
Taaffe, D. R., Harris, T. B., Ferrucci, L., Rowe, J., & Seeman, T. E. (2000). Cross-sectional and
prospective relationships of interleukin-6 and c-reactive protein with physical
performance in elderly persons: Macarthur studies of successful aging. Journals of
Gerontology Series A Biological Sciences and Medical Sciences, 55(12), M709-M715.
https://doi.org/10.1093/gerona/55.12.m709
Terlizzi, E. P., & Norris, T. (2021, Oct). Mental health treatment among adults: United states,
2020. Centers for Disease Control and Prevention.
https://www.cdc.gov/nchs/products/databriefs/db419.htm

191
Tesema, G., George, M., Hadgu, A., Haregot, E., Mondal, S., & Mathivana, D. (2019). Does
chronic high-intensity endurance training have an effect on cardiovascular markers of
active populations and athletes? Systematic review and meta-analysis. BMJ Open, 9(10),
e032832. https://doi.org/10.1136/bmjopen-2019-032832
Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E., Denovan‐Wright, E. M., & Laprairie,
R. B. (2019). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐
dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol, 176(10),
1455-1469. https://doi.org/10.1111/bph.14440
Thomas, K., & Davies, A. (2005). Neurotrophins: A ticket to ride for bdnf. Current Biology,
15(7), R262-R264. https://doi.org/https://doi.org/10.1016/j.cub.2005.03.023
Thompson, D., Pepys, M. B., & Wood, S. P. (1999). The physiological structure of human creactive protein and its complex with phosphocholine. Structure, 7(2), 169-177.
https://doi.org/10.1016/S0969-2126(99)80023-9
Thorand, B., Baumert, J., Döring, A., Herder, C., Kolb, H., Rathmann, W., Giani, G., & Koenig,
W. (2006). Sex differences in the relation of body composition to markers of
inflammation. Atherosclerosis, 184(1), 216-224.
https://doi.org/10.1016/j.atherosclerosis.2005.04.011
Timmons, B. W., Hamadeh, M. J., Devries, M. C., & Tarnopolsky, M. A. (2005). Influence of
gender, menstrual phase, and oral contraceptive use on immunological changes in
response to prolonged cycling. Journal of Applied Physiology, 99(3), 979-985.
https://doi.org/10.1152/japplphysiol.00171.2005

192
Timmons, B. W., Hamadeh, M. J., & Tarnopolsky, M. A. (2006). No effect of short-term 17βestradiol supplementation in healthy men on systemic inflammatory responses to
exercise. American Journal of Physiology-Regulatory, Integrative and Comparative
Physiology, 291(2), R285-R290. https://doi.org/10.1152/ajpregu.00605.2005
Timmons, B. W., Tarnopolsky, M. A., Snider, D. P., & Bar-Or, O. (2006). Immunological
changes in response to exercise: Influence of age, puberty, and gender. Medicine and
Science in Sports and Exercise 38(2), 293-304.
https://doi.org/10.1249/01.mss.0000183479.90501.a0
Timmusk, T., Palm, K., Metsis, M., Reintam, T., Paalme, V., Saarma, M., & Persson, H. (1993).
Multiple promoters direct tissue-specific expression of the rat bdnf gene. Neuron, 10(3),
475-489. https://doi.org/10.1016/0896-6273(93)90335-o
Toll, A., Berge, D., Burling, K., Scoriels, L., Treen, D., Monserrat, C., Marmol, F., Duran, X.,
Jones, P. B., Perez-Sola, V., Fernandez-Egea, E., & Mane, A. (2020). Cannabis use
influence on peripheral brain-derived neurotrophic factor levels in antipsychotic-naive
first-episode psychosis. European Archives of Psychiatry and Clinical Neuroscience,
270(7), 851-858. https://doi.org/10.1007/s00406-020-01117-y
Toran-Allerand, C. D. (2004). Minireview: A plethora of estrogen receptors in the brain: Where
will it end? Endocrinology, 145(3), 1069-1074.
Trajkovska, V., Marcussen, A. B., Vinberg, M., Hartvig, P., Aznar, S., & Knudsen, G. M.
(2007). Measurements of brain-derived neurotrophic factor: Methodological aspects and
demographical data. Brain Research Bulletin, 73(1-3), 143-149.
https://doi.org/10.1016/j.brainresbull.2007.03.009

193
Tsai, C. L., Pai, M. C., Ukropec, J., & Ukropcová, B. (2019). Distinctive effects of aerobic and
resistance exercise modes on neurocognitive and biochemical changes in individuals with
mild cognitive impairment. Curr Alzheimer Res, 16(4), 316-332.
https://doi.org/10.2174/1567205016666190228125429
Tsalik, E. L., Jaggers, L. B., Glickman, S. W., Langley, R. J., van Velkinburgh, J. C., Park, L. P.,
Fowler, V. G., Cairns, C. B., Kingsmore, S. F., & Woods, C. W. (2012). Discriminative
value of inflammatory biomarkers for suspected sepsis. Journal of Emergency Medicine,
43(1), 97-106. https://doi.org/10.1016/j.jemermed.2011.05.072
Tudor-Locke, C., & Bassett, D. R. (2004). How many steps/day are enough? Sports Medicine,
34(1), 1-8. https://doi.org/10.1186/1479-5868-8-79
Tudor-Locke, C., Johnson, W. D., & Katzmarzyk, P. T. (2009). Accelerometer-determined steps
per day in us adults. Medicine and Science in Sports and Exercise, 41(7), 1384-1391.
https://doi.org/10.1249/MSS.0b013e318199885c
Tudor-Locke, C., Leonardi, C., Johnson, W. D., Katzmarzyk, P. T., & Church, T. S. (2011).
Accelerometer steps/day translation of moderate-to-vigorous activity. Preventive
Medicine, 53(1-2), 31-33. https://doi.org/10.1016/j.ypmed.2011.01.014
Turcotte, C., Blanchet, M. R., Laviolette, M., & Flamand, N. (2016). The cb(2) receptor and its
role as a regulator of inflammation. Cellular and Molecular Life Sciences, 73(23), 44494470. https://doi.org/10.1007/s00018-016-2300-4

194
Urabe, H., Kojima, H., Chan, L., Terashima, T., Ogawa, N., Katagi, M., Fujino, K., Kumagai,
A., Kawai, H., Asakawa, A., Inui, A., Yasuda, H., Eguchi, Y., Oka, K., Maegawa, H.,
Kashiwagi, A., & Kimura, H. (2013). Haematopoietic cells produce bdnf and regulate
appetite upon migration to the hypothalamus. Nature Communications, 4, 1526.
https://doi.org/10.1038/ncomms2536
Vaduganathan, M., Pareek, M., Qamar, A., Pandey, A., Olsen, M. H., & Bhatt, D. L. (2018).
Baseline blood pressure, the 2017 acc/aha high blood pressure guidelines, and long-term
cardiovascular risk in sprint. American Journal of Medicine, 131(8), 956-960.
https://doi.org/10.1016/j.amjmed.2017.12.049
Valentine, T. R., Weiss, D. M., Jones, J. A., & Andersen, B. L. (2019). Construct validity of
promis cognitive function in cancer patients and noncancer controls. Health Psychology,
38(5), 351-358. https://doi.org/10.1037/hea0000693
Wagner, G., Herbsleb, M., Cruz, F. d. l., Schumann, A., Brünner, F., Schachtzabel, C., Gussew,
A., Puta, C., Smesny, S., & Gabriel, H. W. (2015). Hippocampal structure, metabolism,
and inflammatory response after a 6-week intense aerobic exercise in healthy young
adults: A controlled trial. Journal of Cerebral Blood Flow & Metabolism, 35(10), 15701578. https://doi.org/10.1038/jcbfm.2015.125
Walker, O. S., Holloway, A. C., & Raha, S. (2019). The role of the endocannabinoid system in
female reproductive tissues. Journal of Ovarian Research, 12(1), 3.
https://doi.org/10.1186/s13048-018-0478-9
Ware, M. A., Jensen, D., Barrette, A., Vernec, A., & Derman, W. (2018). Cannabis and the
health and performance of the elite athlete. Clinical Journal of Sport Medicine, 28(5),
480-484. https/doi.org/10.1097/jsm.0000000000000650

195
Warren, S. G., Humphreys, A. G., Juraska, J. M., & Greenough, W. T. (1995). Ltp varies across
the estrous cycle: Enhanced synaptic plasticity in proestrus rats. Brain Research, 703(12), 26-30. https://doi.org/10.1016/0006-8993(95)01059-9
Watanabe, S., Mu, W., Kahn, A., Jing, N., Li, J. H., Lan, H. Y., Nakagawa, T., Ohashi, R., &
Johnson, R. J. (2004). Role of jak/stat pathway in il-6-induced activation of vascular
smooth muscle cells. American Journal of Nephrology, 24(4), 387-392.
https://doi.org/10.1159/000079706
Webb, M. A., Mani, H., Robertson, S. J., Waller, H. L., Webb, D. R., Edwardson, C. L.,
Bodicoat, D. H., Yates, T., Khunti, K., & Davies, M. J. (2018). Moderate increases in
daily step count are associated with reduced il6 and crp in women with pcos. Endocrine
Connections, 7(12), 1442-1447. https://doi.org/10.1530/ec-18-0438
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011). International cognition and cancer
task force recommendations to harmonise studies of cognitive function in patients with
cancer. Lancet Oncology, 12(7), 703-708. https://doi.org/10.1016/S1470-2045(10)702941
Wens, I., Keytsman, C., Deckx, N., Cools, N., Dalgas, U., & Eijnde, B. O. (2016). Brain derived
neurotrophic factor in multiple sclerosis: Effect of 24 weeks endurance and resistance
training. European Journal of Neurology, 23(6), 1028-1035.
https://doi.org/10.1111/ene.12976
Wheeler, M., Merten, J. W., Gordon, B. T., & Hamadi, H. (2020). Cbd (cannabidiol) product
attitudes, knowledge, and use among young adults. Substance Use & Misuse, 55(7),
1138-1145. https://doi.org/10.1080/10826084.2020.1729201

196
Wheeler, M. J., Green, D. J., Ellis, K. A., Cerin, E., Heinonen, I., Naylor, L. H., Larsen, R.,
Wennberg, P., Boraxbekk, C. J., Lewis, J., Eikelis, N., Lautenschlager, N. T., Kingwell,
B. A., Lambert, G., Owen, N., & Dunstan, D. W. (2020). Distinct effects of acute
exercise and breaks in sitting on working memory and executive function in older adults:
A three-arm, randomised cross-over trial to evaluate the effects of exercise with and
without breaks in sitting on cognition. British Journal of Sports Medicine, 54(13), 776781. https://doi.org/10.1136/bjsports-2018-100168
Williams, N. N. B., Ewell, T. R., Abbotts, K. S. S., Harms, K. J., Woelfel, K. A., Dooley, G. P.,
Weir, T. L., & Bell, C. (2021). Comparison of five oral cannabidiol preparations in adult
humans: Pharmacokinetics, body composition, and heart rate variability.
Pharmaceuticals, 14(1). https://doi.org/10.3390/ph14010035
Wingate, S. (1997). Cardiovascular anatomy and physiology in the female. Critical Care
Nursing Clinics of North America, 9(4), 447-452.
https://pubmed.ncbi.nlm.nih.gov/9444167/
Wood, L. J., Nail, L. M., & Winters, K. A. (2009). Does muscle-derived interleukin-6 mediate
some of the beneficial effects of exercise on cancer treatment-related fatigue? Oncology
Nursing Forum, 36(5), 519-524. https://doi.org/10.1188/09.onf.519-524
Wright, C. E., Strike, P. C., Brydon, L., & Steptoe, A. (2005). Acute inflammation and negative
mood: Mediation by cytokine activation. Brain Behav Immun, 19(4), 345-350.
https://doi.org/10.1016/j.bbi.2004.10.003
Yamamoto, H., & Gurney, M. E. (1990). Human platelets contain brain-derived neurotrophic
factor. Journal of Neuroscience, 10(11), 3469-3478. https://doi.org/10.1523/jneurosci.1011-03469.1990

197
Yang, L. Y., & Arnold, A. P. (2000). Interaction of bdnf and testosterone in the regulation of
adult perineal motoneurons. Journal of Neurobiology, 44(3), 308-319.
https://doi.org/10.1002/1097-4695(20000905)44:3<308::aid-neu2>3.0.co;2-m
YorkWilliams, S. L., Gust, C. J., Mueller, R., Bidwell, L. C., Hutchison, K. E., Gillman, A. S., &
Bryan, A. D. (2019). The new runner's high? Examining relationships between cannabis
use and exercise behavior in states with legalized cannabis. Frontiers in Public Health, 7,
99. https://doi.org/10.3389/fpubh.2019.00099
Zang, L., Wang, S. Q., Mao, N., Fu, X. J., Lin, X. J., Meng, D. J., & Li, G. (2019). Effect of
different walking number on inflammation and nutrition in patients with chronic kidney
disease. Sichuan Da Xue Xue Bao Yi Xue Ban, 50(2), 252-255.
https://pubmed.ncbi.nlm.nih.gov/31106548/
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F.
(2020). Chronic adipose tissue inflammation linking obesity to insulin resistance and type
2 diabetes. Frontiers in Physiology, 10, 1607. https://doi.org/10.3389/fphys.2019.01607
Zeiger, J. S., Silvers, W. S., Fleegler, E. M., & Zeiger, R. S. (2019). Cannabis use in active
athletes: Behaviors related to subjective effects. PLoS One, 14(6), e0218998.
https://doi.org/10.1371/journal.pone.0218998
Zhang, H. Y., Bi, G. H., Li, X., Li, J., Qu, H., Zhang, S. J., Li, C. Y., Onaivi, E. S., Gardner, E.
L., Xi, Z. X., & Liu, Q. R. (2015). Species differences in cannabinoid receptor 2 and
receptor responses to cocaine self-administration in mice and rats.
Neuropsychopharmacology, 40(4), 1037-1051. https://doi.org/10.1038/npp.2014.297

198
Zhang, H. Y., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., Gardner, E. L., Wu, J., & Xi, Z.
X. (2014). Cannabinoid cb2 receptors modulate midbrain dopamine neuronal activity and
dopamine-related behavior in mice. Proceedings of the National Academy of Sciences,
111(46), E5007-5015. https://doi.org/10.1073/pnas.1413210111
Ziegenhorn, A. A., Schulte-Herbrüggen, O., Danker-Hopfe, H., Malbranc, M., Hartung, H.-D.,
Anders, D., Lang, U. E., Steinhagen-Thiessen, E., Schaub, R. T., & Hellweg, R. (2007).
Serum neurotrophins--a study on the time course and influencing factors in a large old
age sample. Neurobiology of Aging, 28(9), 1436-1445.
https://doi.org/10.1016/j.neurobiolaging.2006.06.011
Zimmer, P., Baumann, F. T., Oberste, M., Schmitt, J., Joisten, N., Hartig, P., Schenk, A., Kuhn,
R., Bloch, W., & Reuss-Borst, M. (2018). Influence of personalized exercise
recommendations during rehabilitation on the sustainability of objectively mmeasured
physical activity levels, fatigue, and fatigue-related biomarkers in patients with breast
cancer. Integrative Cancer Therapies, 17(2), 306-311.
https://doi.org/10.1177/1534735417713301
Zoladz, J. A., Majerczak, J., Zeligowska, E., Mencel, J., Jaskolski, A., Jaskolska, A., &
Marusiak, J. (2014). Moderate-intensity interval training increases serum brain-derived
neurotrophic factor level and decreases inflammation in parkinson's disease patients.
Journal of Physiology and Pharmacology, 65(3), 441-448.
https://pubmed.ncbi.nlm.nih.gov/24930517/

199
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., Dursun,
S. M., & Tumas, V. (2009). Cannabidiol for the treatment of psychosis in parkinson's
disease. Journal of Psychopharmacology, 23(8), 979-983.
https://doi.org/10.1177/0269881108096519
Zupan, M. F., Arata, A. W., Dawson, L. H., Wile, A. L., Payn, T. L., & Hannon, M. E. (2009).
Wingate anaerobic test peak power and anaerobic capacity classifications for men and
women intercollegiate athletes. Journal of Strength and Conditioning Research, 23(9),
2598-2604. https://doi.org/10.1519/JSC.0b013e3181b1b21b

APPENDIX A
INSTITUTIONAL REVIEW BOARD APPROVAL

202

APPENDIX B
CERTIFICATE OF ANALYSIS

205

